Welcome to SBS 2011 - SLAS

SBS 17th Annual Conference & Exhibition Advancing the Science of Drug Discovery 

Welcome to SBS 2011 

On behalf of the Society for Laboratory Automation and Screening (SLAS), 

we welcome you to the 17th Annual SBS Conference and Exhibition in 

Orlando, Florida. We are proud to host this exciting event, which includes: 

• Engaging keynote presentations by SBS Achievement Award winner 

Robert J. Lefkowitz, SBS Accomplishment Award winner Brian Shoichet, 

and Professor Hugh Rosen of The Scripps Research Institute 

• An outstanding scientific program and thought-provoking poster presentations 

• An exhibit floor thriving with leading companies from around the world 

• Informative vendor tutorials and collaborative Special Interest Groups (SIGs) 

• Innovative new programs and awards 

SBS 2011 provides a place for you to come together with other scientists, engineers 

and professionals involved in the science of drug discovery and screening to learn, 

and share ideas, research and innovation. 

As a conference participant, you may choose from 15 diverse scientific sessions 

organized in three tracks, with each session punctuated by a keynote presentation: 

Track I: Innovations in the Screening Sciences 

This track captures the excitement of recent advances in all aspects of the screening 

sciences, with a focus on innovations in instrumentation, reagents and technologies 

that are impacting “HTS to Lead” efforts. 

Track II: Translational Research 

These sessions describe the changing face of drug discovery in the 21st century and 

introduce collaborative paradigms and resources that enhance translational research. 

Track III: Sequenced Genomes: Reducing Opportunities to Practice 

This track explores how the availability of sequenced genomes and the inevitability 

of inexpensive phenotyping are impacting therapeutic agent and consumer product 

discovery. And most importantly, these sessions illustrate how screening sciences 

are ideally positioned to take advantage of these opportunities. 

Paul Bernasconi and Peter Hodder 

SBS 2011 Program Chairs 

SLAS.org/events/sbs11 | 1

Gaylord Palms Resort and Convention Center | March 27–31, 2011 | Orlando, Florida, USA 

Table of Contents 

Welcome to SBS 2011 page 1 

Industry Sponsors, Friends of SLAS, and Media Partners page 4 

Scientific Committee and SLAS Leadership page 5 

What’s New and Exciting at SBS 2011 page 7 

SLAS Welcomes Its Corporate Members page 8 

General Information page 12 

SBS 2011 Beachcomber Bash page 14 

SLAS Member Center page 15 

Tony B. Academic Travel Award Winners page 15 

SLAS Career Connections page 16 

Special Educational Sessions page 17 

Keynote Speakers page 18 

Benefits of SLAS Membership page 19 

Conference Floor Plan page 20 

Schedule-at-a-Glance page 22 

Short Course Program page 28 

Technical Session Program Overview page 30 

Podium Abstracts page 36 

Podium Speaker Index page 81 

Poster Program page 82 

Special Interest Groups page 100 

Exhibitor Workshops page 102 

Exhibitor Tutorials page 103 

Exhibition page 109 

New Product Launches page 110 

Exhibitor List page 112 

Exhibit Hall Floor Plan page 115 

Exhibitor Descriptions page 116 

Advertisers page 152 



Thank You to the Sponsors/Media Partners of SBS 2011! 

Premier Sponsor: 

Bronze Sponsors: 

Conference Sponsors: 

Media Partners: 

4 | SLAS.org/events/sbs11


Scientific Committee and SLAS Leadership 

SBS 2011 Scientific Committee 

Program Chairs 

Paul Bernasconi, Ph.D. 

BASF Corporation 

Peter Hodder, Ph.D. 

The Scripps Research Institute 

Roger Bosse, Ph.D., PerkinElmer 

Paul Burn, Ph.D., Sanford Project 

Sabrina Corazza, Ph.D., Axxam SpA 

Claude DuFresne, Ph.D., Merck 

Ken Duncan, Ph.D., Bill and Melinda Gates Foundation 

Achim Grenz, Ph.D., F. Hoffmann-La Roche Ltd 

Bob Hertzberg, Ph.D., GlaxoSmithKline 

Keith Houck, Ph.D., Environmental Protection Agency 

Jim Inglese, Ph.D., NIH Chemical Genomics Center 

Bill Janzen, Ph.D., University of North Carolina at 

Chapel Hill 

Scott Martin, Ph.D., St. Louis University 

Jonathan O’Connell, Ph.D., Bristol-Myers 

Squibb Company 

Ulrich Schopfer, Ph.D., Novartis Institutes for 

BioMedical Research 

Daniel Sipes, Ph.D., Genomics Institute of the 

Novartis Research Foundation 

Andrew Su, Ph.D., Genomics Institute of the 


Phil Tagari, Ph.D., Amgen 

Poster Co-Chairs 

Julio Martin, GlaxoSmithKline 

Julie Li, Sanofi Aventis 

SLAS Board of Directors 

Michelle Palmer, Ph.D., Broad Institute of Harvard and MIT 

Jason Abbas, M.S., Syngenta Seeds 

Robert Ames, Ph.D., GlaxoSmithKline 

David Dorsett, M.B.A., Bristol-Myers Squibb Company 

Bill Janzen, Ph.D., University of North Carolina - Chapel Hill 

Jeff Paslay, Ph.D., Paslay Consulting 

Erik Rubin, Ph.D., Bristol-Myers Squibb Company 

Mary Jo Wildey, Ph.D., Merck Research Labs 

Andy Zaayenga, Ph.D., HighRes Biosolutions 

Biomolecular Sciences 

Section (BSS) Executive 

Council 

Sue Holland-Crimmin, Ph.D., GlaxoSmithKline 

Lorenz Mayr, Ph.D., Novartis Pharma 

Steve Rees, Ph.D., GlaxoSmithKline 

Melvin Reichman, Ph.D., Lankenau Institute for 

Medical Research Chemical Genomics Center 

John Wang, Ph.D., Wang Consulting 

Andy Zaayenga, Ph.D., HighRes Biosolutions 

Laboratory Automation 

Section (LAS) Executive 

Council 

Chris Detter, Ph.D., Los Alamos National Laboratory 

Hansjörg Haas, Ph.D., Thermo Fisher Scientific 

R. Scott Martin, Ph.D., Saint Louis University 

Robyn Rourick, M.S., Genentech 

Craig Schulz, Ph.D., Amgen 

Nitin Sood, M.S., Agilent Technologies 


SLAS On-Demand Offers Scientific Education 365/24/7 

A Powerful Resource To Keep You Current 

The Society for Laboratory Automation and Screening (SLAS) offers around-the-clock on-demand 

scientific education, a powerful resource to help keep you in-the-know on relevant and timely scientific 

topics from leaders in the field. 

Choosing from world-class podium presentations or instructional seminars, you can decide when 

and how to take advantage of these on-demand learning opportunities. There’s no rush, no pressure, 

no deadline—just a robust online library of educational resources at your fingertips: 

Conference Presentations On-Demand 

• SBS Annual Conference & Exhibition (11th through 16th) 

Virtual Courses On-Demand 

• Introduction to Biomarkers and Their Utilization in Pharmaceutical Science 

• Pharmacodynamics for Drug Discovery 

• Human Primary Cells & Stem Cells in Drug Discovery Application 

• Fundamentals of ADME and Toxicology Assessment for Pre-Clinical Drug Discovery 

• Enzymology for Drug Discovery 

• Label-Free Technologies for Drug Discovery and Physiology 

• And more 

Global Symposia On-Demand 

• SBS Stem Cell Symposium 

Learn from the convenience and 

comfort of your home or office. 

Visit SLAS.org/events/on-demand.cfm 

for complete details, to register, and to 

stay current on available topics!


What’s New and Exciting at SBS 2011 

During this five-day event more than 2,000 scientists, innovators, researchers and industry 

analysts from around the globe gather to learn about the latest trends and basic and 

applied research that are transforming the way new pharmaceuticals are developed. 

SBS 2011 offers: 

• Enhanced SLAS Career Connections—see page 16 

• Engaging Keynote Presentations—see page 18 

Provides a forum for job seekers and employers to connect, and career 

coaches offering free coaching services to participants by appointment. 

» SBS Achievement Award winner Robert J. Lefkowitz, M.D., Duke University 

» SBS Accomplishment Award winner Brian Shoichet, Ph.D., University of California, San Francisco 

» Hugh Rosen, M.D., Ph.D., The Scripps Research Institute 

• 15 Diverse Scientific Sessions Organized Into Three Tracks—see page 30 

» Innovations in the Screening Sciences 

» Translational Research 

» Sequenced Genomes: Reducing Opportunities to Practice 

• Enhanced Exhibit Hall Hours and New Exhibit Hall Receptions—see page 109 

Enhanced exhibit hall hours ensure that participants have plenty of time for convenient, hands-on exploration of new 

technologies and to discuss new techniques with exhibitors. In addition, this year we have added Exhibit Hall Receptions 

during the last hour of open exhibits on Monday and Wednesday. These receptions allow participants to visit exhibitors 

with whom they haven’t yet connected while convening with friends and colleagues and enjoying complimentary 

beverages and hors d’oeuvres. 

• SLAS New Product Award Designation—see page 110 

Recognizes up to three of the best and most promising new products launched on the exhibit floor. 



SLAS Welcomes Its Corporate Members 

Society for Laboratory Automation and Screening invites companies in the field of laboratory science and 

technology for the drug discovery, agrochemical, biotechnology, chemical, clinical diagnostic, consumer 

product, energy, food, forensic, pharmaceutical, security and other industries to take advantage of SLAS 

Corporate Membership. In addition to providing many marketing benefits, Corporate Membership also 

offers organizations a number of administrative and financial advantages. For more information on SLAS 

Corporate Membership opportunities, visit slas.org/community/corporate_members.cfm or contact 

Amy McGorry at +1.877.990.SLAS (7527) ext. 101 or amcgorry@slas.org 

Sterling Corporate Members 

Agilent Technologies (www.chem.agilent.com) 

Agilent Technologies is a leading manufacturer of automation platforms and benchtop instrumentation for laboratory processes. 

Agilent’s suite of innovative products and commitment to service provide a winning combination for complete automation 

solutions. To learn more about our innovative instruments and how we can meet your automation needs today and in the future, 

please contact an Agilent sales representative. 

Axygen, Inc. (www.axygen.com/) 

Known for innovation, Axygen, Inc. is a world-wide manufacturer specializing in consumables for automation and high-throughput 

screening, PCR products, sealing options, reservoirs and deep-well plates, and general laboratory plastics—including Maxymum 

Recovery pipette tips and micro-tubes. Platforms supported include Tecan, Beckman, V-11, Zymark, PerkinElmer, Packard, 

Hamilton, and many more… 

Balluff (www.balluff.com) 

Balluff is a global manufacturer of sensing and feedback devices used in instrument stop/start control, precision positioning 

(linear and rotary), precision liquid level measurement, RFID tracking, vision sensing, and cylinder/valve control. Balluff presents 

many proven, cost-effective, and “off-the-shelf” solutions for integration into a wide range of automated laboratory instrument 

processes. Together with a network of experienced automation integration specialists and machine builders, Balluff will be there 

to assist you with successfully achieving your laboratory automation goals and help in providing high-throughput rates and 

error-free processes with the least amount of wasted time and materials as possible. 

Boca Bearing (www.bocabearings.com) 

The Boca Bearing Company has been an industry leader in ceramic hybrid, full ceramic and standard bearing technology since 

1987. With sizes ranging from as small as 3 millimeters in addition to flanged sizes, Boca Bearings has an extensive inventory of 

special sizes and styles, including hybrids, phenolic caged, plastic caged, three piece thrust bearings and more. Currently, Boca 

Bearing Company has over 5000 different sizes and well over 3 million items in stock. Boca Bearings can easily help you find the 

right bearings suitable for many specialty applications. 



Computype (www.computype.com/laboratory) 

Computype is a leading manufacturer of labels designed for use in laboratory automation. Computype offers Barcode and 

Data Matrix identification products for your plates, tubes, slides, and other labware that allow you to focus on the task at 

hand. We’ll work with you to build solutions tailored to fit your needs using pre-printed and blank labels, label printers, 

automatic label applicators, software, and our Label Ease pre-labeled labware service. 

Corning (www.corning.com/lifesciences) 

As a leading developer, manufacturer and global supplier of scientific laboratory products for more than 90 years, Corning 

is the trusted partner of researchers seeking new approaches to increase efficiencies, reduce costs and compress timelines 

in the drug discovery process. Using our unique expertise in the combined fields of optics, materials science, surfaces, and 

biology, we provide a full range of innovative solutions that improve productivity and enable breakthrough discoveries. 

Douglas Scientific (www.douglasscientific.com) 

Revolutionary High Throughput Screening on a patented, continuous Array Tape platform. Our patented tape automation has 

transformed traditional microplate processing by delivering disruptive throughput and cost savings for our laboratory clients. 

Our modular platform enables the flexibility to address various screening processes and chemistries. 

FlexLink Systems, Inc. (www.flexlink.com) 

As the “First Choice for Production Logistics,” FlexLink provides profitable automation solutions to demanding world-leading 

customers. Based on our unique application experience and global network, we offer innovative production solutions. For 

over 20 years, FlexLink has provided quality solutions to a variety of markets, including the Pharmaceutical and Medical 

Device industries. We offer custom solutions, standard reconfigurable modules, and software that allows for efficient, 

variable, and progressive production flow, batch control, and traceability. Our conveyor platforms significantly increase 

lab efficiency, reduce cost, are compact, and easy to integrate. We offer RFID for dynamic routing and automatic QA. 

High efficiency motor technology substantially lowers your energy consumption while intelligent drives and puck handling 

units afford gentle handling of products. 

Gems Sensors & Controls (www.gemsmedicalsolutions.com) 

For over 50 years Gems Sensors & Controls has been developing, designing and manufacturing fluidic systems, from simple 

components to complex systems. By leveraging our expertise and technologies, Gems is able to deliver custom, engineered 

fluidics systems and integrated sub-assemblies to OEMs. As a preferred supplier of level, flow and pressure sensors, solenoid 

valves, pumps and related sub-assemblies, we combine our unique array of intelligent sensors, world class lean manufacturing 

tools and ISO certified quality processes to significantly increase efficiency, productivity and quality. Your design or ours; we 

build, test and ship to meet your needs. 



INHECO GmbH (www.inheco.com) 

INHECO GmbH is a leading manufacturer of innovative and high precision thermal management products for LabAutomation 

& Medical Lab Applications. Our standard and OEM solutions include temperature controlled shakers, heated and cooled 

positions, thermal cyclers, incubators, temperature controllers and verification tools. 

Labcyte, Inc. (www.labcyte.com) 

We move liquids with sound! Labcyte Echo systems are powered by acoustic droplet ejection, using sound energy to transfer 

ultra-low volumes of liquids. This ‘touchless’ technology provides better results by eliminating pipette tips and compound loss on 

surfaces, while saving consumables costs. Accuracy is maintained from the first drop through the last for a wide variety of fluids. 

Prepare assay plates for siRNA screening, compound screening with biochemical and cell-based assays, PCR reactions and more 

all on a single liquid handling platform, with no tips and no cross-contamination. Labcyte Echo, POD and Deerac liquid handling 

systems are the leaders for miniaturizing biological assays. 

Labman Automation Ltd. (www.labman.co.uk) 

Bespoke automation, machine design, device manufacture all under one roof at Labman. We provide a truly flexible approach 

to helping individual scientists or whole laboratories reach their goals faster and cheaper with one-off specialist equipment. 

Labman customizes its machines to suit your application; we don’t customise your application to suit our machines. We provide 

guide quotes, short reports and detailed designs. Alternatively, Labman runs an encoded website project management facility 

for customers with direct hands on design requirements. Labman make anything from PTFE coated clips to lights out automated 

analytical laboratories. 

LabVantage Solutions, Inc. (http://www.labvantage.com) 

LabVantage Solutions, Inc., an innovative global provider of enterprise solutions tailored for leading laboratories, serves discovery, 

development, formulation, process research, raw material testing, and quality management laboratories across multiple industries. 

LabVantage’s SAPPHIRE, a zero-footprint laboratory information management suite, is tailored to manage an organization’s 

critical laboratory information across its worldwide R&D pipeline and manufacturing supply chain to optimize productivity and 

more effectively share knowledge. LabVantage is headquartered in Bridgewater, NJ, U.S.A, with direct or partner coverage in the 

United Kingdom, Europe, EMEA and Asia Pacific. 

MagneMotion Inc. (www.magnemotion.com) 

MagneMotion provides Linear Synchronous Motors (LSMs) and advanced transport solutions for high performance assembly 

and manufacturing automation based on our advanced electro-magnetic technology and controls. The systems are ideal for 

applications such as assembly automation, lab automation, pharmaceutical manufacturing, packaging, food and beverage and 

medical device manufacturing to name a few. MagneMotion systems offer higher throughput and production capacity through 

independent and bi-directional payload propulsion and control, moving payloads at varying speeds to positions along a guideway 

system, also suitable for cleanroom environments (IP 65). MagneMotion’s next generation transport systems replace outdated 

technologies, such as belt and chain conveyors. MagneMotion’s LSM technology is embodied in two product lines, MagneMover 

LITE, for payloads less than 2kg and the QuickStick line, for payloads up to metric tonnes. 



METTLER TOLEDO (http://www.mt.com/quantos) 

QUANTOS is the world’s first benchtop system for automatically dispensing small sample quantities of powders. At its heart 

is an intelligent dispensing head including storage container for dispensing highly potent or hazardous powdery substances. 

Thanks to the high-precision mechanism and intelligent electronics, the dispensing heads are perfectly adapted to the dispensing 

instrument. Each dispensing step moves closer to the target weight without exceeding tolerances. The dispensing instrument 

is based on proven METTLER TOLEDO weighing technology, which controls and monitors the entire dispensing process. 

QUANTOS dispenses with highest precision up to 20 times faster than by hand - and with greatly improved safety! At the touch 

of a button QUANTOS dispenses directly, accurately, and automatically into a great variety of containers. Even highly experienced 

hands struggle to attain this precision: QUANTOS dispenses to 0.5 mg with 0.005 mg readability. 

Bronze Corporate Members 

HEMCO Corporation (http://www.hemcocorp.com/) 

HEMCO Corporation manufactures innovative enclosures to isolate lab robotics and automated processes. Enclosures are 

engineered and built to meet exact size and design requirements depending on the application. Enclosures can have HEPA 

filtered supply for clean workstation needs, vented exhaust for the removal of hazardous fumes, temperature control equipment 

to maintain strict environmental requirements, and HEPA- in and HEPA-out systems for bio-containment applications. HEMCO 

also offers clean rooms from ISO 5 (class 100) to ISO 8 (class 100,000). Sizes, door options, airlocks, pass thru’s, lab furniture, 

and environmental control are a sampling of features that can be a part of our clean room system. 

Invetech (www.invetech.us) 

Invetech provides innovative contract development and manufacture for devices, instruments, consumables and custom 

automation. For more than 20 years, Invetech has worked with leading in-vitro diagnostics, life sciences, drug discovery and 

pharmaceutical companies. Our team of 200+ professionals use systematic ISO 9001, QSR compliant development processes 

and FDA registered manufacturing facilities, to deliver high-quality, fast-to-market results. 

MICROMO (www.micromo.com) 

MICROMO is a leader with full service micro motion solutions. MICROMO offers excellence in micro motor and encoder 

technology as well as design customization. MICROMO brings together value-added services and cutting-edge technologies 

from around the world through high efficiency, high performance offerings, such as brushed, brushless, stepper, thin-profile DC, 

piezoelectric and linear motors for diverse applications (www.micromo.com). Founded in 1962 and based in Florida, MICROMO 

is a member of the FAULHABER Group and represents FAULHABER products in the Americas. 



General Information 

Attire 

Casual business attire is recommended during all 

conference sessions, special events and in the Exhibit Hall 

(Men—slacks, polo shirts; women—slacks, skirts.). Please 

note, some restaurants may require a sports coat and/or 

tie. You may also want to wear a light jacket or sweater, 

as meeting rooms are air conditioned. 

Conference Location 

Gaylord Palms Resort and Convention Center 

6000 W. Osceola Parkway; Kissimmee, Florida 34746 

+1.407.586.0000; www.gaylordhotels.com 

Conference Badges 

Your SBS 2011 badge represents your admission ticket to the 

conference, special events and the Exhibit Hall. The SLAS 

policy is firm. We ask that participants display their badge 

prominently upon entering all SLAS and conference functions. 

Exhibits 

Location: Exhibit Hall (Located on the lower level 

of the Gaylord Convention Center) 

Monday, March 28 11:00 am – 6:30 pm 

Tuesday, March 29 12:00 – 4:30 pm 

Wednesday, March 30 12:00 – 5:30 pm 

Opening Ceremony/Ribbon Cutting 

Monday, March 28 11:00 am 

SLAS extends sincere appreciation for the support 

of exhibitors. 

Electronic Devices 

As a courtesy to meeting participants, electronic devices 

must be operated in silent/vibrate mode within specific 

sessions; devices that beep, ring, etc. are prohibited. 

SLAS asks that you please do not conduct cell phone 

conversations while attending the scientific sessions. 

Your cooperation is appreciated. 

IKON Business Center 

Location: Across from the “Jump for Joy” Dolphin Fountain, 

Gaylord Convention Center 

Open everyday, 7:00 am to 8:00 pm 

24-hour Internet access, 24-hour self-service 

printing, and copying 

IKON Business Center offers large document reproduction, 

offset printing and bindery services. For last-minute changes 

or projects, the business center offers 24-hour self-service 

printing and copying. 

12 | SLAS.org/events/sbs11 

Internet Connectivity Options 

All SBS Conference attendees who are staying at the Gaylord 

Palms have free unlimited use of wired and wireless internet in 

the sleeping rooms. If you are not staying at the Gaylord Hotel 

or you do not want to walk back to your room, you may utilize 

the Internet Café in the exhibit hall during open hours. Please 

note the computers are on a first-come, first-served basis 

and we request you limit your time to 15 minutes per session. 

Wireless connections are available for $9/day in the hotel 

lobby areas (this does not include the meeting lobby areas 

in the Gaylord Convention Center). You may also utilize the 

computers and internet at the IKON Business Center at their 

posted rates. No free wireless connections are available in 

the convention center space. 

Posters 

While posters remain up throughout the day of presentation, 

they are only staffed by the authors as noted below: 

Monday Poster Session (MP) 

11:30 am – 1:00 pm (presenters are available) 

Tuesday Poster Session (TP) 

12:00 – 1:30 pm (presenters are available) 

Wednesday Poster Session (WP) 

12:00 – 1:30 pm (presenters are available) 

Press Conferences 

Press conferences are open to registered press only. 

For an updated schedule of press conferences, stop by 

the SBS 2011 Press Office located in Destin 1, Gaylord 

Convention Center. 

Printed Program and Abstracts 

The title and abstracts printed in this program are entered 

online by authors. It is not possible to fully edit this material. 

Information is subject to change. 

Refreshments (Boxed Lunch) 

Location: Exhibit Hall (Located in the lower level 




Wednesday, March 30 12:00 – 1:30 pm

Receptions 


Monday, March 28 

SBS Welcome/Networking Reception 

5:00 – 6:30 pm, Exhibit Hall 

Join the exhibitors in welcoming the SBS attendees to Florida. 

Light hors d’oeuvres and beverages are served. 

Wednesday, March 30 

Reception in the Exhibit Hall Celebrating 

JBS 2010 Authors 

4:30 – 5:30 pm 

Join your fellow conference attendees as the poster 

winners are announced! Light hors d’oeuvres and 

beverages are served. 

SBS 2011 Beachcomber Bash 

7:00 – 10:00 pm, Gaylord Palms Resort, 

South Beach Pool 

Join your friends and colleagues poolside at the Beachcomber 

Bash, featuring PerkinElmer’s band “Molecular Groove,” for 

cold beverages, fabulous desserts, and a rockin’ good time. 

Registration 

Location: Lobby (Located on the lower 

level of the Gaylord Convention Center) 

Sunday, March 27 7:30 am – 5:00 pm 


Tuesday, March 29 7:30 am – 5:30 pm 

Wednesday, March 30 7:30 am – 5:30 pm 

Thursday, March 31 8:30 am – 12:30 pm 

SLAS On-Demand Offers Scientific 

Education Around the Clock 

Location: Lobby (Located on the lower 

level of the Gaylord Convention Center) 

Sponsored By: 

Sponsored By: 

Tuesday, March 29 7:00 am – 5:30 pm 

Wednesday, March 30 8:00 am – 2:00 pm 

SLAS On-Demand is a powerful resource to help keep you 

in-the-know on relevant and timely scientific topics from leaders 

in the field. Choosing from world-class podium presentations 

and instructional seminars, you can decide when and how to 

take advantage of these on-demand learning opportunities. 

The synchronized audio allows you to watch the slides and hear 

the presentation as it was given onsite at the event. Flexible 

formats allow you to watch on portable devices—such as the 

iPad, BlackBerry and iPhone—as well as on your computer. 

So, catch a conference session you missed, share an 

exceptional session with colleagues, or use SLAS On-Demand 

to reference presentations even if you heard them live the first 

time around. SLAS On-Demand materials sold during SBS 2011 

and available online at slas.org/events/ondemand.cfm. 

Shuttle Service to Theme Parks 

Gaylord Palms offers complimentary scheduled shuttle 

bus service to Walt Disney World theme parks and 

Downtown Disney. A daily schedule is available at the 

concierge desk. 

Smoking 

There is no smoking permitted anywhere in the 

convention center. 

Tape Recording/Video Recording Policy 

Please observe the SLAS policy which prohibits operation 

of tape recorders, video recorders, cameras, or camera 

phones, except for official association equipment, at all 

conference sessions, committee meetings, in the Exhibit 

Hall, and during the plenary sessions. Note: Throughout 

SBS 2011 we will be videotaping and taking photographs 

to be used for future SLAS promotions. If you do not wish 

to appear on camera, please notify the videographer or 

photographer and your request will be honored. 

Ribbon Guide 

Please feel free to approach any volunteer leader 

or team member with a question or concern. 

Ribbon Pickup—Be sure to pick up your ribbon 

at the registration desk located on the lower 

level of the Gaylord Convention Center. 

» Awards and Grants 

Advisory Committee 

» Board of Directors 

» Committee Member 

» Conference Chair 

» Education Advisory 

Committee 

» Emeritus Member 

» Exhibitor 

» Finance Advisory 

Committee 

» Innovation AveNEW 

Panel 

» Innovation Award Finalist 

» Innovation Award Panel 

» JALA Author 

» JALA Editorial Board 

» JBS Author 

» JBS Editorial Board 

» Membership Advisory 

Committee 

» New Product Award 

Judge 

» Poster Judge 

» Poster Presenter 

» Press 

» Program Advisory 

Committee 

» Scientific Committee 

» Section Executive 

Council 

» Session Chair 

» Short Course Instructor 

» SLAS Member 

» SLAS Professional Team 

» Speaker 

» Special Interest Group 

» Sponsor 

» Student and Early Career 

Professionals Committee 

» Tony B. Academic Travel 

Award Winner 

» Young Scientist 

Award Winner 



SBS 2011 Beachcomber Bash 

Wednesday, March 30, 2011, 7:00 – 10:00 pm 

Location: South Beach Pool 

Rock the House at the SBS 2011 Beachcomber Bash 

Celebrate the energy of SBS 2011. Reminisce with old friends. Build relationships 

with new friends. Collaborate with colleagues. Enjoy a fantastic spread of 

complimentary fine food and beverages. And let the good times roll. Join us 

on Wednesday evening for the Beachcomber Bash, featuring Premier Sponsor 

PerkinElmer’s very own rock band, Molecular Groove, the “hardest working band 

in science!” The Beachcomber Bash, sure to blow the roof off the Gaylord Palms 

Resort, is the perfect time to kick back, relax, reflect and renew! 


Sponsored by:


SLAS Member Center 

Welcome to the 

SLAS Member Center 

Location: Exhibit Hall (Located on the lower level 


Meet SLAS leaders and staff; get together with other members and 

friends; learn more about SLAS programs and services; listen as 

The Lab Man conducts podcast interviews; take an up-close look 

at the winning student posters; relax and enjoy light refreshments. 

Plus… 

Take a JBS Break! 

FREE 10 MINUTE MASSAGE compliments 

of the Journal of Biomolecular Screening. 

(Services are limited and provided 

on a first come, first served basis.) 

Passport to Prizes 

Drawing: Wednesday, March 30, 4:30 pm 

New to SBS 2011, don’t miss our Passport to Prizes game. 

Make sure you play and enter to win great prizes! Prizes 

include a Kindle, iPad, iPod Touch, Bose headphones and 

other electonics, as well as an array of gift cards from 

American Express, Southwest Airlines and Amazon.com. 

Meet The Lab Man 

Join the renowned Lab Man in the 

SLAS Member Center during live 

recordings of a series of podcasts: 

Monday, March 28, 3:00 pm 

Learn More About SLAS Special Interest Groups 

Tuesday, March 29, 1:00 pm 

Meet the First Place Winner of the SBS 2011 Student 

Poster Competition 

Tuesday, March 29, 3:00 pm 

Preview the New (Coming Soon!) SLAS E-Zine and E-Brief 

Wednesday, March 30, 1:00 pm 

Talk With Representatives of the Three Companies Honored 

With SBS 2011 New Product Award Designations 

Tony B. Academic 

Travel Award Winners 

SLAS selected seven up-and-coming 

researchers as SBS 2011 Tony B. Academic 

Award recipients. Each recipient receives 

complimentary travel, hotel accommodations 

and registration for SBS 2011 and participates 

as a poster presenter. 

Congratulations Tony B. Academic 

Travel Award Winners: 

Arjan van Adrichem, Institute for Molecular 

Medicine; Discovery of Small Molecule 

Inhibitors of the Putative Oncoprotein 

MgcRacGAP 

Emmanuel Sturchler, SCRIPPS; 

GABAB Receptor Allosteric Ligands 

Exhibit Pathway-Selective and Context- 

Dependent Effects 

Joong Hyun Kim, Korea Research Institute 

of Bioscience & Biotechnology; Instrument- 

Free and High-Throughput Screening of 

Mutagenic/Carcinogenic DNA Sensitizing 

Drugs Using Gold Nanoparticles and 

Functional DNAs. 

Ju Hun Yeon, Seoul National University; 

Blood-Brain Barrier and Brain Vessel 

Formation Using a Microfluidic Platform 

Men-Wong Taing, The University of 

Queensland; In-Vitro Assessment of Mango 

Extracts and the Phytochemicals Resveratrol, 

Quercetin, Mangiferin and epigallocatechin 

Gallate on Lipid Accumulation in a Mouse 

Adipocyte Cell Line 

Nishith Gupta, Humboldt University; 

Essentiality of a Constitutive Pan-Hexose 

Permease for the Plasmodium Life Cycle 

and Transgenic Models for Screening of 

Anti-Malarial Sugar Analogs 

Travis Moore, Seoul National University; 

Microfluidic Platform for High-throughput 

Drug Screening of Angiogenesis Inhibitors 

During Endothelial Vessel Formation and 

Anastomosis 


Job Seekers 


SLAS Career Connections is one of the select 

few highly discrete, automated employment 

programs that brings together its online 

professional services with its respected 

career center and development sessions 

at SBS 2011. 

Monday, March 28, 11:00 am – 6:30 pm 

Tuesday, March 29, 12:00 – 4:30 pm 

Location: Gainesville 

In response to the constricting job market around the world, SLAS introduces SLAS Career Connections. 

Career advisor Marshall Brown, PCC, of Marshall Brown and Associates, Washington, D.C. will staff SLAS 

Career Connections at SBS 2011. Together with colleague Alan De Back, Marshall Brown will provide 

professional and discrete career services for SBS 2011 participants. Career advisors are on hand for private, 

one-to-one dedicated time to conduct mock interviews, review résumés, provide coaching and networking 

guidance, and strategize market opportunities with job seekers and hiring managers. This is a free service. 

SLAS Career Connections at SBS 2011 provides 

job seekers a means to browse the job boards, 

and network with recruiting professionals. 

» Online Résumé Submission 

» Search Jobs Available At SBS 2011 

» Free! One-to-One Career Coaching Sessions 

Employers 

Your company can conduct highly confidential 

and professional in-person interviews, and have 

a major presence in an informal setting that nurtures 

networking and relationship building. SBS 2011 

posting packages are available. 

» Special Job Posting Rates Available for SBS 2011 

» Private Interview Space Available 

» Access to over 2,000 SBS 2011 participants 

» Enhanced Career Coaching Services at SBS 2011 

» Marshall Brown and Associates partners with 

SLAS to provide FREE services 


New! Maximize 

Your Conference 

Experience Through 

Effective Networking 

Monday, March 28, 7:30 – 8:30 am 

Location: Sarasota 

Learn how to best and most effectively 

utilize your time by connecting with the 

right people at SBS 2011. In this session, 

Marshall Brown, Career and Executive 

Coach, offers helpful tips and tools to 

facilitate your interactions with peers and 

leaders in the scientific community during 

your visit to Orlando. This session looks 

at key strategies for developing personal 

business relationships that help you get 

things done, make connections and build a 

strong framework for your career success.


Special Education Sessions 

Sunday, March 27, 1:00 – 4:00 pm 

BioAssay Ontology: Development of an Industry Standard for the Description and Categorization of Small Molecule 

High-Throughput Screening Data 

Location: Miami 1–2 

Presenters: Stephan Schürer, University of Miami; Vance Lemmon, University of Miami 

Large and diverse data sets that are generated in high-throughput screening (HTS) campaigns in industry, non-profit, and 

academic organizations are presently difficult to explore. We have begun to develop a bioassay ontology and software tools to 

formalize the knowledge in HTS data sets in order to facilitate their analysis and integration with other databases. This interactive 

program presents the progress that has been made to date, demonstrates software that we have developed and seeks feedback 

from the community. Individuals interested in assay standards, analysis and integration of HTS results should participate. This 

project is supported by a grant from the National Human Genome Research Institute. 


Analytical and Life Science Systems Association (ALSSA) 

(Invitation Only) 

Location: Miami 

This exclusive invitation-only briefing assesses several recent developments and trends in laboratory automation technologies 

and applications and the strategic implications for users and suppliers. Featured speakers include senior level executives from 

customers and users from both the pharma and food processing industries. 

Monday, March 28, 12:15 – 1:15 pm 

SLAS Strategic Plan Town Hall 

Location: Daytona 2 

Successful organizations require a strategic plan founded in sound, systematic and rational principles, and supported 

by diligent implementation, monitoring and evaluation. As the first step in establishing results-based accountability for 

the future growth of SLAS, the SLAS Strategic Plan Working Group began by addressing these essential points: Where 

are we; what do we have to work with; where do we want to be; and how do we get there? The Working Group and SLAS 

professional team members researched, debated, developed and ultimately documented this inaugural strategic plan. 

The SLAS Board of Directors then took its turn considering, discussing and debating the plan before unanimously 

approving it in September. As a member-driven society, however, our work is just beginning. 

This plan is not a rigid step-by-step recipe of next steps. It is a multi-dimensional context that will guide our decisions 

and a framework to measure our progress in the months and years ahead. Because this is a major time of transition for 

our newly formed organization, we expect many elements and pressures to impact the organization, however, continued 

adherence to this plan will ensure that our focus remains true to our mission and goals. 

With this in mind, members of the Strategic Plan Working Group, Board of Directors, and the professional team need to 

hear from you—the SLAS members. Please take advantage of this meeting opportunity to voice your ideas and perspective 

to help us further refine this first-ever SLAS strategic plan. 



Thought-Provoking Keynote Presentations 

Thought-provoking presentations by impressive scientific pacesetters offer personal insights into innovation 

and achievement. Learn from them and be inspired by them. 


Location: Osceola A 

SBS Achievement Award Winner; 9:00 am 

Robert J. Lefkowitz, M.D., Duke University School of Medicine, Durham, North Carolina 


Beta Arrestin Mediated Signaling by 7 Transmembrane Receptors: New Therapeutic Opportunities 

Robert J. Lefkowitz studies receptor biology and signal transduction and is best known for his detailed 

characterizations of the sequence, structure and function of the beta-adrenergic receptor and the proteins 

required for its regulation. Upon recognizing the sequence and functional homology with the visual protein 

rhodopsin, Dr. Lefkowitz proposed that adrenergic receptors and rhodopsin were related and the first 

members of a new protein family, the seven transmembrane receptors or G-protein coupled receptors. 

This superfamily is now known to be the largest, most diverse, and most therapeutically accessible. Author 

or co-author of more than 800 publications, Dr. Lefkowitz is among the most highly cited researchers in the 

fields of biology, biochemistry, pharmacology, toxicology, and clinical medicine according to Thomson-ISI. 

SBS Accomplishment Award Winner; 10:00 am 

Brian Shoichet, Ph.D., University of California, San Francisco, San Francisco, California 

Mechanism and Effects of Colloidal Aggregation in Early Discovery and Drug Pharmacology 

Research in the Shoichet Lab at the University of California, San Francisco seeks to bring chemical 

reagents to biology, using a combination of computational simulation and experiment. Using a protein- 

centric approach, new ligands are sought to complement protein structures. This typically involves 

molecular docking and the development of model experimental systems to experimentally test new 

algorithms. A new direction adopts a ligand-centric approach that seeks new targets for known drugs 

and reagents. Whereas this lacks the physical foundation of structure-based docking, it returns to an 

older, pharmacological view of biological relationships, bringing to it a quantitative model. A biological 

focus for both areas is the discovery of reagents to modulate GPCRs. This research is supported by 

the National Institutes of Health. 

Thursday, March 31, 12:00 – 1:30 pm 


Hugh Rosen, M.D., Ph.D., The Scripps Research Institute, Scripps, Florida 

Allostery and S1P Receptors: A Syzygy of Pharmacology and High-Resolution Crystal Structure 

Approaches to S1P1 receptor therapeutics will be presented, including uHTS approaches, pharmacological 

clues for allostery, pocket mapping by mutagenesis, insights from a high-resolution S1P1 crystal structure, 

implications for signal bias and the biological consequences of receptor modulation.

Your SLAS Membership Keeps You On Top of 

the Latest in Scientific Research and Discovery 

Welcome to the Society for Laboratory Automation and Screening (SLAS). Your membership makes you an integral 

part of an international community of more than 10,000 dedicated academic, industrial and government scientists, 

engineers and informatics professionals, and science-and technology-focused product development, marketing and 

sales specialists. Our community is committed to continuing education for those concentrated on research and 

discovery through laboratory science and technology. 

As part of this community and as a member of SLAS, you’ll have access to scientific educational opportunities, 

such as leading conferences and exhibitions, global symposia and virtual courses. You’ll glean practical information 

and insights through tools such as our world-renowned wiki LabAutopedia and our extensive online product directory 

The Market Place—each helping you to increase the effectiveness and efficiency of your work. And, you’ll find 

professional career-building and valuable networking opportunities that can open many doors to personal and 

professional success. 

SLAS Membership Highlights: 

Scientific Education 

• SLAS scientific conferences and exhibitions, 

global symposia, in-person and virtual courses 

• SLAS on-demand learning, offering numerous 

presentations from past events 

• LabAutopedia—our collaborative online compilation 

of the world’s laboratory technology knowledge 

Award-Winning Information Resources 

• The Journal of Biomolecular Screening (JBS): 

the leading peer-reviewed journal focusing on drug 

discovery sciences 

• The Journal of Laboratory Automation (JALA): 

the only peer-reviewed, multi-disciplinary international 

forum devoted exclusively to the advancement 

of technology 

Career-Building Resources 

• SLAS Career Connections—our totally automated 

and interactive employment program 

SLAS.org—The online hub of the SLAS community 

• Event information and access 

• The Learning Center, including the educational 

resources listed above and more 

• Access to information resources such as academic 

screening centers, standards and more 

• Member directories 

• The Market Place—a robust online product directory 

that places hundreds of new and existing technology 

products and services at your fingertips 

• Online directories of resources, institutions, 

terminology, and procedures 

• State-of-the-art social networking forums and special 

interest groups dedicated to information exchange 

in the laboratory 

• SBS News 

• The Buzz e-Newsletter 

• LabSnap e-Newsletter 

• The SLAS.org industry news RSS feed, 

updated daily 

• Career advice from professional career coaches 

• Special Interest Groups (SIGs) 

• Awards and grant information 

• Career resources 

• Industry news RSS feed 

• SLAS-specific news 

The Society for Laboratory Automation and Screening—Rich in Education, Information and Career Resources. 

Maximize your membership and take advantage of all that is available to help you advance laboratory science and technology. 

For membership information, call +1.877.990.SLAS (7527).


Conference Floor Plans 

Wireless internet access available in 

all guestrooms and hotel atrium areas. 



Freight Elevators Registration Service Areas Guest Elevators Restrooms 

KEY 

Down One Level to 

Bridge to Hotel 

Escalator to Exhibit 

Hall & Convention Center Entrance 

Sun Lobby 

Captiva 

Gainesville 

Osceola Lobby 

6 

6 

Sanibel Sarasota 

B D 5 1 2 3 1 2 3 5 

B 

D 

Sun Ballroom 4 

Miami Naples 4 

Osceola Ballroom 

1 2 3 1 2 3 

3 

3 

A C 2 

A C 

2 1 2 1 2 2 2 

1 

1 

1 1 

Stage 

Sun Foyer 

Daytona Destin 

Osceola Foyer 

Tallahassee 

1 2 3 

1 

Tampa 

2 

3 



Schedule-at-a-Glance 

Sunday, March 27 

7:30 am – 5:00 pm Registration Open; Location: Lobby 

8:30 am – 5:00 pm Short Courses 

» Automated Assays for Drug Discovery: A Toolbox Approach to Selecting an 

Appropriate Assay; Location: Osceola 1 

» BacMam101: Practical Aspects of Making and Using BacMam Vectors; 

Location: Osceola 2 

» Establishing Cell-Based Assays for Screening; Location: Osceola 3 

» In Vitro ADME Screening: Basic Concepts and Practical Methods; 


» Label-Free/Biophysics Methods for Screening; Location: Osceola 5 

» High-Content Screening; Location: Osceola 6 

9:00 am – 12:00 pm Exhibitor Workshops 

» From Well to Cell and Beyond: Widen the Physiological Perspective—Part One; 

Sponsored by PerkinElmer; Location: Naples 

10:00 am Short Course Coffee Break; Location: Osceola B 

12:00 – 1:00 pm Short Course Lunch; Location: Osceola B 

1:00 – 4:00 pm BioAssay Ontology: Development of an Industry Standard for the Description 

and Categorization of Small Molecule High-Throughput Screening Data; 


1:30 – 4:30 pm Exhibitor Workshops 

» Overcoming Kinase Inhibitor Discovery Challenges Using KINOMEscan, 

the Industry’s Largest Kinase Panel, and PathHunter ® HTS-Friendly Cell-Based 

Assays; Sponsored by DiscoveRx Corporation; Location: Sarasota 

» From Well to Cell and Beyond: Widen the Physiological Perspective—Part Two; 

Sponsored by PerkinElmer; Location: Naples 

2:30 pm Short Course Coffee Break; Location: Osceola B 

5:00 – 6:00 pm Short Course Reception; Location: Osceola B 



7:30 – 8:30 am Maximize Your Conference Experience Through Effective Networking; 


8:30 am Opening Session; Location: Osceola A 

9:00 am Keynote Speaker: SBS Achievement Award Winner, Robert J. Lefkowitz, 

Duke University School of Medicine; Location: Osceola A 

10:00 am Keynote Speaker: SBS Accomplishment Award Winner, Brian Shoichet, 

University of California, San Francisco; Location: Osceola A 

11:00 am – 6:30 pm Exhibit Hall Open 

11:00 am – 6:30 pm SLAS Career Connections; Location: Gainesville 

11:30 am – 1:00 pm Poster Session 1 and Lunch in the Exhibit Hall 

12:15 – 1:15 pm SLAS Strategic Plan Town Hall; Location: Daytona 2 


* Check the signs outside of the technical session 

rooms for speaker or schedule updates.


1:30 – 4:30 pm Technical Sessions 

» Track I: Session 1: SLAS Session: Next Generation Technologies: Microfluidics; 


» Track II: Session 1: Translational Research: Resources and Collaborative 

Paradigms in Academia, Not-for-Profit and Industry; Location: Osceola C 

» Track III: Session 1: Target Resuscitation: Drug Repositioning Opportunities; 

Location: Osceola B 

2:30 pm Coffee Break; Location: Exhibit Hall 

5:00 – 6:30 pm Welcome Reception; Location: Exhibit Hall 

Tuesday, March 29 


8:00 – 8:55 am Exhibitor Tutorials 

» Multiplexed Analysis of GPCR Signaling in Live Cells for Drug Discovery; 

Sponsored by: Promega; Location: Tampa 

» “Transcreening” Epigenetic Targets; Sponsored by: BellBrook Labs; 

Location: Naples 1–2 

» Drug Testing Using 3D Microtissues; Sponsored by: Insphero AG; 

Location: Osceola 1–2 

» Epigenetic Target Profiling - The Tailor-Made Solution for Cellular Epigenetic 

Selectivity Analysis; Sponsored by: KINAXO Biotechnologies GmbH; 

Location: Osceola 5-6 

» Introducing SRU Biosystems’ High Resolution Label-Free BIND ® Scanner; 

Sponsored by: SRU Biosystems; Location: Osceola 3–4 

» Enabling Drug Discovery Through the Use of Simple, Robust Automation; 

Sponsored By: BioTek Instruments, Inc.; Location: Tallahassee 

» Optimizing 3D Cell Growth Using Alvetex—A Unique New Product for Routine 

3D Cell Culture; Sponsored by: reinnervate; Location: Miami 1–2 

» Automated High Throughput and High Content Analysis by Flow Cytometry; 

Sponsored by: Beckman Coulter; Location: Sanibel 

» Introduction and Validation of the IonWorks Barracuda Automated 

Electrophysiology Instrument; Sponsored by: Molecular Devices, Inc.; 


9:00 am – 12:00 pm Technical Sessions 

» Track I: Session 2: Innovations in Screening Biology: Assays, Techniques and 

Instrumentation; Location: Osceola A 

» Track II: Session 2: Government, Foundation, NGO and Industry Funded Research 

Initiatives; Location: Osceola C 

» Track III: Session 2: Target Mining: Interpretation and Annotation, Data Analysis, 

Deorphaning; Location: Osceola B 

10:00 am Coffee Break; Location: Osceola Foyer 

12:00 – 4:30 pm Exhibit Hall Open 

12:00 – 4:30 pm SLAS Career Connections; Location: Gainesville 

12:00 – 1:30 pm Poster Session 2 and Lunch in the Exhibit Hall 



12:30 – 1:25 pm Exhibitor Tutorials 

» SPR in Early Phases of Low Molecular Weight Lead Discovery—Part One; 

Sponsored by: Bio-Rad Laboratories; Location: Naples 1–2 

» SPR-Based Analysis of Membrane Proteins Using MemLAYER—Part Two; 

Sponsored by: Bio-Rad Laboratories; Location: Naples 1–2 

» Accelerated High Content Screening and Homogeneous Quantification of 

Soluble IgG Levels; Sponsored by: Genetix; Location: Sanibel 

» Kinetic Profiling Services for Epigenetic Targets: Residence Time Optimization, 

Kinetic Selectivity, Fragment Screening and High Throughput Thermodynamics; 

Sponsored by: Proteros Biostructures GmbH; Location: Tampa 1-3 

» IonFlux System—Automated Electrophysiology With Plate Reader Simplicity; 

Sponsored by: Fluxion Biosciences, Inc.; Location: Osceola 1-2 

» A Multiplexed 96-Well Format Apoptosis Screening Assay Using the HTFC 

Screening System; Sponsored by: IntelliCyt; Location: Osceola 3-4 

» Case Studies for the High Throughput Transfection of Functional Targets Using the 

MaxCyte ® STX Scalable Transfection System; Sponsored by: MaxCyte, Inc.; 


» Label-Free Impedance Technology in Cardiac Safety Pharmacology, In Vitro 

Toxicology and GPCR HTS Drug Discovery; Sponsored by: Roche Applied Science; 


» Measure, Detect and Improve With RTS Tube Auditor; Sponsored by: RTS Life 

Sciences; Location: Miami 1-2 

» Profiling and Characterizing Kinases Using a Flexible Multi-Assay Screening 

System; Sponsored by: BMG LABTECH, Hudson Robotics and Promega; 

Location: Tallahassee 

» PathHunter ® Receptor Internalization: A Novel Platform for Quantifying GPCR 

Trafficking and Studying Ligand Bias; Sponsored by: DiscoveRx Corporation; 

Location: Daytona 

2:00 – 4:00 pm Special Interest Groups (SIGs) 

» Academic Outreach; Location: Sanibel 

» ADMET; Location: Tampa 

» Automation Quality Control; Location: Miami 

» Data and Image Analysis; Location: Osceola 1–2 

» Drug Repositioning; Location: Sarasota 

» Microplate Standards; Location: Tallahassee 

» Sample Management; Naples 1–2 

» Screen Design and Assay Technology; Location: Osceola 5–6 

» Stem Cells; Location: Osceola 3–4 


» Analysis of Post Translational Modifications in Cellular Signaling; 

Sponsored by: Cell Signaling Technology; Location: Osceola 1–2 

» Recent Advances in Label-Free Screening for Pharmaceutical and 

Biotherapeutic R&D; Sponsored by: ForteBio; Location: Osceola 3–4 

» Expanding the Boundaries of High-Content Analysis: Latest Tools, Software and 

Biology From GE Healthcare; Sponsored by: GE Healthcare; Location: Naples 1–2 

» User-Upgradable High Throughput Screening System—SpectraMax Paradigm 

Platform; Sponsored by: Molecular Devices, Inc.; Location: Sarasota 

» Efficient Analysis of Label-Free Data With Genedata Screener Kinetics Analyzer; 

Sponsored by: Genedata; Location: Osceola 5–6 

» Customization and Modular Assembly of Key Cell Biology Capabilities to 

Address Changing Needs in the Drug Discovery Workflow; Sponsored by: 

Life Technologies; Location: Tampa 

» Introducing the Access Laboratory Workstation to Easily Add Automation 

to Any Echo ® Liquid Handler; Sponsored by: Labcyte, Inc.; Location: Sanibel 1–3 

9:00 – 10:30 pm JBS VIP Reception for Authors (Invitation Only) 





8:00 – 8:55 am Exhibitor Tutorials 

» ADP-Glo Bioluminescent ADP Detection Platform: Sensitive Screening and Profiling 

of Kinases and ATPases; Sponsored by: Promega; Location: Tampa 

» Approaches to Automatable High Content Assays in 3D Extracellular Matrices; 

Sponsored by: BellBrook Labs; Location: Naples 1–2 

» Scaling up Your HCS Operations With Genedata Screener High Content Analyzer; 

Sponsored by: Genedata; Location: Osceola 5–6 

» Stem Cell Toxicology and Drug Discovery Applications: iCell Cardiomyocytes 

Plus Molecular Devices Screening Platforms; Sponsored by: Molecular Devices, Inc.; 


» Epigenetics Drug Discovery: Success Delivered by BioFocus; Sponsored by: 

BioFocus; Location: Osceola 1–2 

» An In Vitro Model of Acute Epilepsy Suitable for MTS: Synchronized Repetitive 

Calcium Oscillations in Primary Neurons Cultured in a 384- Well Microplate; 

Sponsored by Hamamatsu; Location: Miami 1–2 


» Track I: Session 3: Critical Reagents and Technologies in HTS to Lead Efforts; 


» Track II: Session 3: Molecular Discovery in Non-Traditional, Neglected and Rare 

Diseases; Location: Osceola C 

» Track III: Session 3: Applications in Consumer Products, Cosmetics, Nutraceuticals 

and Agriculture; Location: Osceola B 


11:30 am SLAS New Product Award Announcement; Location: Exhibit Hall 

12:00 – 1:30 pm Poster Session 3 and Lunch in the Exhibit Hall 

12:00 – 5:30 pm Exhibit Hall Open 


» Shifting Ligand Binding Assay Paradigm With Tag-Lite; Sponsored by: CisBio 

Bioassays; Location: Sarasota 

» Understanding The Dynamics Of Cell-Based Assays—From Designing The Assay 

To Finding Out What Went Wrong; Sponsored by: Corning Inc.; Location: Tampa 

» Best Practices: Microplate Washing Methodologies and Optimizing Liquid Handler 

Performance; Sponsored by: BioTek Instruments, Inc.; Location: Osceola 1–2 

» Use of Disposable Label-Free Real-Time Biosensors in the Drug Discovery of 

Monoclonal Antibodies; Sponsored by: ForteBio; Location: Osceola 3–4 

» RNAi Genetic Screening for Drug Target Discovery; Sponsored by: Cellecta; 


» Screening of Enzymes and Ion Channels Through a Combination of Unique 

Instrumentation, Reagents, and Software; Sponsored by: BMG LABTECH, Hudson 

Robotics and Life Technologies; Location: Tallahassee 

» Label-Free Compound Screening and Characterization of Interactions With Novel 

Membrane Receptor Targets Using Biacore SPR and MicroCal ITC Instruments 

From GE Healthcare; Sponsored by: GE Healthcare; Location: Naples 1–2 

» Meganucleases and TAL Nucleases: Efficient Tools to Engineer Isogenic Cell Lines 

for Drug Discovery; Sponsored by: Cellectis Bioresearch; Location: Miami 



2:00 – 4:30 pm Technical Sessions 

» Track I: Session 4: Innovations in Label Free, Multiplexed and High Content Assays; 


» Track II: Session 4: Case Studies for Hot Targets: From the Lab to Lead Compounds; 

Location: Osceola C 

» Track III: Session 4: The Application of Modern Drug Target Validation 

Technologies: Profiling, HT Sequencing, RNAi, cDNA, Compounds, Peptides, 

Proteins and Structural Biology; Location: Osceola B 

4:30 – 5:30 pm Reception in the Exhibit Hall Celebrating JBS 2010 Authors 

7:00 – 10:00 pm SBS 2011 Beachcomber Bash, Sponsored by PerkinElmer; 

Location: South Beach Pool 

Thursday, March 31 



» Track I: Session 5: Innovations in Screening and Sample Management: 

Technologies and Processes; Location: Naples 

» Track II: Session 5: Leveraging a National Resource: The Molecular Libraries 

Probe Development Network (MLPCN); Location: Osceola C 

» Track III: Session 5: Prediction and Elucidation of Target Liabilities; 



12:00 – 1:30 pm Closing Luncheon and Keynote Speaker: Hugh Rosen, The Scripps 

Research Institute; Location: Osceola A 


Join the SLAS Social Media Communities 

Our online communities are growing every day. Stay up-to-date 

and join in the discussions. Sign-up now!

Your SLAS Membership Keeps You On Top of 

the Latest in Scientific Research and Discovery 

Welcome to the Society for Laboratory Automation and Screening (SLAS). Your membership makes you an integral 

part of an international community of more than 10,000 dedicated academic, industrial and government scientists, 

engineers and informatics professionals, and science-and technology-focused product development, marketing and 

sales specialists. Our community is committed to continuing education for those concentrated on research and 

discovery through laboratory science and technology. 

As part of this community and as a member of SLAS, you’ll have access to scientific educational opportunities, 

such as leading conferences and exhibitions, global symposia and virtual courses. You’ll glean practical information 

and insights through tools such as our world-renowned wiki LabAutopedia and our extensive online product directory 

The Market Place—each helping you to increase the effectiveness and efficiency of your work. And, you’ll find 

professional career-building and valuable networking opportunities that can open many doors to personal and 

professional success. 

SLAS Membership Highlights: 

Scientific Education 

• SLAS scientific conferences and exhibitions, 

global symposia, in-person and virtual courses 

• SLAS on-demand learning, offering numerous 

presentations from past events 

• LabAutopedia—our collaborative online compilation 

of the world’s laboratory technology knowledge 

Award-Winning Information Resources 

• The Journal of Biomolecular Screening (JBS): 


discovery sciences 

• The Journal of Laboratory Automation (JALA): 


forum devoted exclusively to the advancement 

of technology 

Career-Building Resources 

• SLAS Career Connections—our totally automated 

and interactive employment program 

SLAS.org—The online hub of the SLAS community 

• Event information and access 

• The Learning Center, including the educational 

resources listed above and more 

• Access to information resources such as academic 

screening centers, standards and more 

• Member directories 

• The Market Place—a robust online product directory 

that places hundreds of new and existing technology 

products and services at your fingertips 

• Online directories of resources, institutions, 

terminology, and procedures 

• State-of-the-art social networking forums and special 

interest groups dedicated to information exchange 

in the laboratory 

• SBS News 

• The Buzz e-Newsletter 

• LabSnap e-Newsletter 

• The SLAS.org industry news RSS feed, 

updated daily 

• Career advice from professional career coaches 

• Special Interest Groups (SIGs) 

• Awards and grant information 

• Career resources 

• Industry news RSS feed 

• SLAS-specific news 

The Society for Laboratory Automation and Screening—Rich in Education, Information and Career Resources. 

Maximize your membership and take advantage of all that is available to help you advance laboratory science and technology. 

For membership information, call +1.877.990.SLAS (7527).


Short Course Program Overview 

Sunday, March 27, 8:30 am – 5:00 pm 

Automated Assays for Drug Discovery: 

A Toolbox Approach to Selecting an 

Appropriate Assay 


This course focuses on one central question: given a multitude 

of assay technologies available for a given target, how does 

one go about selecting an appropriate technology? What 

criteria should one examine during this process? This course 

describes a toolbox approach—a generic, flexible set of 

assay methodologies and shows how they can be applied to 

some of the major target classes in molecular and cell-based 

screening. Assay case studies are presented, and course 

participants will engage in discussions of toolbox formats 

comparing the robustness of different assays as well as 

cost and user-friendliness. 

Instructors 

E. Michael August, Boehringer-Ingelheim Pharmaceuticals, 

Inc. (Lead instructor); Mohammed Kashem, Boehringer- 

Ingelheim Pharmaceuticals, Inc.; Siqi Lin, Boehringer- 

Ingelheim Pharmaceuticals, Inc. 

BacMam101: Practical Aspects of Making 

and Using BacMam Vectors 


BacMam engineered recombinant baculovirus vectors can 

efficiently deliver expression cassettes to a wide variety of 

mammalian cell types. The ease of generation, the safety 

and the unparalleled experimental versatility of BacMam 

vectors makes transient gene delivery in support of cell-based 

assays a viable option for high-throughput screening. This 

course covers basic practical aspects of vector generation 

and provides detailed instruction on how to optimally utilize 

BacMam vectors for development and support of cellbased 

assays. There is plenty of time available during the 

class for discussion as well as Q&A. The course describes 

the basic principles of viral generation, insect cell culture 

and recombinant baculovirus growth procedures as well as 

provides details of how to develop BacMam based assays. 


Robert Ames, GlaxoSmithKline (Lead Instructor); Frederick 

M. Boyce, Massachusetts General Hospital; Jim Fornwald, 

GlaxoSmithKline; Elizabeth Davenport, GlaxoSmithKline; 

Tom Kost, GlaxoSmithKline; Christopher Kemp, Kempbio, Inc.; 

George Hanson, Life Technologies 


Establishing Cell-Based Assays for Screening 


Cell-based assays are essential tools in the drug-discovery 

industry. They are important in high-throughput screening as 

well as target identification and secondary compound profiling. 

Selecting the most appropriate assay from the large number 

available and establishing that assay within a minimal time 

frame are critical to a project’s success. This course begins 

with an overview of critical factors to consider for selection, 

maintenance, and characterization of cells necessary to 

develop successful cell-based assays for HTS. 

Specific application examples covered by individual 

instructors include: 

1. An overview of cell viability, cytotoxicity, and apoptosis 

assays including multiplexing with genetic reporters 

2. The scale-up and use of frozen cells for GPCR assays such 

as cAMP, cellular reporters, calcium mobilization or label-free 

electrical impedance measurements 

3. An overview of the application and use of RNAi technology 

for screening 


Terry Riss, Promega Corporation (Lead Instructor); Lisa Minor, 

InVitro Strategies, LLC; Geoffrey Bartholomeusz, UT M.D. 

Anderson Cancer Center; Eric Johnson, Merck 

In Vitro ADME Screening: 

Basic Concepts and Practical Methods 


This course covers principles and methods of in vitro ADME 

(Absorption, Distribution, Metabolism and Excretion) testing. 

Selected topics include solubility, plasma protein binding, 

absorption including Caco-2, metabolic stability, cytochrome 

P450 inhibition and induction. 


Charles L. Crespi, Becton Dickinson and Company 

(Lead Instructor); Anshul Gupta, AstraZeneca; 

Michael Rooney, AstraZeneca; David Stresser, 

BD Biosciences


Label-Free/Biophysics Methods for 

Screening 


Biophysical/label-free methods are becoming an important 

tool in lead finding and drug discovery complementing, but not 

replacing, more classical assay technologies. A collection of 

long-standing, “gold-standard” label-free methods are rapidly 

being augmented by novel, higher throughput techniques, 

presenting both an extensive but also confusing landscape 

of biophysics tools in drug discovery. A key question is how 

to enable efficient and more systematic use of the biophysics 

portfolio in early drug discovery programs. Ultimately they 

are expected to offer not only novel ways of hit finding, but 

also more efficient ways to identify and advance true hits for 

chemistry and later stage biology. This course focuses on 

those “biochemical” biophysics technologies with highest 

impact and applicability for screening and lead finding (e.g. 

protein thermal denaturation and aggregation [DSF aka 

Thermofluor, DSLS aka Stargazer]; SPR, interferometry and 

waveguide grating [e.g. SPR aka Biacore, Corning Epic, SRU 

BIND, BLI aka Fortebio]; NMR; calorimetry (DSC, ITC); mass 

spectrometry; dynamic light scattering]. In the focus of this 

short course are biochemical assay applications and the 

detection, quantification and qualification of ligand/protein 

binding events. 


Johannes Ottl, Novartis Pharma NIBR (Lead Instructor); 

Delphine Collin, Boehringer Ingelheim Pharmaceuticals, Inc.; 

Kristin Coan, Novartis Pharma AG 

High-Content Screening 


High-content screening is a powerful technology platform 

for implementing functional cell-based assays that allow 

truly multiparametric analysis in the physiological context 

of intact cells. This course provides a state-of-the-art overview 

of the components of HCS (instrumentation, fluorescent labels, 

HC assay development, automated image analysis and 

multi-parametric data analysis) together with some showcases 

of small molecule and RNAi high-content screens in industry 

and academia. 


Eberhard Krausz, Janssen Research & Development (J&J) 

(Lead Instructor); Stephan C. Schurer, The Scripps Research 

Institute Florida; Vance Lemmon, University of Miami; 

James G. Evans, Anon Consulting 



and join in the discussions. Sign-up now! 



Technical Session Program Overview 

Track I: Innovations in the Screening Sciences 

To stand still is to lose ground; innovation in High-Throughput Screening Technologies (HTS) is exploding. This track 

captures the excitement in all aspects of HTS. See what’s new in screening automation, instrumentation, detection 

technologies and sample management. 

Track II: Translational Research 

Well established as an essential tool in industry, the screening sciences have been embraced by academic institutions, 

not-for-profit organizations, government-funded labs and non-government organizations (NGOs). These organizations 

complement the work done in industry or form cross-functional patnerships to achieve transcendent goals. Come and 

hear how this shift is changing research and the relations between industry, government and academia. 

Track III: Sequenced Genomes: Reducing Opportunities to Practice 

The availability of sequenced genomes and the inevitability of inexpensive phenotyping have created huge opportunities 

in therapeutic agents and consumer products discovery. Come and share how and why screening sciences are ideally 

positioned to take advantage of these opportunities. 


1:30 – 4:30 pm Osceola A 


Check the signs outside of the technical session rooms for speaker or schedule updates 

Track I » Session 1: SLAS Session: 

Next Generation Technologies: Microfluidics 

Session Chairs: Bill Janzen, University of North Carolina at Chapel Hill 

and Scott Martin, St. Louis University 

1:30 – 2:00 pm Page 37 

Plenary: Micro- and Nanofluidic Devices: Acquiring Chemical and 

Biochemical Information Quickly From Small Quantities of Material; 

Michael Ramsey, University of North Carolina, Chapel Hill 

Enhanced Information From Microtiter Plate Screening by Scanning 

2:00 – 2:30 pm Page 37 Wells Integrated Into Microfluidic Devices; Dana M. Spence, Michigan State 

University 

3:00 – 3:30 pm Page 38 

Micro- and Nanofluidic Devices for Cancer Screening and Virus Sensing; 

Stephen C. Jacobson, Indiana University 

Perfusion Culture Microchamber Array Chip for High-Throughput 

3:30 – 4:00 pm Page 38 Cell-Based Assays; Shinji Sugiura, National Institute of Advanced Industrial 

Science and Technology (AIST) 

4:00 – 4:30 pm Page 38 

Well Plate Microfluidic Devices for Investigation of Dynamic Platelet 

Behavior Under Variable Shear Loads; Carolyn Conant, Fluxion Biosciences 

Track II » Session 1: Translational Research: 

1:30 – 4:30 pm Osceola C 

Resources and Collaborative Paradigms in Academia, 

Not-for-Profit and Industry 

Session Chair: Paul Burn, Sanford Research Center 

1:30 – 2:00 pm Page 40 Plenary: Putting Research Into Practice; Paul Burn, Sanford Research Center 

Changing the Rules for the Research “Game” in Academia—Accelerating 

2:00 – 2:30 pm Page 40 Discovery Through Novel Means of Collaboration; Mark Atkinson, 

The University of Florida 

3:00 – 3:30 pm Page 41 

Collaboration as a Central Strategy for Successful Translational Research; 

John Reed, Sanford-Burnham Medical Research Institute


3:30 – 4:00 pm Page 41 

4:00 – 4:30 pm Page 41 

1:30 – 4:30 pm Osceola B 

1:30 – 2:00 pm Page 43 

2:00 – 2:30 pm Page 43 

3:00 – 3:30 pm Page 43 

3:30 – 4:00 pm Page 44 

4:00 - 4:30 pm Page 44 


9:00 am – 12:00 pm Osceola A 

9:00 – 9:30 am Page 46 

9:30 – 10:00 am Page 46 

10:30 – 11:00 am Page 46 

11:00 – 11:30 am Page 47 

11:30 am – 12:00 pm Page 47 

Challenges and Successes of Translational Research in the Public Domain: 

Retrospective and Prospective Analyses and Case Histories of “Probes to 

Leads” From Six Years of the Molecular Libraries Program; Thomas “T.C.” 

Chung, Conrad Prebys Center for Chemical Genomics at Sanford-Burnham 

Medical Research Institute 

Translation in Action: MRCT's Centre for Therapeutics Discovery; 

Justin Bryans, MRC Technology 

Track III » Session 1: Target Resuscitation: 

Drug Repositioning Opportunities 

Session Chair: Roger Bosse, PerkinElmer 

Plenary: Drug Repositioning: How it Fits With Current Drug-Discovery 

Trends; Christopher A. Lipinski, Melior Discovery 

Prodrugs: Regulatory and Clinical Development Requirements For Approval; 

Ken Phelps, Camargo Pharmaceutical Services, LLC 

Exploring Ligand-Directed Functional Selectivity of GPCR With Bret-Based 

Biosensor Arrays and Label-Free Impedance Measurements; Linking 

Signaling Signature to Drug Efficacy; Michel Bouvier, Drug Discovery Group, 

University of Montreal 

A Rapid Assay for Identifying New Drug Candidates From Approved 

Drugs for Repositioning to Treat Giardiasis; Catherine Chen, NIH Chemical 

Genomics Center 

HTS for REST Inhibitors in Neural Progenies of Human ES Cells; 

Anselme Perrier, I-Stem 

Track I » Session 2: Innovations in Screening Biology: 

Assays, Techniques and Instrumentation 

Session Chair: Jonathan O’Connell, Bristol-Myers Squibb Company 

Plenary: The Evolution of HTS at Bristol-Myers Squibb: Enabling 

the Support of the Most Relevant Bio-Assays; Jonathan O’Connell, 

Bristol-Myers Squibb Company 

Etv6-NTRK3, A Constitutively Active Tyrosine Kinase Found in Variety 

of Tumors, is Unique in its Mechanism of Transformation; 

Jack Allen, Merrimack Pharmaceuticals 

High-Throughput Screening With Real-Time PCR: Reducing it to Practice; 

Andrea Weston, Bristol-Myers Squibb Company 

New Ion Channel Screening Technologies Enabling Development of High 

Quality and High-Throughput Assays in a Plate-Based Screening Group; 

Juha Kammonen, Pfizer 

Creating a Holistic Screening Strategy for Label-Free Technology in a Plate 

Based Screening Group; Rachel Russell, Pfizer Global Research & Development 



9:00 am – 12:00 pm Osceola C 

9:00 – 9:30 am Page 49 

9:30 – 10:00 am Page 49 

10:30 – 11:00 am Page 49 

11:00 – 11:30 am Page 50 

11:30 am – 12:00 pm Page 50 

9:00 am – 12:00 pm Osceola B 

9:00 – 9:30 am Page 52 

9:30 – 10:00 am Page 52 

10:30 – 11:00 am Page 52 

11:00 – 11:30 am Page 53 

11:30 am - 12:00 pm Page 53 


9:00 am – 12:00 pm Osceola A 

9:00 – 9:30 am Page 55 

9:30 – 10:00 am Page 55 

10:30 – 11:00 am Page 55 

11:00 – 11:30 am Page 56 

11:30 am – 12:00 pm Page 56 


Track II » Session 2: Government, Foundation, 

NGO and Industry Funded Research Initiatives 

Session Chair: Ken Duncan, Bill and Melinda Gates Foundation 

Plenary: Drug Discovery Focused on Neglected Diseases Through Initiatives 

Funded by Governments, Foundations and Private Donors; Ken Duncan, 

Bill and Melinda Gates Foundation 

The Importance of Metabolic Status to Tuberculosis Drug Discovery; 

Clifton Barry, NIAID, NIH 

Screening for Novel Antimalarials; R. Kip Guy, St. Jude Children’s Research 

Hospital 

Cancer Research Technology: Bridging the Industry-Academia Interface in 

Oncology; Tim Hammonds, Cancer Research Technology 

Simultaneous Screening of a Large Natural Product Library Against a 

Panel of 10 Anti-Apoptotic Proteins in Search of Novel Cancer Therapeutics; 

Paul Diaz, Sanford-Burnham Medical Research Institute 

Track III » Session 2: Target Mining: Interpretation 

and Annotation, Data Analysis, Deorphaning 

Session Chair: Andrew Su, Genomics Institute of the Novartis Research 

Foundation 

Plenary: The Gene Wiki: Crowdsourcing Knowledge Extraction From 

the Biomedical Literature; Andrew Su, Genomics Institute of the Novartis 

Research Foundation 

Systems and Personalized Medicine; Joel Dudley, Stanford University, 

School of Medicine 

Causal Reasoning on Biological Networks: Interpreting Transcriptional 

Changes; Daniel Ziemek, Pfizer Worldwide Research and Development 

Drug Effects Viewed From a Protein Network Perspective; 

William Loging, Boehringer-Ingelheim Pharmaceuticals, Inc. 

Understanding Lung Cancers by Whole Genome Sequencing; 

Jinfeng Liu, Genentech 

Track I » Session 3: Critical Reagents and Technologies 

in HTS to Lead Efforts 

Session Chairs: Ulrich Schopfer, Novartis Institutes for BioMedical Research 

and Achim Grenz, F. Hoffman-La Roche Ltd 

Plenary: Bridging the Gap Between Phenotypic Screens and Molecular 

Targets; Ulrich Schopfer, Novartis Institute for BioMedical Research, Inc. 

Identifying Helicobacter Pylori AddAB DNA Repair Enzyme Inhibitors Using 

a Novel Bacteriophage E. Coli Infectivity Assay in Highly Miniaturized 

Formats; Timothy Spicer, The Scripps Research Institute 

Target Identification and Validation Using Chemical and Functional 

Genetics Screening Approaches; Vic Myer, Novartis Institutes for Biomedical 

Research, Inc. 

HT RNAi Screening of Anti-Cancer Targets With Pooled shRNA Libraries; 

Alex Chenchik, Cellecta, Inc. 

Human “Knock-in” “Knock-out” Cell Lines for Precision Functional 

Genomics and Targeted Drug Discovery; Chris Torrance, Horizon Discovery 

Ltd, IQ Cambridge



Track II » Session 3: Molecular Discovery in 

Non-Traditional, Neglected and Rare Diseases 

Session Chair: Bob Hertzberg, GlaxoSmithKline 

9:00 – 9:30 am Page 58 

Plenary: Opening the Doors and Giving Back: GSK’s Strategy to Deliver 

Medicines for Diseases of the Developing Worlds; Bob Hertzberg, 

GlaxoSmithKline 

High-Throughput Screening to Identify Inhibitors of the Respiratory 

9:30 – 10:00 am Page 58 Chain of Mycobacterium Tuberculosis; Khisimuzi Mdluli, Global Alliance 

for TB Drug Development 

10:30 – 11:00 am Page 59 

The Development of RNA-Modulating Therapies; Judith C.T. van Deutekom, 

Prosensa Therapeutics BV, Leiden 

11:00 – 11:30 am Page 59 

Humanitarian and Commercial Cloud-Based Collaborative Drug Discovery; 

Kellan Gregory, Collaborative Drug Discovery (CDD), Inc. 

Potent and Selective Inhibitors of the Plasmodium Falciparum M18 

11:30 am – 12:00 pm Page 59 

Aspartyl Aminopeptidase (AAP) of Human Malaria Identified via a QFRET 

uHTS Campaign; Virneliz Fernandez Vega, The Scripps Research Institute, 

Scripps Florida 

Track III » Session 3: Applications in Consumer Products, 

9:00 am – 12:00 pm Osceola B Cosmetics, Nutraceuticals and Agriculture 

Session Chair: Sabrina Corazza, Axxam SpA 

9:00 – 9:30 am Page 61 

Plenary: New Frontiers for HTS Application: How and Why; Sabrina Corazza, 

Axxam SpA 

9:30 – 10:00 am Page 61 

Receptor Mediated Discovery of Novel Taste Modulators; Jay Slack, 

Givaudan Flavors Corp. 

10:30 – 11:00 am Page 61 

Insecticidal Compounds “Well” Spotted: Screening Live Bugs in a 

High-Throughput System; Juergen Langewald, BASF 

11:00 – 11:30 am Page 62 Needs of the Food and Beverage Industries; Anthony J. Clark, PepsiCo 

11:30 am – 12:00 pm Page 62 

Deorphanization and Characterization of Human Odorant Receptors 

in Heterologous Cells; Pierre Chatelein, TecnoScent 

Track I » Session 4: Innovations in Label-Free, Multiplexed 

2:00 – 4:30 pm Osceola A and High-Content Assays 

Session Chair: James Inglese, NIH Chemical Genomics Center 

Plenary: Quantitative High-Throughput Screening of Phenotypic Assays 

2:00 – 2:30 pm Page 64 Enabled by Laser-Scanning-Coupled Microscopy; James Inglese, NIH 

Chemical Genomics Center 

2:30 – 3:00 pm Page 64 

Kinetic Image Cytometry: Toxicity HCS in Human Cardiomyocytes 

for Early Drug Discovery; Jeffrey Price, Sanford Burnham 

3:00 – 3:30 pm Page 64 

Binding Assays in Biological Liquids Using Microscale Thermophoresis; 

Stefan Duhr, NanoTemper Technologies 

3:30 – 4:00 pm Page 65 

Use of Label-Free Technology to Monitor GPCR Desensitization; 

Patricia McDonald, Scripps Research Institute 

4:00 – 4:30 pm Page 65 

Enabling Lead Discovery at Epigenetics Targets With RapidFireTM Mass 

Spectrometry; Melanie Leveridge, GlaxoSmithKline 



2:00 – 4:30 pm Osceola C 

2:00 – 2:30 pm Page 67 

2:30 – 3:00 pm Page 67 

3:00 – 3:30 pm Page 67 

3:30 – 4:00 pm Page 68 

4:00 – 4:30 pm Page 68 

2:00 – 4:30 pm Osceola B 

2:00 – 2:30 pm Page 70 

2:30 – 3:00 pm Page 70 

3:00 – 3:30 pm Page 70 

3:30 – 4:00 pm Page 71 

4:00 – 4:30 pm Page 71 


9:00 am – 12:00 pm Naples 

9:00 – 9:30 am Page 73 

9:30 – 10:00 am Page 73 

10:30 – 11:00 am Page 73 

11:00 – 11:30 am Page 74 

11:30 am – 12:00 pm Page 74 


Track II » Session 4: Case Studies for Hot Targets: 

From the Lab to Lead Compounds 

Session Chair: Phillip Tagari, Amgen 

Plenary: Inhibitors of 2-OG Oxygenases for the Treatment of Anemia and 

Cancer; Phillip Tagari, Amgen Inc. 

Comprehensive Enzyme Profiling for Targeted Cancer Drug Discovery: 

A Target Class Approach to Histone Methyltransferases; Margaret Porter 

Scott, EpiZyme, Inc. 

Identification and Characterization of Potent and Selective Antagonists of 

the Nuclear Receptor RORc; Xiao Hu, Lycera Corporation 

Targeting the Ubiquitin Pathway: Beyond the Proteasome; Craig Allan Leach, 

Progenra Inc. 

Development of Novel Anti-Cancer Therapeutics That Reduce Tumor- 

Initiating Cell Frequency; Timothy Hoey, OncoMed Pharmaceuticals, Inc. 

Track III » Session 4: The Application of Modern 

Drug Target Validation Technologies: Profiling, 

HT Sequencing, RNAi, cDNA, Compounds, Peptides, 

Proteins and Structural Biology 

Session Chair: Daniel Sipes, Genomics Institute of the Novartis Research 

Foundation 

Plenary: Expanding the Utility of Miniaturized HTS: From Screening to 

Profiling and Target Identification; Daniel Sipes, Genomics Institute of the 


Technologies Recently Developed for the Determination of the Cellular 

Activity of Small Molecules; Frederick J. King, The Novartis Institutes for 

Biomedical Research 

Now What? Approaches to Following Up Large-Scale Screening; 

John Hogenesch, University of Pennsylvania 

Parallel Small-Scale Expression and ELT Screening of Drug Targets 

to Explore Druggability and Generate Chemical Probes; Jeffrey Gross, 


Target Validation Strategies for Protease Research; Lorenz Mayr, Novartis 

Pharma AG 

Track I » Session 5: Innovations in Screening and 

Sample Management: Technologies and Processes 

Session Chair: Claude DuFresne, Merck 

Plenary: Recent Developments in Technologies and Processes in Support 

of Lead Optimization Efforts; Claude DuFresne, Merck 

The Impact of Non-Contact Picoliter Dispense Technology in the 

Elimination of Serial Dilution; Daniel Thomas, GlaxoSmithKline 

Labware Leachables: Do You Know What’s In Your Assay Well?; 

John Watson, Bristol-Myers Squibb R&D 

Investigating the Stability of High Concentration DMSO Solutions; 

Ioana Popa-Burke, GlaxoSmithKline 

The Optimization of Instrumentation, Workflow and Data Analysis for In 

Vitro ADME Assays: A Business Case; Thomas Arnhold, Boehringer Ingelheim 

Pharma GmbH and Co KG



9:00 – 9:30 am Page 76 

9:30 – 10:00 am Page 76 

10:30 – 11:00 am Page 76 

11:00 – 11:30 am Page 77 

11:30 am – 12:00 pm Page 77 

9:00 am – 12:00 pm Osceola B 

9:00 – 9:30 am Page 79 

9:30 – 10:00 am Page 79 

10:30 – 11:00 am Page 79 

11:00 – 11:30 am Page 80 

11:30 am – 12:00 pm Page 80 

Track II » Session 5: Leveraging a National Resource: 

The Molecular Libraries Probe Development Network 

(MLPCN) 

Session Chair: Christopher Austin, NIH Chemical Genomics Center 

Plenary: The MLPCN: Mission, Collaborative Operation, and 

Accomplishments; Christopher Austin, NIH Chemical Genomics Center 

High Content Screening: A Platform to Discover Novel Drug-Like & 

Chemical Biological Probes for Several Target Classes; Thomas “T.C.” Chung, 

Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical 

Research Institute 

Infectious Agents and Drug Discovery: How to Conduct HTS Screening 

Campaigns Under BSL-2 and BSL-3 Level Containment; E. Lucile White, 

Southern Research Specialized Biocontainment Screening Center 

Integrating Novel Technologies to Identify Small-molecules that Drive 

Translational Research and Therapeutics; Michelle Palmer, Broad Institute 

of Harvard and MIT 

Change in Heartbeat: When Vast Chemical Diversity Meets Ion Channel 

Targets; Min Li, Johns Hopkins Ion Channel Center 

Track III » Session 5: Prediction and Elucidation 

of Target Liabilities 

Session Chair: Keith Houck, Environmental Protection Agency 

Plenary: Elucidation of Adverse Bioactivity Profiles as Predictors of Toxicity 

Potential; Keith Houck, Environmental Protection Agency 

Utilities of In Vitro Safety Pharmacology in Early Drug Discovery: Mitigation 

of ADRs; Laszlo Urban, Novartis Institutes for Biomedical Research 

From Data to Knowledge: Integration of Compound Structure and Activity 

With Clinical ADRs; Eugen Lounkine, Novartis Institutes for Biomedical Research 

Identification of Systemic Toxicity Triggers Associated With VEGF-R 

Inhibitors; Paul Nioi, Amgen Inc. 

In Silico Modeling for Predicting In Vivo Kinetics and Toxicity During Drug 

Discovery; Simon Thomas, Cyprotex Discovery Ltd 






Podium Presentation Abstracts 


Track I: Innovations in the Screening Sciences; 

Session 1: SLAS Session: Next Generation Technologies: 

Microfluidics 

Session Chairs: Bill Janzen, University of North Carolina at Chapel Hill and Scott Martin, St. Louis University 


1:30 – 2:00 pm 

Plenary: Micro- and Nanofluidic Devices: Acquiring Chemical and Biochemical Information Quickly From 

Small Quantities of Material 


2:00 – 2:30 pm 

Enhanced Information From Microtiter Plate Screening by Scanning Wells Integrated Into Microfluidic Devices 

Dana M. Spence, Michigan State University 

3:00 – 3:30 pm 

Micro-and Nanofluidic Devices for Cancer Screening and Virus Sensing 


3:30 – 4:00 pm 

Perfusion Culture Microchamber Array Chip for High-Throughput Cell-Based Assay 

Shinji Sugiura, National Institute of Advanced Industrial Science and Technology (AIST) 

4:00 – 4:30 pm 

Well Plate Microfluidic Devices for Investigation of Dynamic Platelet Behavior Under Variable Shear Loads 

Carolyn Conant, Fluxion Biosciences 



Micro- and Nanofluidic Devices: Acquiring Chemical and 

Biochemical Information Quickly From Small Quantities of Material 


The first demonstration of micromachined devices that emulate the functions of laboratory chemical instrumentation, i.e., the 

silicon gas chromatograph (GC), is now over three decades old. Due largely to the modest performance of these early devices, 

further developments in MEMS-based chemical instrumentation were slow to materialize. Microfabricated fluidic devices 

that accomplished chemical measurement strategies were first reported in the early 1990s and have several demonstrated 

advantages over conventional approaches. Our laboratory has been involved in developing microfabricated fluidic devices for 

nearly two decades. Our more recent efforts have included the development of two-dimensional separation systems coupled 

to integrated electrospray ionization emitters for proteomic analyses and devices for clinical diagnostic assays that perform flow 

cytometry or antigenic protein assays. We have also been interested in shrinking fabricated fluidic structure to the nanoscale for 

characterization of individual molecules. One application of such nanofluidic technologies is the rapid sequencing of individual 

DNA molecules to address health care issues such as personalized medicine. Additionally, we have been investigating the 

prospects of miniaturizing mass spectrometry for applications ranging from environmental monitoring to clinical diagnostic 

applications. An overview of our activities in these areas will be presented. 

Enhanced Information From Microtiter Plate Screening 

by Scanning Wells Integrated Into Microfluidic Devices 

Dana M. Spence, Michigan State University 

Measurements based on 96-well microtiter plate technology are a key component in many discovery-based endeavors. 

An important feature of this technology is the standardization of the dimensions of the plate that enable automated handling 

of the plate itself, fluid delivery and removal from the wells on the plate, and the detection schemes used to monitor analytes 

of interest in the wells. Collectively, these features contribute to the overall high throughput screening and measurements that 

are performed with the microtiter plate. Our group, however, believes that the information obtained during the measurement or 

screening portion of the analysis could be improved by integration of multiple cell types, including those in the bloodstream, into a 

single device. Therefore, in this presentation, information will be provided describing our new microfluidic-based trans-endothelial 

resistance measurement for cell layer integrity and growth. Next, using biotechnological advances in microfluidics, data will be 

presented that was obtained by pumping red cells underneath the endothelial cells and measuring various cell to cell signaling 

events that occurred. Examples of the utility of this device will be shown, including our ability to elucidate possible mechanisms of 

action of certain approved drugs and possible drug candidates. Moreover, data will also be shown demonstrating how this device 

can contribute to improving other biomedical areas of interest, including some recent developments from our lab involving stored 

blood banking. 



Micro-and Nanofluidic Devices for Cancer Screening and Virus Sensing 


Interest in microfluidics has increased over the past decade primarily because device miniaturization enables execution of 

fast, efficient, high throughput assays, integration of multiple sample processing steps, and fabrication of highly parallel device 

architectures. One important aspect is that the separative performance measured per unit length on microfluidic devices is 

similar to or exceeds that of conventional capillary separations. This high performance is due, in part, to the precise sample 

handling on the microfluidic devices. Precise sample handling combined with a compact serpentine channel geometry permits 

us to develop high-efficiency electrophoretic separations of N-glycans for screening applications. Presently, we are analyzing 

N-glycans derived from blood serum samples of patients with esophageal adenocarcinoma, high-grade dysplasia, and Barrettís 

esophagus and comparing the results with those from disease-free individuals. Statistical analysis of the electropherograms 

permits discriminatation among the various disease states. We are also shrinking the lateral dimensions of micromachined 

channels to nanometer length scales for resistive-pulse sensing of virus particles. Some aspects of microchannel transport 

transfer directly to operation of smaller nanoscale channels, but nanofluidic systems can be significantly influenced by 

phenomena such as double layer overlap, surface charge, ion current rectification, diffusion, and entropic forces, which are 

either insignificant or absent in larger microchannels. We are studying transport properties of ions and particles through these 

nanochannel devices and applying what we have learned to sense virus particles and to monitor their assembly under various 

reaction conditions. 

Perfusion Culture Microchamber Array Chip for High-Throughput Cell-Based Assay 

Shinji Sugiura, National Institute of Advanced Industrial Science and Technology (AIST) 

We report a perfusion culture microchamber array chip for high throughput drug dose response assays. The developed 

microchamber array chip was equipped with a serial dilution microfluidic network and an array of 384 microchambers for 

parallel quadruplicate assays using 12 drugs with 8 varying concentrations, which was confirmed to be applicable to the 

50 percent growth inhibitory concentration (IC50) assay. We also report a liquid handling apparatus and an incubation unit 

for semi-automatic operations. 

Well Plate Microfluidic Devices for Investigation of 

Dynamic Platelet Behavior Under Variable Shear Loads 

Carolyn Conant, Fluxion Biosciences 

Here, we report development of a commercial well plate microfluidic (WPM) based system that offers high throughput, low 

reagent consumption, and high experimental flexibility in an easy to use well plate format. The system consists of well plates 

with an integrated array of microfluidic channels, a pneumatic interface, an automated microscope, and a software package 

for control and data acquisition. 





Track II: Translational Research; 

Session 1: Resources and Collaborative Paradigms 

in Academia, Not-for-Profit and Industry 

Session Chairs: Paul Burn, Sanford Research Center 


1:30 – 2:00 pm 

Plenary: Putting Research into Practice 

Paul Burn, Sanford Research Center 

2:00 – 2:30 pm 

Changing the Rules for the Research “Game” in Academia - Accelerating Discovery Through Novel Means 

of Collaboration 

Mark Atkinson, The University of Florida 

3:00 – 3:30 pm 

Collaboration as a Central Strategy for Successful Translational Research 

John Reed, Sanford-Burnham Medical Research Institute 

3:30 – 4:00 pm 

Challenges and Successes of Translational Research in the Public Domain: Retrospective and Prospective 

Analyses and Case Histories of “Probes to Leads” From Six Years of the Molecular Libraries Program 

Thomas “T.C.” Chung, Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute 

4:00 – 4:30 pm 

Translation in Action: MRCT’s Centre for Therapeutics Discovery 




Putting Research into Practice 

Paul Burn, Sanford Research Center 

Many basic, academic research institutions, biotech companies, and industry have an exemplary track record of fostering 

environments that lead to the advancement of science resulting in scientific discoveries. Only a very few, however, are able and 

have succeeded in translating these early discoveries into clinical proof of concepts studies in humans and ultimately to the 

delivery of novel therapeutic approaches and medicines. This is true in particular for indications such as type 1 diabetes that 

are underrepresented in the program portfolios of Biotech and big Pharma companies. Here, we present “The Sanford Project” 

an emerging translational research initiative aimed at delivering a cure for type 1 diabetes within the setting of Sanford Health, 

the largest rural health care provider in the US. 

Changing the Rules for the Research “Game” in Academia 

—Accelerating Discovery Through Novel Means of Collaboration 

Mark Atkinson, The University of Florida 

While many intellectual gains have occurred in the field of type 1 diabetes (T1D) research over the past four decades, the period 

for which we considered the disorder to be autoimmune in its nature, a means to unequivocally prevent or reverse the disease 

has yet to been identified. This, despite the formation of large consortia to identify genes forming genetic susceptibility for T1D, 

test therapeutic interventions, determine the natural history of the disease, and more. While some may disagree, this lack in 

cure-related progress has not likely been blocked by lack of research funding, as considerable support opportunities have been 

available, through governmental agencies, private foundations, and philanthropy. Beyond this, spontaneous animal models of 

T1D exist, pharmaceutical industry interest in the disease is appreciable, and research publications touting important discoveries 

of this disease (reported in an ever increasing number of journals) has never been higher. Yet again, the disease has no cure. 

One theoretical impediment to research progress involves the long held “competitive” nature of academia, a survival of the fittest 

mechanism that provides minimal (or unclear) rewards for collaboration. To that end and as a test of that hypothesis, a group 

of self-aggregating investigators recently formed (i.e., the Brehm Coalition) for the purpose of accelerating discovery in T1D 

through operations that are designed to reward collaboration over competition. Guiding principles, largely unique in settings of 

academia, include those of: self-aggregation; flexible management; intimate collaboration facilitated by frequent and convenient 

video conferencing; emphasis on competence of the group rather than that of individuals; respect and trust in each other (i.e., 

complete sharing of all data); dependence on each other for results; cooperation on and even performance in one another’s 

experiments; and sharing of institutional cores and resources. In addition, emphasis is placed within the Coalition on training 

the next generation of researchers that will, to the best of their abilities, adopt these principles whenever possible, as well as 

in reaching out to fellow colleagues within a given institution for like purpose. While too early to claim long term success, early 

results for this means of approaching research appear promising across a variety of metrics (both intellectual and emotional) and 

hopefully, with time, this will result in a way to meaningfully impact this disorder. In addition, if proven successful, this method 

for approaching research with an emphasis on collaboration may find application across a wide variety of academic disciplines, 

accelerating discovery. 



Collaboration as a Central Strategy for Successful Translational Research 

John Reed, MD, Sanford-Burnham Medical Research Institute 

Translating laboratory discoveries into innovative therapeutics and diagnostics is one of the greatest challenges in the 

biomedical research enterprise today. Successful translational research rarely is achieved by lone individuals, and 

more often requires multi-disciplinary teams, armed with the appropriate resources to challenge disease and achieve 

breakthroughs in healthcare. Several examples of strategies developed at Sanford-Burnham Medical Research Institute for 

promoting successful translational research will be provided, including a description of efforts in high-throughput screening 

(HTS) and drug discovery as well as initiatives in pharmacogenomics and biomarker discovery. Central to the strategy are (a) 

building technological infrastructure in the form of “shared resources” (core facilities) that provide investigators with access 

to advanced technologies (instrumentation, etc.) along with dedicated professional staff skilled in delivering high quality 

results and (b) a culture of collaboration, where scientists, physicians, and other professionals join forces to tackle unmet 

challenges in healthcare. 

Challenges and Successes of Translational Research in the Public Domain: 

Retrospective and Prospective Analyses and Case Histories of “Probes to Leads” 

From Six Years of the Molecular Libraries Program 


We present a retrospective analysis of >90 HTS & Probe Development projects undertaken by Sanford-Burnham during 

6 years of NIH’s MLPCN to highlight the unique challenges and critical factors of screening in the academic milieu. Case 

histories of successful and unsuccessful projects exemplify solutions and lessons, as well as discovery & development of 

potent state-of-art probes with novel target or pathway specificity, linkage to other translational research programs (e.g. CBC) 

and prospects for novel therapies. 

Translation in Action: MRCT’s Centre for Therapeutics Discovery 


Academic based drug discovery is fast becoming a significant player in target validation and the delivery of new potential 

treatments for disease, and there are a number of centres enjoying considerable success in this field. The Medical Research 

Council Technology’s Centre for Therapeutics Discovery (CTD) in the UK is one such centre. The downsizing of “Big Pharma” has 

enabled the CTD to acquire high quality drug discovery skills and mesh them with some of the World’s best academic medical 

research scientists to create a high quality drug discovery capability within academia. There is massive potential within academic 

research for the discovery of novel drugs, but in order to unlock this and gain buy-in from Pharma, the targets and molecules of 

interest need to be progressed to a stage that addresses their concerns. The CTD’s primary aim is to collaborate with academics 

and Pharma on “de-risking” both small molecule and antibody based research projects by progressing them to a point where the 

targets have been validated by proof of concept studies in vitro and/or in vivo. In so doing, CTD leverages its own expertise in 

screening, medicinal chemistry and antibody generation and humanisation in a truly synergistic model with academia and Pharma. 

A brief description of the processes, initiatives and recent successes will be described. 





Track III: Sequenced Genomes: 

Reducing Opportunities to Practice; 

Session 1: Target Resuscitation: Drug Repositioning 

Opportunities 

Session Chair: Roger Bosse, PerkinElmer 


1:30 – 2:00 pm 

Plenary: Drug Repositioning: How it Fits With Current Drug Discovery Trends 

Christopher A. Lipinski, Melior Discovery 

2:00 – 2:30 pm 

Prodrugs: Regulatory and Clinical Development Requirements For Approval 


3:00 – 3:30 pm 

Exploring Ligand-Directed Functional Selectivity of GPCR With Bret-Based Biosensor Arrays and Label-Free 

Impedance Measurements; Linking Signaling Signature to Drug Efficacy 

Michel Bouvier, Drug Discovery Group, University of Montreal 

3:30 – 4:00 pm 

A Rapid Assay for Identifying New Drug Candidates From Approved Drugs for Repositioning to Treat Giardiasis 

Catherine Chen, NIH Chemical Genomics Center 

4:00 – 4:30 pm 

HTS for REST Inhibitors in Neural Progenies of Human ES Cells 




Drug Repositioning: How it Fits with Current Drug Discovery Trends 

Christopher A. Lipinski, Melior Discovery 

Drug Repositioning (aka drug repurposing, indications discovery) is finding a new use for an existing drug. We now recognize 

that 85–90 percent of single mechanism, target based knockouts are phenotypically silent because of network robustness. 

The positive counterpart to this observation is that a drug that exhibits a robust phenotypic response in humans is by definition 

modulating a sensitive network signaling pathway. In addition, it is invariably the case that an effective drug never has just a 

single mechanism of action. This means that there is a rich reservoir of potentially useful new indications for existing drugs. In 

many cases, we can discern a link to the originally described mechanism but sometimes a new beneficial effect is due to an 

“off target” effect. Based on fundamental principles one can anticipate a parallel growth between drug repositioning and multi 

targeted drug discovery, which is the deliberate search for drugs with multiple mechanisms. 

Prodrugs: Regulatory and Clinical Development Requirements For Approval 


A prodrug of an existing or derailed pipeline drug product is an attractive way to improve drug safety or efficacy. The choice 

of regulatory pathway, 505(b)(1) or 505(b)(2), will determine the cost and time to market approval. This choice is driven by the 

characteristics of the prodrug, but mainly by where the prodrug cleaves to become the existing drug. Methods to determine 

where this cleavage occurs and the resulting drug development program will be discussed and illustrated using case studies. 

Exploring Ligand-Directed Functional Selectivity of GPCR With Bret-Based Biosensor Arrays 

and Label-Free Impedance Measurements; Linking Signaling Signature to Drug Efficacy 

Michel Bouvier, Drug Discovery Group, University of Montreal 

Traditionally known for their ability to selectively activate a unique hetero-trimeric G protein, individual G protein-coupled 

receptors (GPCR) have since been shown to activate multiple G protein subtypes as well as G-protein independent signaling 

cascades. In addition, different ligands were found to selectively promote the engagement of distinct signaling partner 

subsets of a given receptor. Some compounds were also found to have clearly distinct and some times opposite efficacies 

toward different pathways engaged by the same receptor. This phenomenon—known as ligand-biased signaling or functional 

selectivity--offers interesting opportunities to develop compounds with increased selectivity profiles but presents important 

challenges for the drug discovery process, in particular in the context of high throughput screening. Since in many cases 

the specific signaling pathway that should be targeted for optimal therapeutic activity is unknown, methods that would allow 

monitoring multiple signaling pathways simultaneously would be great assets. We therefore developed new assays based on 

luminescence and resonance energy transfer as well as label-free impedance measurements that allow monitoring multiple 

signaling pathways and the ability to assess the structural determinants of ligand-biased signaling. Using these two types of 

assays, we dissected the signaling cascades engaged by ligands that have biased efficacy toward various effectors, including 

distinct G proteins, the adenylyl cyclase, the mitogen-activated protein kinase, Rho, ßarrestin and calcium pathways and 

revealed distinct conformational rearrangements of the signaling modules involved. Combined with molecular modeling of 

the recently solved 3D structures of the ßARs, these studies should provide the basis for the rational design of drugs with 

predetermined biased signaling profiles and improved therapeutic activities. 



A Rapid Assay for Identifying New Drug Candidates From 

Approved Drugs for Repositioning to Treat Giardiasis 

Catherine Chen, NIH Chemical Genomics Center 

Giardia lamblia is a human protozoan pathogen that causes diarrheal disease with an annual worldwide prevalence of 280 

million. Resistance to conventional drugs has been reported and the search for new drugs is an unmet medical need. We have 

developed a novel ATP content assay to assess parasite viability during the life cycle stage responsible for establishing host 

infections. A pilot screen of 4096 pharmacologically active small molecules revealed several approved drugs with novel and 

selective anti-Giardia properties. These candidate drugs could proceed to clinical trial quickly once their effects are confirmed 

in animal models. 

HTS for REST Inhibitors in Neural Progenies of Human ES Cells 


REST is a transcriptional repressor involved in the regulation of multiple cellular transitions including the inhibition of neuronal 

differentiation in non-neural cell and the transitions from pluripotent to neural progenitor and to mature neuron. Moreover, 

REST has been reported in epithelial cancer to act as a tumor suppressor. REST-mediated silencing activity is lifted through 

down-regulation of the protein level and decreased occupancy by REST of target gene promoter. These regulations are 

coordinated through extensive feedbacks with CREB proteins (cAMP response element-binding protein) and the brainrelated 

miRNAs, two distinct classes of regulators of neuronal gene expression. Transcriptional dysregulation is central to the 

pathogenic mechanisms of several neurodegenerative diseases including Huntingtonís disease (HD). One example involving 

REST is the disruption in HD patients of BDNF, the brain-derived neurotrophic factor observed. BDNF is produced by cortical 

neurons and required for survival and differentiation of striatal neurons (the type of neurons primarily affected in HD). Normal 

huntingtin protein is involved in the physiological control of BDNF synthesis and transport in the brain; in HD, both processes 

are simultaneously disrupted, leading to the translocation of REST to the nucleus where it represses transcription of many 

important genes. Here, our research objective was to identify drug capable of modulating REST activity in the human brain 

using neural progenies of human pluripotent stem cell as a convenient and relevant cellular model. We have developed a 

protocol for the reliable generation of neural stem cells (NSCs) from human pluripotent stem cells (embryonic or induced). 

These NSCs are self-renewable, bankable, neurogenic and genetically modifiable. NSCs are highly homogenous and can be 

efficiently differentiated into an almost pure population of neurons upon mitogens withdrawal. Here we report the development 

of a REST-activity reporter system for high-throughput screening of chemical compounds capable of modulating REST activity 

in hESC-derived NSCs. REST acts on its target genes via binding to RE1/NRSE (Repressor Element 1/Neuron-Restrictive 

Silencer Element), a 21 nucleotide consensus binding site found in the promoter of a number of neuronal and non-neuronal 

genes (potentially 1946 locations in the human genome). We have thus based our reporter system on the control by REST of a 

luciferase expression cassette via multiple RE1 sites placed upstream of a strong constitutive promoter. This assay effectively 

reads REST-activity in human neural cells and has been used to screen around 7000 small molecules (including 1120 FDAapproved 

drugs). Several families of small molecules capable of modulating the reporter signal were identified. Five selected 

hit-compounds modulating luciferase expression levels in NSCs via specific inhibition of REST-activity are under investigation. 

Interestingly, one of these compounds had previously been identified as a compound capable of blocking mutant huntington 

toxicity in rat neurons. 






Session 2: Innovations in Screening Biology: 

Assays, Techniques & Instrumentation 

Session Chairs: Jonathan O’Connell, Bristol-Myers Squibb Company 


9:00 – 9:30 am 

Plenary: The Evolution of HTS at Bristol-Myers Squibb: Enabling the Support of the Most Relevant Bio-Assays 

Jonathan O’Connell, Bristol-Myers Squibb Company 

9:30 – 10:00 am 

Etv6-NTRK3, a Constitutively Active Tyrosine Kinase Found in a Variety of Tumors, is Unique in its Mechanism 

of Transformation 


10:30 – 11:00 am 

High-Throughput Screening With Real-Time PCR: Reducing it to Practice 


11:00 – 11:30 am 

New Ion Channel Screening Technologies Enabling Development of High Quality and High-Throughput Assays 

in a Plate-Based Screening Group 

Juha Kammonen, Pfizer Global Research & Development 

11:30 am – 12:00 pm 

Creating a Holistic Screening Strategy for Label-Free Technology in a Plate Based Screening Group 

Rachel Russell, Pfizer Global Research & Development 



The “Evolution of HTS” at Bristol-Myers Squibb: 

Enabling the Support of the Most Relevant Bio-Assays 

Jonathan O’Connell, Bristol-Myers Squibb Company 

“Smaller, faster, cheaper” has been used multiple times to describe the driving factors of High Throughput Screening (HTS) over 

the last decade. But, what about quality, relevance and impact? This presentation will discuss the implementation of the most 

relevant assays on platforms designed to find the best possible leads. The design of the process and infrastructure to maximize 

the possibility of success will be discussed with a strong emphasis on what’s next. 

Etv6-NTRK3, a Constitutively Active Tyrosine Kinase Found in a Variety of Tumors, 

is Unique in its Mechanism of Transformation 


The chromosomal translocation t(12;15)(p13;q25) has been observed in both secretory breast carcinoma and pediatric soft tissue 

malignancies. This translocation event results in the fusion of the sterile alpha motif (SAM) oligomerization domain of transcription 

factor Etv6 with the tyrosine kinase domain of NTRK3. Although the role of Etv6-NTRK3 (EN) in cancer is well-documented, little is 

known about the signaling pathways that are activated downstream of this fusion protein. We used tandem mass spectrometry to 

identify 17 sites of tyrosine phosphorylation on EN including seven sites of tyrosine phosphorylation on the Etv6-derived portion 

of EN. Each site of tyrosine phosphorylation on EN was then screened using protein domain microarrays containing virtually all 

human Src Homology 2 (SH2) and Phospho-Tyrosine Binding (PTB) domains. This process identified numerous protein interaction 

events including many for sites on the Etv6-derived portion. Site-directed mutagenesis in combination with phenotypic assays 

identified one site, Y314 on the Etv6-derived portion of the protein, as required for EN-induced cellular transformation both in vitro 

and in vivo. 

High-Throughput Screening With Real-Time PCR: Reducing it to Practice 


Since its inception nearly 15 years ago, real-time quantitative PCR (RT-qPCR) has been regarded as a gold standard for 

quantifying endogenous gene expression levels. While numerous platforms for measuring mRNA expression have been 

developed, RT-qPCR is arguably the most sensitive and specific technology available with the widest dynamic range. Initially, 

RT-qPCR found a niche as a secondary platform for verifying gene expression changes that were first identified by gene 

microarrays that were much more amenable to genome-wide studies, but less sensitive than the more costly and laborintensive 

approach of real-time qPCR. Until recently, the concept of using RT-qPCR to screen large compound collections 

has been unrealistic due to the cost, and the complicated multi-step method which is prone to cumulative error, particularly if 

implementing in an automated mode. Recent advances in instrumentation and reagents are showing promise as a means to 

overcome these hurdles. Specifically, a thermocycler that can accommodate 1536-well plates has become available, as have 

improved reagents to streamline the workflow for real-time PCR, enabling one-step reactions directly from cellular lysates. 

We have married these advances in qPCR reagents and instrumentation with improved capabilities in acoustic liquid 

dispensing to develop a feasible and cost-effective strategy for robust, automated, high-throughput screening with realtime 

qPCR. Specifically, we have evaluated the feasibility of conducting a one-step RT-qPCR reaction, within a 500 nl 

reaction volume or less, directly from cell lysates, in both 384- and 1536-well plates. The automated workflow, along with 

the consistency and accuracy of these reactions for high-throughput screening will be discussed. Enabling this technology 

in a high-throughput screening environment has the potential to replace less sensitive and artifact-prone cell-based reporter 

assays, and to enable larger gene expression screens using more relevant cell models including primary cells. 



New Ion Channel Screening Technologies Enabling Development of High Quality 

and High-Throughput Assays in a Plate-Based Screening Group 

Juha Kammonen, Pfizer Global Research & Development 

Increasing confidence in ion channel targets based on human genetics is causing the number of in vitro assays required to 

support medicinal chemistry to go up. At the same time, the need for high-content, more physiologically relevant data from 

primary or pluripotent cells, rather than throughput alone, has increased the demand for flexibility. Traditional plate-based 

screening methods have relied on indirect measurements of ion conductance, as automated electrophysiology technologies 

have not been able to provide the necessary throughput for all ion channel targets. While offering higher throughput, these 

methods have always required secondary assays for hit confirmation and to remove artifacts specific to the technology 

used. Also, the need for high cell numbers has meant plate-based assays are not amenable to use of primary cells. We 

have adopted two new technologies that enable us to satisfy both requirements of throughput and high data quality, while 

simultaneously streamlining the process of ion channel screening by removing a step from the screening cascade. One 

allows us to rapidly characterize new cell lines, primary cells and tool compounds, using a gold standard manual patch 

quality instrument with improved usability and throughput compared to traditional manual patch electrophysiology. A new 

microfluidics based, continuous read and perfusion bench top instrument with plate reader simplicity enables whole-cell 

electrophysiology assays to be run for any ion channel target at a higher throughput than before, removing the bottleneck 

of the traditionally slow process of ion channel screening. With the added benefits of the ease of transferring an assay 

from development to screening in one step, as well as comparing and confirming compound activity very quickly between 

recombinant cell lines and primary cells within one group, these technologies introduce a new ion channel screening 

paradigm into a traditionally plate-based screening group. 

Creating a Holistic Screening Strategy for Label-Free Technology 

in a Plate Based Screening Group 

Rachel Russell, Pfizer Global Research & Development 

An outline of the hurdles in identifying a label free screening strategy for a plate based screening team. Utilization of examples 

of where label free technology in the reagent provision space through to assay development and screening has enabled the 

use of primary, rather than recombinantly expressing cells, leading to a forward thinking approach as to how primary screening 

is/should evolve. 






Session 2: Government, Foundation, NGO and Industry 

Funded Research Initiatives 

Session Chair: Ken Duncan, Bill and Melinda Gates Foundation 


9:00 – 9:30 am 

Plenary: Drug Discovery Focused on Neglected Diseases through Initiatives Funded by Governments, 

Foundations and Private Donors 

Ken Duncan, Bill and Melinda Gates Foundation 

9:30 – 10:00 am 

The Importance of Metabolic Status to Tuberculosis Drug Discovery 


10:30 – 11:00 am 

Screening for Novel Antimalarials 

R. Kip Guy, St. Jude Children’s Research Hospital 

11:00 – 11:30 am 

Cancer Research Technology: Bridging the Industry-Academia Interface in Oncology 

Tim Hammonds, Cancer Research Technology 

11:30 am – 12:00 pm 

Simultaneous Screening of a Large Natural Product Library Against a Panel of 10 Anti-Apoptotic Proteins 

in Search of Novel Cancer Therapeutics 




Drug Discovery Focused on Neglected Diseases Through Initiatives 

Funded by Governments, Foundations and Private Donors 

Ken Duncan, Bill & Melinda Gates Foundation 

Drug discovery is no longer exclusively carried out in the laboratories of Pharma companies, or carried out with the express 

purpose of generating profit. Many organizations now undertake sophisticated research programs, often using different 

models with extensive collaborations to achieve the critical mass and breadth of skills required to be successful. This has 

been particularly true in drug discovery programs aimed at finding new treatments for rare diseases and the neglected 

diseases that disproportionately affect people in developing countries, where Pharma interest has been low because of the 

lack of a viable market to recoup investment. Governments and private foundations have stepped in to provide funding, and 

this brings with it an obligation to make products available to those most in need at the lowest possible cost. Partnership with 

industry using shared resources and funding through in-kind contribution has often been critical to success. This session will 

focus on drug discovery programs being conducted in non-traditional environments or being carried out in non-traditional 

ways. Examples of programs that have succeeded in finding new leads and drug candidates for the rare and neglected 

diseases will be highlighted. 

The Importance of Metabolic Status to Tuberculosis Drug Discovery 


One of the major hurdles in the discovery of new agents active against Mtb is the lack of fully validated targets that can be 

starting points for structure based design efforts. In vitro screening conditions often employ environmental variables fixed 

at non-physiological conditions resulting ultimately in a disappointing correlation between in vitro and in vivo activities of 

compounds directed against particular targets. qHTS is a powerful tool for identifying hits that provides quantitative data 

from a primary screen. We have employed qHTS to a systematically altered set of environmental conditions against a set of 

bioactive compounds containing drugs with known mechanism of action. By monitoring variation in sensitivity across sets 

of related agents with known targets we hope to assess the vulnerability of these targets across the major environmental 

conditions thought to be important in in vivo growth of the TB bacillus as well as identifying compounds and families that 

have novel targets important only under selected conditions to systematically explore target space in this important human 

pathogen. Employing microarrays, whole-genome resequencing of drug-resistant mutants, and novel sources of biologically 

active material allows mechanistic information to be inferred that can suggest areas of unique vulnerability under in vivo 

conditions. 

Screening for Novel Antimalarials 

R. Kip Guy, St. Jude Children’s Research Hospital 

There has historically been a dearth of chemotypes that can be used to drive drug development campaigns for malaria. 

We utilized a phenotypic whole cell screen of erythrocytic co-cultures of malaria to identify novel chemical compounds 

that suppressed growth of or killed malaria. Representative members of the hit set were carefully profiled in a number of 

assays to understand selectivity, mechanism of action, and potential for development. 



Cancer Research Technology: Bridging the Industry-Academia Interface in Oncology 

Tim Hammonds, Cancer Research Technology 

Cancer Research Technology Limited (CRT) has over 20 years experience in oncology technology transfer, combining a 

technology transfer office with an early discovery laboratory facility of 85 scientists, mainly drawn from pharma and biotech. 

This presentation will describe how in the new era of open innovation, CRT is exploiting its unique position in oncology 

discovery research and employing new models for collaboration between industry and academia, highlighting strategic 

alliances and focussed academic consortia as examples. 

Simultaneous Screening of a Large Natural Product Library Against a Panel 

of 10 Anti-Apoptotic Proteins in Search of Novel Cancer Therapeutics 


We will present an analysis of the pharmacophores obtained from a systematic target-based High-Throughput Screening 

(HTS) campaign of approximately 140,000 natural product (NP) extracts against a panel of ten apoptosis inhibitor proteins 

that have been implicated in human cancers: Bcl-2, Bcl-xL, Mcl-1, Bfl-1, Bcl-W, Bcl-B, cIAP-1 BIR2 domain, cIAP-1 BIR3 

domain, cIAP-2 BIR2 domain, and cIAP-2 BIR3 domain. 







Session 2: Target Mining: Interpretation and Annotation, 

Data Analysis, Deorphaning 

Session Chair: Andrew Su, Genomics Institute of the Novartis Research Foundation 


9:00 – 9:30 am 

Plenary: The Gene Wiki: Crowdsourcing Knowledge Extraction from the Biomedical Literature 

Andrew Su, Genomics Institute of the Novartis Research Foundation 

9:30 – 10:00 am 

Systems and Personalized Medicine 

Joel Dudley, Stanford University and Lucile Packard Children’s Hospital 

10:30 – 11:00 am 

Causal Reasoning on Biological Networks: Interpreting Transcriptional Changes 

Daniel Ziemek, Pfizer Worldwide Research & Development 

11:00 – 11:30 am 


Drug Effects Viewed From a Protein Network Perspective 


11:30 am – 12:00 pm 

Understanding Lung Cancers by Whole Genome Sequencing 




The Gene Wiki: Crowdsourcing Knowledge Extraction from the Biomedical Literature 

Andrew Su, Genomics Institute of the Novartis Research Foundation 

Comprehensively annotating the function of all human genes is a formidable challenge for the biological community. An 

analysis of the current state of gene annotations reveals that we are only in the earliest stages of this goal. One significant 

bottleneck is the community’s reliance on centralized efforts to manually review the biomedical literature. Following Web 2.0 

trends, we initiated the Gene Wiki project, the goal of which is to create a collaboratively-written, continuously-updated, and 

community-reviewed review article for every gene in the human genome. In short, the Gene Wiki bypasses the bottleneck in 

centralized curation by directly engaging the entire community of scientists to annotate gene function. Since its initiation in 

2008, this “community intelligence” initiative has proved to be extremely successful. The Gene Wiki is currently viewed over 

four million times and edited over one thousand times per month. 

Systems and Personalized Medicine 

Joel Dudley, Stanford University, School of Medicine 

Dr. Butte’s lab builds and applies tools that convert the billions of points of molecular, clinical, and epidemiological data 

measured by researchers and clinicians over the past decade into diagnostics, therapeutics, and new insights into disease. 

Dr. Butte will highlight how using publicly-available molecular data enables the discovery of new gene variants and biomarkers 

for diseases like diabetes, suggests novel roles for drugs in the treatment of disease, and for the first time allows us to probe 

the inner commonality across disease. Dr. Butte will also discuss his recent papers on the clinical evaluation of a personal 

genome and the environment-wide association study (EWAS). 

Causal Reasoning on Biological Networks: Interpreting Transcriptional Changes 

Daniel Ziemek, Pfizer Worldwide Research and Development 

More than 10 years after the start of routine generation of large scale omics datasets, the biologically meaningful and 

comprehensive interpretation of single experiments still poses significant challenges. At the same time, the amount of 

knowledge in the literature on molecular relationships has grown significantly over the past decade. Causal Reasoning has 

been proposed as a methodology for arriving at concise hypothetical molecular causes of observed transcript changes. 

This methodology relies on a large graph of causal relationships curated from the literature. This talk will explain the 

method, its associated scoring functions as well as demonstrate concrete use-cases relevant to pharmaceutical research. 



Drug Effects Viewed From a Protein Network Perspective 


Understanding how drugs affect cellular networks and how resulting signals are translated into drug effects holds the key to 

the discovery of medicines. Herein we examined this relationship by determining protein network structures associated with 

the generation of specific in vivo drug-effect patterns for more than 1000 medicines. These protein network topology models 

reveal that drugs with discrete positions in cellular protein networks have very similar physiological effects. The results of these 

analyses will be presented. 

Understanding Lung Cancers by Whole Genome Sequencing 


Next generation sequencing technologies have greatly reduced the barrier for whole genome analysis of human cancer 

samples. Working with the Complete Genomics team, we sequenced normal and tumor tissues from three cancer patients 

with non-small cell lung adenocarcinoma. In the tumor tissue from the smoker patient, we identified over 50,000 single 

nucleotide somatic mutations, and observed a distinct pattern of selection against mutations within expressed genes 

compared to non-expressed genes and in promoter regions up to 5 kb upstream of all protein-coding genes. The nonsmoker 

patients harbor much reduced number of point mutations and structural variations, and the patterns of mutations 

appear to be distinct from the smoking induced DNA damage signature. We also analyzed fully sequenced lung cancer cell 

lines with the aim to identify genomic markers predictive of anti-cancer drug responses. 






Session 3: Critical Reagents and Technologies in 

HTS to lead Efforts 

Session Chairs: Ulrich Schopfer, Novartis Institutes for BioMedical Research and Achim Grenz, F. Hoffman-La Roche Ltd 


9:00 – 9:30 am 

Plenary: Bridging the Gap Between Phenotypic Screens and Molecular Targets 

Ulrich Schopfer, Novartis Instititutes for Biomedical Research, Inc. 

9:30 – 10:00 am 

Identifying Helicobacter Pylori AddAB DNA Repair Enzyme Inhibitors Using a Novel Bacteriophage 

E. Coli Infectivity Assay in Highly Miniaturized Formats 

Timothy Spicer, The Scripps Research Institute 

10:30 – 11:00 am 

Target Identification and Validation Using Chemical and Functional Genetics Screening Approaches 

Vic Myer, Novartis Instititutes for Biomedical Research, Inc., United States 

11:00 – 11:30 am 

HT RNAi Screening of Anti-Cancer Targets With Pooled shRNA Libraries 


11:30 am – 12:00 pm 

Human “Knock-in” & “Knock-out” Cell-Lines for Precision Functional Genomics and Targeted Drug Discovery 

Chris Torrance, Horizon Discovery Ltd, IQ Cambridge 



Bridging the Gap Between Phenotypic Screens and Molecular Targets 

Ulrich Schopfer, Novartis Instititutes for Biomedical Research, Inc. 

While the trend towards cellular, phenotypic assays is strong, the challenge of de-convoluting hits and discovering their 

molecular target is daunting as ever. Often hits from complex, context-rich assays are followed up in biochemical or 

biophyiscal assays, but the question remains if this process does not lose those hits that one had hoped to find in the 

first place. We will introduce the session by reviewing key technologies that have emerged to address this problem and 

look at application case studies. 

Identifying Helicobacter Pylori AddAB DNA Repair Enzyme Inhibitors Using a 

Novel Bacteriophage E. Coli Infectivity Assay in Highly Miniaturized Formats 

Timothy Spicer, The Scripps Research Institute 

Helicobacter pylori is a gram negative bacterium that is highly invasive to humans and infects approximately half of the world’s 

population. A significant number of infected people acquire a chronic inflammation of the stomach lining and develop gastric 

ulcers and potentially cancer. The host cells elicit DNA damage in the bacterial cells, which must be repaired in order for the 

bacteria to persist. The AddAB helicase-nuclease is required for DNA repair and efficient H. pylori stomach colonization and 

therefore is an attractive target for antibacterial drug discovery. A simple assay for intracellular AddAB nuclease activity is 

the blocking of growth of lytic bacteriophage T4 gene 2 mutants. T4 gene 2 mutants will grow in E. coli expressing H. pylori 

addAB only in the presence of an inhibitor of AddAB; a specific inhibitor of AddAB will block E. coli growth only in the presence 

of this phage. We have optimized, implemented and screened the Molecular Libraries Probe Center Network Collection 

(>300K compounds) using this novel microbial infectivity assay in 1536-well format. This along with other novel miniaturized 

microbial phage infectivity assays will be presented, including the identification of selective inhibitors of AddAB. We plan to 

test these inhibitors for their effects on AddAB using genetic and enzymatic assays, to discover their mode of action on this 

important enzyme. 

Target Identification and Validation Using Chemical and Functional Genetics 

Screening Approaches 

Vic Myer, Novartis Instititutes for Biomedical Research, Inc. 

The year 2010 marked an important scientific anniversary, as 10 years ago the first complete draft of the human genome 

was released (Nature, vol 409,num 6822). This event was heralded widely as the beginning of a new scientific era, promising 

tailored pharmaceuticals and a plethora of new disease relevant targets. This promise remains largely untapped despite 

the accumulation of massive amounts of sequence and expression data. While the genome serves as an invaluable tool for 

contextualizing many pathways and networks, assigning specific function to significant numbers of gene products remains a 

challenge for the field therefore presenting an opportunity for scientific and pharmaceutical leadership. This presentation will 

provide an overview of screening based target identification and validation approaches practiced across Novartis. Specifically 

the areas of genetic screening, chemical genetics and the reagent collections designed to bridge the gap will be highlighted. 



HT RNAi Screening of Anti-Cancer Targets With Pooled shRNA Libraries 


High throughput (HT) genetic screening using genome-wide pooled bar-coded lentiviral-based shRNA libraries in combination 

with HT sequencing has been used to identify genes modulating proliferation and survival in prostate, leukemia, and a panel 

of isogenic mammary epithelial cells (HMEC). Gene targets identified in these screens have been subsequently shown to lead 

to cell death in vitro when suppressed, and thus have potential as therapeutic targets. In addition to identifying specific single 

targets, the screening platform has been adapted to screen large sets of genes for synergistic combinations that generate a 

synthetic lethal phenotype when knocked down simultaneously. Advantages and limitations of pooled format genetic screens 

with genome-wide pooled shRNA libraries will be discussed. 

Human “Knock-in” & “Knock-out” Cell-Lines for Precision Functional Genomics and 

Targeted Drug Discovery 

Chris Torrance, Horizon Discovery Ltd, IQ Cambridge 

Many putative cancer genes have now been identified from global genome sequencing efforts and there is a growing need 

for cell-based models and tools that can accurately dissect their function and be deployed to accelerate the discovery of 

novel targeted drugs. Unlike transgenic mice technologies, the ability to routinely alter any endogenous DNA-sequence in 

human cells has been challenging. Horizon’s GENESISTM gene-editing platform (based on rAAV-virus mediated homologous 

recombination vectors) is the first technology that enables the precise engineering of any DNA-variation in any human cellline, 

including the introduction of subtle point mutations and SNPs, just as they occur in real patients. The ability to rapidly, 

accurately and stably engineer human genomes without introducing confounding off-target effects, promises to transform 

the pursuit of novel targeted, or personalized, medicines. Towards this aim, Horizon has built a large suite of geneticallydefined 

and patient-relevant “X-MAN” (gene X, Mutant And Normal) human isogenic cell-line pairs, which are now being used 

by many academic and industrial researchers to elucidate novel targets and biomarkers and direct drugs towards specific 

patient populations. Data will be presented on in-house programs and collaborations using panels of isogenic “knock-in” and 

“knock-out” cell lines harboring or lacking mutant cancer genes e.g., EGFR, K-RAS and PI3K. Several applications in drug 

discovery will be covered, including the dissection of therapeutic sensitivity or resistance biomarkers to inform more focused 

clinical trials and the screening of entire compound or siRNA libraries for novel drug candidates or drug targets, respectively. 

In these case studies, the critical importance of mimicking the tumor microenvironment e.g., reduced growth factor, nutrient 

or oxygen concentrations, within in vitro based assays will be emphasized in order to reveal the key phenotype(s) and optimal 

targeted drug responses mediated by specific disease-causing genotypes. 






Session 3: Molecular Discovery in Non-traditional, 

Neglected and Rare Diseases 

Session Chair; Bob Hertzberg, GlaxoSmithKline 


9:00 – 9:30 am 

Plenary: Opening the Doors and Giving Back: GSK’s Strategy to Deliver Medicines for Diseases of the 

Developing World 

Bob Hertzberg, GlaxoSmithKline 

9:30 – 10:00 am 

High-Throughput Screening to Identify Inhibitors of the Respiratory Chain of Mycobacterium Tuberculosis 

Khisimuzi Mdluli, Global Alliance for TB Drug Development 

10:30 – 11:00 am 

The Development of RNA-Modulating Therapies 

Judith C.T. van Deutekom, Prosensa Therapeutics BV 

11:00 – 11:30 am 

Humanitarian and Commercial Cloud-Based Collaborative Drug Discovery 


11:30 am – 12:00 pm 

Potent and Selective Inhibitors of the Plasmodium Falciparum M18 Aspartyl Aminopeptidase (AAP) 

of Human Malaria Identified via a QFRET uHTS Campaign 

Virneliz Fernandez Vega, The Scripps Research Institute 



Opening the Doors and Giving Back: 

GSK’s Strategy to Deliver Medicines for Diseases of the Developing World 

Bob Hertzberg, GlaxoSmithKline 

The developing world carries a large proportion of the global disease burden, and many important diseases have been mostly 

neglected by the pharmaceutical industry. GSK is taking a leadership step by opening its doors in an effort to help deliver new 

and better medicines for people living in the worldís poorest countries. We have created an “Open Laboratory” focused on drug 

discovery for neglected diseases including malaria and TB. Projects are prioritized by unmet medical need and not by commercial 

benefit. The Open Lab is based on a bold strategy intended to facilitate collaboration between academia, governments and 

industry. Scientists from all over the world are invited to work alongside of GSK drug discovery scientists with access to GSK 

resources including compound collections and screening facilities. Furthermore, we have established an open approach to 

innovation and intellectual property, recently exemplified by our publication of chemical structures and biological data for 13,500 

hits from a high throughput screen for antimalarial agents. This talk will describe the Open Lab concept and some of the initial 

discoveries emanating from this endeavor. 

High-Throughput Screening to Identify Inhibitors of the 

Respiratory Chain of Mycobacterium tuberculosis 

Khisimuzi Mdluli, Global Alliance for TB Drug Development 

Mycobacterium tuberculosis (MTB) infections are of serious concern, causing 2 million deaths every year and latently persisting 

in over a billion individuals worldwide. MTB is an obligate aerobe that is capable of long-term persistence under conditions of 

low oxygen tension. The hypoxic, non-replicating mycobacterial population is presumed to be the reason for the protracted 

treatment durations that can last for 6-9 months for drug-sensitive tuberculosis, and up to two years for drug resistant disease. 

Mycobacterial electron transport is an essential system for maintaining an energized plasma membrane with a functional 

membrane potential for energy production in both the aerobic and anaerobic environments, and is therefore a unique and 

important anti-mycobacterial target for antibiotic discovery. Inhibitors of this system could have potent anti-mycobacterial 

activities against both actively growing and non-replicating MTB, serving as a source of good anti-tubercular drugs capable of 

disrupting the membrane potential, and inhibiting energy production. The recent discovery of an ATP synthase inhibitor (TMC-207) 

further validates the mycobacterial respiration pathway as essential for survival, and a good target. To avoid randomly picking 

any one of the enzymes involved in this system, we chose to focus on designing a membrane based assay capable of identifying 

inhibitors of various components of the electron transport chain (ETC). Such inhibitors could be developed into drugs that would 

be active against both rapidly growing bacteria and the non-growing persistent bacteria, and could therefore also contribute 

to a future regimen that shortens the duration of therapy. The reaction begins with NADH and isolated inverted mycobacterial 

membranes and measures either NADH oxidation or ATP synthase activity via luciferase. Membranes from M. smegmatis were 

isolated using a three step differential centrifugation procedure. They were highly pure and contained functionally active ETC 

components. These membranes, which were inverted and closed, could oxidize NADH or succinate, reduce oxygen, develop a 

proton gradient, and catalyze via ATP synthase the conversion of ADP and Pi to ATP. The assay was performed in 384 well HTS 

format. The assay, HTS, hit prioritization and subsequent hit validation and target identification processes will be discussed. 



The Development of RNA-Modulating Therapies 

Judith C.T. van Deutekom, Prosensa Therapeutics BV, Leiden, the Netherlands 

RNA-modulating therapeutics like antisense oligonucleotides (AONs) provide an innovative tool for targeted modulation of gene 

expression and/or to correct mutated mRNA causing life threatening disorders. An increasing number of studies show that AONs 

can interfere with splicing in order to induce exon skipping, enhance exon inclusion, or correct splicing mutations, and can 

remove mutant RNA or protein domains, or block RNA expression. Prosensa Therapeutics applies the AON technology platform 

to develop RNA-modulating therapies for a variety of genetic diseases, including neuromuscular and neurodegenerative disorders 

such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1), and Huntington’s Disease (HD). First proof-of-concept 

was recently obtained with PRO051 (GSK2402968) for DMD. Based upon promising results from two clinical phase 1/2 studies the 

compound is now moving into phase 3. We will present highlights and challenges from our development program. 

Humanitarian and Commercial Cloud-Based Collaborative Drug Discovery 


Collaborative Drug Discovery hosts a widely used cloud-based collaborative platform for high-throughput screening SAR data. 

CDD Vault, Collaborate, and Public integrate private, collaborative (selectively shared), and public data spanning the competitive, 

precompetitive, and neglected disease domains. Although the majority of use cases are in secure, private vaults, we will present 

details from publicly disclosed collaborations with GlaxoSmithKline, Pfizer, Novartis, and the Bill & Melinda Gates Foundation, 

as well as more selected examples from hundreds of academic and biotech startup companies. The collaborative drug discovery 

approach integrates experimental and computational screening with distributed data collection, storage, visualization and 

analysis and balancing privacy-security while supporting collaborations, when desired. The approach is a bit like how one can 

control their information on social networks like LinkedIn and Facebook, but appropriate for more complex, and even highly 

sensitively, scientific data. Experiences will be shared with researchers using the “CDD Vault” and a secure, private industrialstrength 

database combining traditional drug discovery informatics (registration and SAR) with social networking capabilities. 

CDD Collaborate enables real-time collaboration by securely exchanging selected confidential data. Traditional drug discovery 

capabilities include the ability to import/export to Excelô and sdfiles, Boolean queries for potency, selectively, and therapeutic 

windows for small molecule enzyme, cell, and animal data, substructure and Tanimoto similarity search, physical chemical 

property search, as well as IC50 calculation/curve generation, heat-maps, and Z/Zí statistics for archived data (protocols, 

molecules, plates, hyperlinked files). CDD Public has unique, constantly growing drug discovery SAR content. Neglected 

disease case studies will be emphasized (Malaria, TB, Chagas, etc), although the approach is equally applicable to 

commercially valuable research. 

Potent and Selective Inhibitors of the Plasmodium Falciparum M18 Aspartyl 

Aminopeptidase (AAP) of Human Malaria Identified via a QFRET uHTS Campaign 

Virneliz Fernandez Vega, The Scripps Research Institute 

With the rise of drug-resistant malarial parasites, novel drug targets and lead compounds are required for the development of new 

therapeutic strategies. In this study, the M18 aspartyl aminopeptidase (AAP) is solely present in the genome of the malaria parasite 

Plasmodium falciparum (PfM18AAP) and exhibits exopeptidase activity exclusively against the N-terminal acidic amino acids 

glutamate and aspartate; making this enzyme a unique target of new therapies for malaria disease. To explore options for novel 

chemical probes of M18 function, a simple and sensitive fluorogenic assay was developed using recombinant active PfM18AAP 

enzyme and a commercially available fluorogenic peptide substrate (H-Glu-NHMec). This homogenous assay was used to screen the 

Molecular Libraries Probe Center Network Collection (~300K compounds) in 1536 well plate format. Parallel fluorogenic counterscreen 

assays were also developed and run, in particular using Cathepsin L1 (CL1) enzyme. Potent and selective inhibitors of M18 were 

identified. The activity of these inhibitors was reproducible in external labs. In addition, follow up assays to determine IC50s for 

newly synthesized compounds to kill malaria in red blood cells demonstrated some of the best activity reported to date. Further 

details of the outcomes of this international collaborative effort to find effective probes towards this important target will be presented. 







Session 3: Applications in Consumer Products, Cosmetics, 

Nutraceuticals and Agriculture 

Session Chair; Sabrina Corazza, Axxam SpA 


9:00 – 9:30 am 

Plenary: New Frontiers for HTS Application: How and Why 

Sabrina Corazza, Axxam SpA 

9:30 – 10:00 am 

Receptor Mediated Discovery of Novel Taste Modulators 

Jay Slack, Givaudan Flavors Corp. 

10:30 – 11:00 am 

Insecticidal Compounds “Well” Spotted: Screening Live Bugs in a High-Throughput System 

Juergen Langewald, BASF 

11:00 – 11:30 am 

Needs of the Food and Beverage Industries 

Anthony J Clark, PepsiCo 

11:30 am – 12:00 pm 

Deorphanization and Characterization of Human Odorant Receptors in Heterologous Cells 

Pierre Chatelein, TecnoScent 



New Frontiers for HTS Application: How and Why 

Sabrina Corazza, Axxam SpA 

High Throughput Screening is a well established process in lead discovery for pharma, biotech industries and more recently 

also for academia. Since its beginnings around 20 years ago, the field of HTS has seen a continuous change in technology, 

processes and adaptation to various needs and is now a mature and validated discipline of modern drug discovery. Starting 

from year 2000, the availability of entire genomes from many different species opened the possibility of identification of potential 

targets for the discovery of new active compounds in life science disciplines outside pharma. To this purpose, the well validated 

HTS approach could certainly boost the capability of exploring vast population of diverse chemical and biochemical molecules 

and well serve the purpose of identifying new active substances also in fields like agricultural and food research as well as 

in cosmetics, modulation of taste and fragrances perception. Proceeding in these operations ascertained that certain target 

classes were playing a key role in different disciplines and molecules discovered in a specific field could find interesting and 

useful applications in other apparently unrelated fields. Some examples will be given, starting from the fascinating class of TRP 

channels and ending with the “fat receptors” paradigm. 

Receptor Mediated Discovery of Novel Taste Modulators 

Jay Slack, Givaudan Flavors Corp. 

Recent advances in the genomics of chemosensation has led to the identification of specific receptors for sweet, umami, and 

bitter tastants, as well as chemisthetic agents such as menthol and capsaicin. These discoveries can be utilized in a practical 

setting for the discovery of novel, high-impact flavor ingredients. Bioassays using chemosensory receptors allows for preliminary 

evaluation of thousands of chemicals, which can be used to establish priorities for downstream chemical optimization and taste 

validation with advanced human sensory techniques. We have developed receptor-based screening platforms for multiple 

chemosensory receptors and employed throughput screening of our diverse chemical libraries. Utilization of this platform has 

led to the discovery of novel scaffolds for targeted ingredient development with applications such as bitter taste reduction. 

We will present examples of results achieved with our receptor platform and discuss how this new approach is being used to 

develop novel taste modulators. 

Insecticidal Compounds “Well” Spotted: Screening Live Bugs in a High-Throughput System 

Juergen Langewald, BASF 

Unlike in pharmacological research, discovery of new active compounds for crop protection is still mainly depending on in-vivo 

assay formats. In-vivo high throughput screens based on whole organisms in non-liquid environments are not very common. 

Off the shelf solutions are rarely available. We will discuss the development of miniaturized insect assays and the evolution of 

an HTS process. We will talk about options for a meaningful data analysis. Finally, we will describe how in-vivo- and in-vitro 

studies can be integrated in insecticide discovery research. 



Needs of the Food and Beverage Industries 

Anthony J. Clark, PepsiCo 

In 2010 Indra Nooyi the CEO and Chairperson of PepsiCo and Mehmood Khan, Pepsicoís first CSO, announced that PepsiCo 

would reduce sugar and fat by 25% & 15% respectively by 2020. Moreover, a 25% reduction in salt was mandated by 2015 

across all our product lines. This bold goal is the result of vast changes in PepsiCo culture toward health and wellness. For 

R & D this meant that innovative, natural, solutions would need to be found quickly not only to maintain taste, but replace the 

functionality that salt, sugar and fat provide products. Furthermore, these goals would all need to be done while growing the 

business. For new ingredient discovery we looked toward a deeper understanding of taste biology to guide development. 

High throughput screening (HTS) is a proven technology for drug discovery in the pharmaceutical industry. Adapting HTS to 

taste receptor technology could revolutionize the Food and Beverage industries buy providing a pipeline of new ingredients, 

such as sugar & salt enhancers or replacers. Although the concept is sound, many challenges remain toward efficient 

ingredient discovery. 

Deorphanization and Characterization of Human Odorant Receptors in Heterologous Cells 

Pierre Chatelein, TecnoScent 

Olfaction plays an indispensable role in human and animals in self and environmental recognition as well as intra- and interspecific 

communication. Following the discovery by Buck and Axel in 1991 of a family of odorant receptors (OR), it has been 

established that the sense of smell begins with the molecular recognition of a chemical odorant by one or more ORs expressed 

in the olfactory sensory neurons. Therefore characterization of the molecular interactions between odorant molecules and ORs 

is a key step in the elucidation of the general properties of the olfactory system and in the development of applications: design of 

new odorants, search for blockers,…The presentation will show the process putted in place in TecnoScent to deorphanize and to 

characterize the interaction between chemical odorants and ORs. The family of human ORS includes ~400 putatively functional 

ORs which are GPCRs. To date over 100 hORs have been deorphanized. 






Session 4: Innovations in Label Free, Multiplexed 

and High Content Assays 

Session Chair: James Inglese, NIH Chemical Genomics Center 


2:00 – 2:30 pm 

Plenary: Quantitative High-Throughput Screening of Phenotypic Assays Enabled by 

Laser-Scanning-Coupled Microscopy 

James Inglese, NIH Chemical Genomics Center 

2:30 – 3:00 pm 

Kinetic Image Cytometry: Toxicity HCS in Human Cardiomyocytes for Early Drug Discovery 

Jeffrey Price, Sanford Burnham 

3:00 – 3:30 pm 

Binding Assays in Biological Liquids using Microscale Thermophoresis 


3:30 – 4:00 pm 

Use of Label-Free Technology to Monitor GPCR Desensitization 


4:00 – 4:30 pm 

Enabling Lead Discovery at Epigenetics Targets With RapidFire Mass Spectrometry 

Melanie Leveridge, GlaxoSmithKline 



Quantitative High-Throughput Screening of Phenotypic Assays Enabled by 

Laser-Scanning-Coupled Microscopy 

James Inglese, NIH Chemical Genomics Center 

Enabling phenotypic assays for high throughput screening (HTS) using high content screening (HCS) technologies is becoming 

indispensable for early stage drug discovery and chemical biology. Despite wide adoption of these technologies, the coupling 

and integration of HTS and HCS remains challenging for large chemical libraries. To address this need, we describe a HTS 

system that couples the acquisition speed of laser cytometry and the image resolving power of microscopy. An informatics 

platform was developed to enable rapid identification of actives from chemical libraries based on a pharmacological parameters 

derived from concentration-response curves and the selective imaging of microtiter plate wells containing cells associated with 

active compound samples. This presentation describes the implementation and validation of this strategy with specific assays 

and address the major challenges of this approach which include real-time HTS data analysis, definition of active samples, and 

decision making. 

Kinetic Image Cytometry: Toxicity HCS in Human Cardiomyocytes for Early Drug Discovery 

Jeffrey Price, Sanford Burnham 

Current single-cell physiology measurements lack the throughput needed for large-scale studies and statistically significant 

analyses of rare phenomena. For example, assessment of cardiotoxicants by electrophysiological recording, which is too low 

throughput for early-stage drug development, has been unable to prevent a doubling of the cost of arrhythmia-induced drug 

failures in the last decade to an estimated US$ 2.55 billion annually. To increase throughput, we developed kinetic imaging 

cytometry (KIC) to automate cell-by-cell analyses of epifluorescence dynamics of intracellular probes and report validation on 

Ca2+ flux effectors. KIC electrically stimulates and records intracellular Ca2+ variations in parallel on hundreds of contracting 

cells per image in a few seconds and scans 96-well plates. Kinetic parameters are automatically recorded for subcellular 

compartments of each cell, and statistical analyses are performed on the entire cell population or gated subsets. Cell-by-cell 

kinetics overcomes ensemble averaging in plate readers that obscures detailed dynamics of heterogeneous cells responding 

with various electrical propagation-induced contraction delays. Experiments performed on human cardiomyocytes derived from 

embryonic and induced pluripotent stem cells validated discrimination of pharmacological effects of arrhythmogenic drugs that 

alter the cardiac AP and Ca2+ release, phenomena typically recorded laboriously one cell at a time via patch clamp or Ca2+ 

imaging, or by more indirect multi-cell field-effect and whole-well techniques that obscure kinetic details. Post-kinetic labeling 

then enables further characterization via correlation of expression markers to individual cell dynamics. KIC enables detailed 

physiological analyses of cardiomyocytes and other excitable cells for basic and applied research, as well as drug screening 

and cardiotoxicity testing. 

Binding Assays in Biological Liquids using Microscale Thermophoresis 


We present a sample-efficient, free-solution method, termed microscale thermophoresis, that is capable of analyzing interactions 

of proteins or small molecules in buffer or biological liquids such as blood serum or cell lysate. The technique is based on the 

analysis of molecule mobility in localized microscopic temperature gradients, which is sensitive to molecule size, charge and 

hydration shell. We present the broad application range of the technology for drug development and basic research utilizing 

fluorescence and label free approaches. We demonstrate its capability of measuring immunologically relevant systems including 

human interferon gamma and the interaction of calmodulin with calcium. The affinity of the small-molecule inhibitor quercetin to 

the kinase PKA was determined in buffer and human serum, revealing a 400-fold reduced apparent affinity in serum. Information 

regarding the influence of the biological matrix on small molecule binding to target proteins obtained in a rapid and direct manner 

should, facilitate more efficient drug development. 



Use of Label-Free Technology to Monitor GPCR Desensitization 


Activation of intracellular second messenger cascades, resulting from GPCR-ligand interactions, induce cytoskeletal 

rearrangement leading to changes in cell morphology. These rapid whole-cell responses can be measured using a label-free 

technology that measures changes in cellular impedance. I will present the use of this label-free technology in interrogating 

GPCR desensitization. 

Enabling Lead Discovery at Epigenetics Targets With RapidFire Mass Spectrometry 

Melanie Leveridge, GlaxoSmithKline 

Post translational modification of histones, such as methylation and demethylation, plays a key role in the regulation of 

gene expression, and disruption of these processes is linked to a number of disease states. Histone demethylase enzymes 

are therefore emerging as attractive therapeutic targets and as such the development of a robust biochemical assay is 

required to identify inhibitors of these enzymes. Mass spectrometry offers a label-free, direct measurement of demethylation, 

which should have advantages over indirect fluorescent-based assay formats, for example reducing compound interference. 

However hit identification and compound screening by mass spectrometry has historically been limited by low throughput 

sample preparation, typically using HPLC. The RapidFire high-throughput mass spectrometry (HTMS) system addresses 

this, enabling sample times of 6-8 seconds per well and hence the screening of thousands of compounds per day. Here 

we describe how this technology has enabled hit identification and confirmation for two histone demethylase targets. 

Comparisons of pharmacology and robustness between fluorescent and mass spectrometry assays will be shown, 

and conclusions drawn on the potential value of HTMS for progression of this emerging target class. 






Session 4: Case Studies for HotTargets: 

From the Lab to Lead Compounds 

Session Chair: Phillip Tagari, Amgen 


2:00 – 2:30 pm 

Plenary: Inhibitors of 2-OG Oxygenases for the Treatment of Anemia and Cancer 

Philip Tagari, Amgen Inc. 

2:30 – 3:00 pm 

Comprehensive Enzyme Profiling for Targeted Cancer Drug Discovery: A Target Class Approach to 

Histone Methyltransferases 

Margaret Porter Scott, EpiZyme, Inc. 

3:00 – 3:30 pm 

Identification and Characterization of Potent and Selective Antagonists of the Nuclear Receptor RORc 

Xiao Hu, Lycera Corporation 

3:30 – 4:00 pm 

Targeting the Ubiquitin Pathway: Beyond the Proteasome 

Craig Allan Leach, Progenra Inc. 

4:00 – 4:30 pm 

Development of Novel Anti-Cancer Therapeutics that Reduce Tumor-Initiating Cell Frequency 

Timothy Hoey, OncoMed Pharmaceuticals, Inc. 



Inhibitors of 2-OG Oxygenases for the Treatment of Anemia and Cancer 

Philip Tagari, Amgen Inc. 

The alpha-ketoglutarate (2-OG) oxygenases are a conserved famly of Fe(II)-dependendent enzymes which catalyse a 

wide variety of reactions that include protein and DNA modification, as well as biosynthesis and biodegradation of a 

range of metabolites. Of particular therapeutic interest are the Hypoxia-inducible factor (HIF) prolyl hydroxylases (PHDs) 

which act as the proximal tissue oxygen sensor and thus regulate HIF transcriptional activity (and its sequalae including 

erythropoiesis), and the Jumonji domain and containing (JmjC) enzymes which are capable of modulating the methyl 

marking of histone tails (via lysine demethylation) and thus may play a role in cancer epigenetics. Attempts to discover 

lead molecules for both classes will be described. 

Comprehensive Enzyme Profiling for Targeted Cancer Drug Discovery: 

A Target Class Approach to Histone Methyltransferases 

Margaret Porter Scott, EpiZyme, Inc. 

Histone methyltransferases (HMTs) represent a large class of chromatin modifying enzymes. Using computational methods, 

we defined a class of 96 putative human HMTs. We developed robust biochemical activity assays for multiple HMTs and 

combined them with medicinal chemistry to develop a biased library of HMT inhibitors. This approach has resulted in the 

rapid discovery of potent, selective inhibitors for multiple HMTs that are being pursued as starting points for cancer drug 

discovery efforts. 

Identification and Characterization of Potent and 

Selective Antagonists of the Nuclear Receptor RORc 

Xiao Hu, Lycera Corporation 

T-helper 17 (Th17) cells are a distinct subset of CD4+ T cells characterized by production of interleukin-17 (IL-17), a highly 

inflammatory cytokine that plays an important role in the pathogenesis of multiple autoimmune diseases. RORC2 (RORgt) 

is the key transcription factor that orchestrates the differentiation of Th17 cells, inducing transcription of the genes encoding 

IL-17. Mice with deficient RORC2 T cells are resistant to the development of multiple autoimmune diseases, thus inhibiting 

RORC2 activity should reduce the severity of autoimmune diseases. RORC2 is an isoform of the nuclear receptor RORC 

(NR1F3), which differs in N-terminal region but shares identical DNA and ligand binding domains with RORC1. Here we report 

the identification and characterization of novel, potent and selective antagonists of RORC. We show that these antagonists 

bind to the ligand binding domain, block the recruitment of coactivator and inhibit the transcriptional activity of RORC. In 

murine and human T cells, they inhibit multiple Th17 cytokines during and after Th17 differentiation. We also present data 

showing the in vivo efficacy of representative compounds in animal models where IL-17 is induced. These potent and selective 

RORC antagonists are thus high quality candidates for further pre-clinical development and subsequent clinical testing. 



Targeting the Ubiquitin Pathway: Beyond the Proteasome 

Craig Allan Leach, Progenra Inc. 

The FDA approval of Velcade ® , an inhibitor of the ubiquitin proteasome, has provided validation of the utility of targeting the 

ubiquitin pathway for therapeutic development. Inhibition of the proteasome is a global and non-selective method of disturbing 

the ubiquitin pathway. Progenra believes that by selectively targeting either the ubiquitin ligases (~600 in mammalian cells) 

or the ubiquitin specific proteases (~100 in mammalian cells) it will be possible to develop therapeutics with significantly less 

toxicity than that of proteaseome inhibitors. Progenra has developed novel technology platforms to identify inhibitors of these 

classes of enzymes and employed them to identify a MuRF1(E3 ligase) inhibitor and a USP7 (protease) inhibitor. Progenra has 

utilized medicinal chemistry to improve the properties of these “hits” and has demonstrated in vivo efficacy of these compound 

classes. The data presented demonstrate the potential of selectively targeting enzymes within the ubiquitin conjugation/ 

deconjugation pathway. 

Development of Novel Anti-Cancer Therapeutics That Reduce 

Tumor-Initiating Cell Frequency 

Timothy Hoey, OncoMed Pharmaceuticals, Inc. 

Cancer stem cells (or tumor initiating cells) have been shown to mediate tumor progression, metastasis, and recurrence after 

therapy. We have isolated and characterized CSCs from a variety of major tumor types and have found that these cells are 

preferentially resistant to many current therapies. We have developed new agents that block key CSC pathways including 

Notch and Wnt. These treatments inhibit tumor growth through multiple mechanisms, promote tumor cell differentiation and 

reduce CSC frequency. 







Session 4: The Application of Modern Drug Target Validation 

Technologies: Profiling, HT Sequencing, RNAi, cDNA, 

Compounds, Peptides, Proteins and Structural Biology 

Session Chair: Daniel Sipes, Genomics Institute of the Novartis Research Foundation 


2:00 – 2:30 pm 

Plenary: Expanding the Utility of Miniaturized HTS: From Screening to Profiling and Target Identification 

Daniel Sipes, Genomics Institute of the Novartis Research Foundation 

2:30 – 3:00 pm 

Technologies Recently Developed for the Determination of the Cellular Activity of Small Molecules 

Frederick J. King, The Novartis Institute of Biomedical Research 

3:00 – 3:30 pm 

Now What? Approaches to Following Up Large-Scale Screening 


3:30 – 4:00 pm 

Parallel Small-Scale Expression and ELT Screening of Drug Targets to Explore Druggability and 

Generate Chemical Probes 

Jeffrey Gross, GlaxoSmithKline 

4:00 – 4:30 pm 

Target Validation Strategies for Protease Research 

Lorenz M. Mayr, Novartis Pharma AG 



Expanding the Utility of Miniaturized HTS: 

From Screening to Profiling and Target Identification 

Daniel Sipes, Genomics Institute of the Novartis Research Foundation 

At GNF, we recently expanded the utility of our proprietary automated platforms for cell-based screening more deeply into the 

drug discovery process. We have utilized GNF-built automation, as well as other commercially available technologies, to enable 

cost effective and rapid cell-based compound profiling. In addition, this approach has enabled scientists to run primary cell 

assays on a scale not otherwise practical. Applying high throughput screening technology in this manner has resulted in the 

ability to rapidly determine compound mechanism-of-action in a biologically relevant context. 

Technologies Recently Developed for the Determination 

of the Cellular Activity of Small Molecules 

Frederick J. King, The Novartis Institute of Biomedical Research 

Several technological advancements over the last decade have expanded the role of high throughput screening platforms 

beyond their traditional use in drug discovery. These additional purposes include chemical genomic approaches to 

therapeutic target identification, where compounds with provocative cellular properties are identified from cell-based screens. 

This is followed by the determination of the corresponding cellular efficacy target and/or mechanism of action (MoA) of the 

small molecules. Compound affinity chromatography, where cellular proteins that physically associate with the compounds 

are identified, has been a popular methodology for small molecule MoA determination. This approach has been shown to be 

successful, yet the process is fairly resource intensive, time consuming and challenging for certain classes of compounds. 

These limitations have encouraged the development of complementary platforms. Two examples will be presented: one that 

provides large scale, low cost compound analysis by leveraging HTS equipment along with well-established reporter gene 

assays and a second approach that applies recent advancements related to complete genomic sequence analyses from cells 

that harbor allelic variations that result from compound treatment. 

Now What? Approaches to Following Up Large-Scale Screening 


RNAi and other genomic screening methods have been available for nearly a decade. A good screen generally gives dozens to 

hundreds of hits. I will discuss our strategy to following up screens. This includes pathway analysis, grouping hits by pathways 

and ontologies. We are also applying data integration and combining data from RNAi screens with other large-scale genomic 

data sets such as gene expression and sequence analysis. Finally, once lists are generated, experimental approaches are 

used to identify the most promising hits. I will discuss using other screening strategies such as viral expression and kinetic 

luminescence imaging to identify genes to take into in vivo experimentation and small molecule screening. 



Parallel Small-Scale Expression and ELT Screening of Drug Targets 

to Explore Druggability and Generate Chemical Probes 

Jeffrey Gross, GlaxoSmithKline 

The availability of molecular probes that are suitable for target validation studies is a clear gap in many evolving biological 

target areas. Here we describe the use of a parallel, Encoded Library Technology (ELT) screening approach that addresses 

this gap by providing a way to rapidly triage large set of targets for identification of those tools. This ELT approach takes 

advantage of the scalable aspects of ELT, the minute (¬µg) protein requirements, and the recent increase in DNA sequencing 

capacity, that now make it now feasible to simultaneously screen and prosecute dozens of drug targets. ELT is a relatively 

new Hit ID approach in which molecular targets are incubated with billion member DNA-encoded combinatorial chemistry 

libraries. DNA sequencing is then used to identify the molecules that had bound to the target, and finally, traditional 

medicinal chemistry is used to synthesize the relevant molecules for in vitro testing. In this example, we have developed 

the methodology to screen six target batches of antibacterial targets in a one day experiment, and used this technique to 

rapidly screen ~ 30 genetically validated targets, yielding novel chemical matter for many of the targets. This approach may 

be especially valuable in other disease areas, such as epigenetics, where better molecular tool are clearly needed. Details 

on the experimental and process design will be discussed. 

Target Validation Strategies for Protease Research 

Lorenz M. Mayr, Novartis Pharma AG 

For the pharmaceutical industry, success in the clinic should be the ultimate criterion for our activities in target validation. 

However, the continued high rate of efficacy failures in many pharmaceutical and biotechnology companies has forced 

us to rethink not only our target validation, but also our hit finding strategies. Today, much more focus is given on a 

thorough validation and mechanistic understanding of a particular target before we go into extensive hit and lead finding 

activities. Target validation strategies do depend on the specific requirement of a particular indication or disease area, but 

nevertheless some general principles have emerged over the last years in our organisation. Lorenz Mayr will discuss with 

specific examples about Novartis’ comprehensive and contemporary framework of approaching target validation in drug 

discovery for proteases through: a) Overview of target validation strategies for proteases; b) Target validation by chemical 

compounds; c) Target validation by antibodies and aptamers; d) Target validation by si/sh RNA technologies; e) Target 

validation by transgenic animals; f) Case studies for protease drug discovery projects; g) Summary and outlook. 






Session 5: Innovations in Screening and Sample 

Management: Technologies and Processes 

Session Chair: Claude DuFresne, Merck 

Location: Naples 

9:00 – 9:30 am 

Recent Developments in Technologies and Processes in Support of Lead Optimization Efforts 

Claude Dufresne, Merck Research Laboratories 

9:30 – 10:00 am 

The Impact of Non-Contact Picoliter Dispense Technology in the Elimination of Serial Dilution 

Daniel Thomas, GlaxoSmithKline 

10:30 – 11:00 am 

Labware Leachables: Do You Know What’s In Your Assay Well? 


11:00 – 11:30 am 

Investigating the Stability of High Concentration DMSO Solutions 


11:30 am – 12:00 pm 

The Optimization of Instrumentation, Workflow and Data Analysis for In Vitro ADME Assays: A Business Case 

Thomas Arnhold, Boehringer Ingelheim Pharma GmbH and Co KG 



Recent Developments in Technologies and Processes 

in Support of Lead Optimization Efforts 

Claude Dufresne, Merck Research Laboratories 

Activities supporting the world of lead optimization differ significantly from those of primary screening. Adapting technologies 

that were designed for screening therefore presents unique challenges. This talk will review a wide range of processes 

implemented in support of the lead optimization phase of drug discovery. Sample handling will be discussed from practical 

viewpoints of storage, dispensing, creation of dose response titration series, and solubility issues. Assay execution 

infrastructures enabling efficient FTE and reagent utilization profiles while meeting the time sensitive needs of medicinal 

chemists will be discussed. By no means will this talk present a realized Holy Grail, but rather review existing approaches 

with the goal of eliciting productive discussions and new industry innovations. 

The Impact of Non-Contact Picoliter Dispense Technology 

in the Elimination of Serial Dilution 

Daniel Thomas, GlaxoSmithKline 

Serial dilutions are used ubiquitously in pharma discovery, especially within therapeutic areas, ADMET and assay development 

in the generation of standard curves and compound response curves (CRCs). Existing compound CRC approaches have 

commonly started with concentrated DMSO solutions which are then serially diluted prior to generating daughter plates for 

assay. Inkjet printing technology is now being used to dispense 20 picoliter droplets of reagents dissolved in a DMSO or 

aqueous solvent, enabling concentration-response-curves to be generated without the need for serial dilution. The required 

number of droplets is rapidly dispensed to obtain dosages from low nanomolar to high micromolar concentrations for a 

typical assay volume. This direct titration method simplifies discovery workflows, saving both time and materials. Using this 

methodology, intermediate plates can be eliminated together with a large reduction in compound/reagent usage as well as 

chemical waste. Direct titrations fundamentally improve the quality of dose-response data by eliminating serial dilution steps, 

avoiding carryover and allowing the user to digitally control the total dispense volume enabling the generation of any dose in 

any well. Ultimately this can be used to create high density bespoke titrations spanning regions of interest, assisting in the 

interrogation of target and compound mechanisms of action or drug-drug interaction studies. In summary, this digital picoliter 

dispense technology dramatically improves data quality while minimizing cost and time, both of which are critical aspects of 

lead generation and optimization that drive decision making. A number of different applications within the early drug discovery 

process will be presented. 

Labware Leachables: Do You Know What’s In Your Assay Well? 


We have determined that chemicals routinely used in plastics manufacture can leach from disposable labware and be 

introduced into biological assays. Moreover, these contaminants can possess biological activity and interfere with downstream 

bioassays. We will present several examples of such contamination, discuss the practices we have put into place to analyze 

and identify the contaminants, and make some recommendations to prevent or minimize the impact of labware contamination. 



Investigating the Stability of High Concentration DMSO Solutions 


Over the past decade, several reports have been published looking at the impact of several factors on the stability of small 

molecules in DMSO solutions. These studies included investigations of the impact of storage temperature, number of freezethaw 

cycles, oxygen/inert environment, water, and container type. The reports were based on studies performed on stock 

solutions of 10mM or less. Fragment-based drug discovery has come into sharp focus in recent years and many pharmaceutical 

and biotech R&D labs are using this approach as a successful (and complimentary) approach to other methods for identifying 

active molecules. Fragments are, by design, low molecular weight compounds (usually less than 250 Da) with lower affinity for 

their target than HTS hits. They have to be screened at higher concentrations (100¬µM or higher, as opposed to a more typical 

1 ‚Äì 10 ¬µM HTS assay concentration), while maintaining the same levels of DMSO (typically 1% or lower). As a result, stock 

solutions of fragment molecules in DMSO have to be made at high concentrations, typically 40mM and up, compared to the 

typical 1-10mM for HTS. All these higher concentration DMSO stocks, as well as higher assay concentrations, are uncharted 

territory for compound management and screening labs in terms of knowledge on how these solutions will behave in storage, 

in time, and how soluble they are in biological assay buffers. In this study we investigated the stability of higher concentration 

DMSO stocks, and looked at their relationship with initial solution purity, intrinsic and calculated physico-chemical properties 

of the compounds, and water uptake in DMSO. We will discuss the factors that had a significant impact on the outcome of 

the solutions in storage. Further studies will include investigating the buffer solubility of these higher concentration stocks at 

relevant biological assay concentrations. 

The Optimization of Instrumentation, Workflow and Data Analysis for In Vitro ADME Assays: 

A Business Case 

Thomas Arnhold, Boehringer Ingelheim Pharma GmbH and Co KG 

A business case/example based on in vitro metabolic stability experiments will be presented demonstrating the optimization 

of individual workflow steps including experiment request, assay planning, automated incubations, automated MS tuning and 

analysis, data capture, result generation and reporting. The presented solution comprises a mixture of commercial or in house 

components combined with the overall aim to increase quality and quantity by reducing manual intervention during execution 

of experiments, but also within its data flow. 






Session 5: Leveraging a National Resource: The Molecular 

Libraries Probe Development Network (MLPCN) 

Session Chair: Christopher Austin, NIH Chemical Genomics Center 


9:00 – 9:30 am 

The MLPCN: Mission, Collaborative Operation, and Accomplishments 

Christopher Austin, NIH Chemical Genomics Center 

9:30 – 10:00 am 

High Content Screening: A Platform to Discover Novel Drug-Like & Chemical Biological Probes for Several 

Target Classes 


10:30 – 11:00 am 

Infectious Agents and Drug Discovery: How to Conduct HTS Screening Campaigns Under BSL-2 and BSL-3 

Level Containment 

E. Lucile White, Southern Research Specialized Biocontainment Screening Center 

11:00 – 11:30 am 

Integrating Novel Technologies to Identify Small-Molecules That Drive Translational Research and Therapeutics 

Michelle Palmer, Broad Institute of Harvard and MIT 

11:30 am – 12:00 pm 

Change in Heartbeat: When Vast Chemical Diversity Meets Ion Channel Targets 

Min Li, Johns Hopkins Ion Channel Center 



The MLPCN: Mission, Collaborative Operation, and Accomplishments 

Christopher Austin, NIH Chemical Genomics Center 

The mission of the Molecular Libraries Probe Production Centers Network (MLPCN) is to produce high-quality small molecule 

probes of important and novel biology, both as research tools to decipher gene and pathway functions, and as starting points 

for the development of new therapeutics for human disease. Since its inception in 2004, MLPCN centers have collaborated with 

hundreds of researchers worldwide on projects in an enormous diversity of target classes, physiological processes, and disease 

states, and produced probes that have led to fundamental insights and therapeutic development programs in virtually all areas 

of biology and medicine. This talk will review the mission, scope, and accomplishments of the MLPCN and the Molecular 

Libraries Program as a whole, including the development of a firmly precompetitive space for small molecule discovery and 

chemical genomics. 

High Content Screening: A Platform to Discover Novel Drug-Like 

& Chemical Biological Probes for Several Target Classes 


High Content Screening (HCS) is a powerful technology that combines the power of high-resolution confocal fluorescence 

microscopy, with automated focusing, microscopic stage control, image acquisition and algorithmic image processing, feature 

analysis, and parameter extraction, to permit the identification of molecules that alter cellular phenotypes, in rich and vivid 

temporal and spatial intracellular detail. Details of HCS on several target classes and phenotypic assays as well as challenges 

and success stories will be shared. 

Infectious Agents and Drug Discovery: How to Conduct HTS Screening 

Campaigns Under BSL-2 and BSL-3 Level Containment 

E. Lucile White, Southern Research Specialized Biocontainment Screening Center 

The need to develop new antimicrobial and antiviral therapeutics has never been more pressing. The development of antibiotic 

resistant organisms such as MSRA and MDR-TB, have created serious public health outbreaks with limited treatment 

options. The need for effective antiviral drugs was highlighted during the 2010 H1N1 flu pandemic. Vaccine production 

lagged far behind the rapidly spreading virus and quarantine was ineffective in controlling the spread of the virus throughout 

the world. If this virus had maintained the mortality rate seen in the initial outbreaks, the number of casualties worldwide 

would have been staggering. Southern Research Institute is actively working on drug development for a range of infectious 

agents and is currently funded as part of the NIH Molecular Libraries Initiative to provide access to the program for projects 

that require containment for their execution. How the HTS Center has implemented high throughput screening with infectious 

agents under both BSL-2 and BSL-3 containment will be discussed. This includes overall strategy, safety issues, equipment 

selection and assay design. A selection of projects funded by this program will be used to illustrate these issues. This work 

was supported in part by Award U54HG005034 from the National Human Genome Research Institute. The content is solely 

the responsibility of the author and does not necessarily represent the official views of the National Human Genome Research 

Institute or the National Institutes of Health. 



Integrating Novel Technologies to Identify Small-Molecules That Drive Translational 

Research and Therapeutics 

Michelle Palmer, Broad Institute of Harvard and MIT 

Advances in human genetics have lead to new drug discovery strategies that may lower the rate of attrition when translated 

to human trials. Molecular characterization of patient tissues is providing new insights into the root cause of many diseases. 

Many of these insights point to targets that have traditionally been challenging for small-molecule therapeutics. Identification 

of drugs to modulate targets such as transcription factors and regulatory RNAs and processes such as disruption of specific 

protein-protein interactions require innovation in chemistry, cell-culture science and mechanism of action studies. At the Broad 

Institute, we have integrated technology initiatives across all aspects of lead identification in an effort to realize the benefit of 

the genes to drugs approach. Research vignettes describing our efforts towards these goals will be provided. 

Change in Heartbeat: When Vast Chemical Diversity Meets Ion Channel Targets 

Min Li, Johns Hopkins Ion Channel Center 

Ion channels are important molecules both in health and in diseases. Intrinsic properties of ion channels have made them 

difficult to access using routine high throughput methodology. Johns Hopkins Ion Channel Center (JHICC) is a member of 

MLPCN dedicated to developing assays and performing high throughput screens for ion channel targets. By combining 

conventional high throughput technologies and automated electrophysiology, we have completed 16 major high throughput 

campaigns including voltage-gated ion channels, various TRP channels, chloride channels and several transporters. The talk 

will summarize the on-going work and future directions at JHICC. 







Session 5: Prediction & Elucidation of Target Liabilities 

Session Chair: Keith Houck, Environmental Protection Agency 


9:00 – 9:30 am 

Plenary: Elucidation of Adverse Bioactivity Profiles as Predictors of Toxicity Potential 

Keith Houck, National Center for Computational Toxicology, Office of Research and Development, US EPA 

9:30 – 10:00 am 

Utilities of in Vitro Safety Pharmacology in Early Drug Discovery: Mitigation of ADRs 

Laszlo Urban, Novartis Institutes for Biomedical Research 

10:30 – 11:00 am 

From Data to Knowledge: Integration of Compound Structure and Activity With Clinical Adverse Drug Reactions 

Eugen Lounkine, Novartis Institutes for Biomedical Research 

11:00 – 11:30 am 

Identification of Systemic Toxicity Triggers Associated With VEGF-R Inhibitors 

Paul Nioi, Amgen Inc. 

11:30 am – 12:00 pm 

In Silico Modeling for Predicting In Vivo Kinetics and Toxicity During Drug Discovery 

Simon Thomas, Cyprotex Discovery Ltd 



Elucidation of Adverse Bioactivity Profiles as Predictors of Toxicity Potential 

Keith Houck, National Center for Computational Toxicology, Office of Research and Development, US EPA 

Toxicity testing in vitro remains a formidable challenge due to lack of understanding of key molecular targets and pathways 

underlying many pathological events. The combination of genome sequencing and widespread application of high-throughput 

screening tools has provided the means to extensively explore the interactions of small molecules with many potential targets 

of toxicity. Through the ToxCast program, we have evaluated the effects of a diverse set of environmental chemicals with 

known in vivo toxicities on a diverse array of molecular targets and pathways using biochemical assays focusing on numerous 

protein super-families as well as with cellular assays looking at effects on a variety of signaling pathways and phenotypic 

endpoints. Initial results included identification of unique bioactivity profiles that correlated with animal toxicity endpoints 

including liver cancer, developmental and reproductive toxicity and disruption of vasculogenesis. To increase our coverage 

of potential toxicity targets we have expanded our assay diversity to include screens focused on critical signaling pathway 

nodes. In addition, we have broadened the chemical diversity beyond our initial focus on pesticides to encompass many 

classes of chemicals of environmental significance. Importantly, we also included a collection of human pharmaceuticals and 

drug candidates that failed during clinical development or post-launch due to toxicity issues. These compounds may serve to 

bridge species differences between standard laboratory models and human effects. Preliminary results show that differences 

between environmental chemicals and pharmaceuticals lay primarily in differences in potency, with both groups of chemicals 

showing relatively wide target promiscuity. Collation of the in vivo toxicity information for both environmental chemicals and 

pharmaceuticals in to a relational database is underway and will serve as an anchor for developing new models correlating in 

vitro bioactivity profiles with in vivo, adverse endpoints. This work was reviewed by U.S. EPA and approved for publication but 

does not necessarily reflect official Agency policy. 

Utilities of In Vitro Safety Pharmacology in Early Drug Discovery: Mitigation of ADRs 

Laszlo Urban, Novartis Institutes for Biomedical Research 

In vitro safety pharmacology has been applied for many years in different forms to drug discovery. However, recent 

development of assay technologies, automation and in silico sciences transformed the panel of assays into a powerhouse 

of early safety profiling with a unique ability to support mitigation based on off-target SAR. 

From Data to Knowledge: Integration of Compound Structure 

and Activity with Clinical Adverse Drug Reactions 

Eugen Lounkine, Novartis Institutes for Biomedical Research 

Adverse drug reactions (ADRs) represent a valuable, albeit limited, data source about complex, phenotypic effects 

of drugs in humans. In order to exploit the full potential of this information, both for increasing compound safety and 

drug repositioning opportunities, it needs to be integrated with the wealth of bioactivity data and chemical descriptors 

currently available for drugs and other compounds. Statistical and knowledge-based computational approaches allow 

for associations of adverse events with targets of marketed drugs. A key challenge is the extrapolation of ADR data 

to pharmacological and chemical space not yet covered by marketed drugs. This can be achieved by assessment 

of compounds selective against ADR-associated targets in large bioactivity databases. Thus, potential liabilities of 

compounds binding targets not covered by marketed drugs can be suggested together with chemical changes to 

compounds that increase their selectivity for primary vs. off-targets. 



Identification of Systemic Toxicity Triggers Associated With VEGF-R Inhibitors 

Paul Nioi, Amgen Inc. 

The key to the discovery of new pharmaceuticals is to develop molecules that interact with the intended target and 

minimize interaction with unintended molecular targets, therefore minimizing toxicity. This is aided by the use of various in 

vitro selectivity assays that are used to select agents most potent for the desired target. Typically, molecules from similar 

chemical series, with similar in vitro potencies, are expected to yield comparable in vivo pharmacological and toxicological 

profiles, predictive of target effects. However, in this study, we investigated the in vivo effects of two analogue compounds 

that similarly inhibit several receptor tyrosine kinases such as vascular endothelial growth factor receptor 1 (VEGFR/Flt1), 

vascular endothelial growth factor 2 (VEGFR2/kinase domain receptor/Flk-1), vascular endothelial growth factor receptor 3 

(VEGFR3/Flt4), platelet-derived growth factor receptor (PDGFR), and Kit receptors, which bear similar chemical structures, 

have comparable potencies, but differ markedly in their rodent toxicity profiles. Global gene expression data were used 

to generate hypotheses regarding the existence of toxicity triggers that would reflect the perturbation of signaling in 

multiple organs such as the liver, adrenal glands, and the pancreas in response to compound treatment. We concluded 

that differences in pharmacokinetic properties of the two analogues, such as volume of distribution, half-life, and organ 

concentrations, resulted in marked differences in the chemical burden on target organs and may have contributed to 

the vast differences in toxicity profiles observed with the two otherwise similar molecules. We propose including select 

toxicokinetic parameters such as Vss, T 1/2, and T max as additional criteria that could be used to rank order compounds 

from the same pharmacological series to possibly minimize organ toxicity. Assessment of toxicokinetics is not an atypical 

activity on toxicology studies, even in early screening studies; however, these data may not always be used in decision 

making for selecting or eliminating one compound over another. Finally, we illustrate that in vivo gene expression profiles 

can serve as a complementary assessor of this activity and simultaneously help provide an assessment of on or off-target 

biological activity. 

In Silico Modeling for Predicting In Vivo Kinetics and Toxicity During Drug Discovery 

Simon Thomas, Cyprotex Discovery Ltd 

Recent advances in in silico modeling techniques for integrating in vitro ADME and tox data to predict in vivo outcomes will be 

reviewed. The potential benefits of early data integration via appropriate modeling strategies will be outlined, and challenges 

and prospects for the future outlined. 



Podium Speaker Index 

Speaker Page Speaker Page Speaker Page 

Allen, Jack 46 

Arnhold, Thomas 74 

Atkinson, Mark 40 

Austin, Christopher 76 

Barry, Clifton 49 

Bouvier, Michel 43 

Bryans, Justin 41 

Burn, Paul 40 

Chatelein, Pierre 62 

Chen, Catherine 44 

Chenchik, Alex 56 

Chung, Thomas “T.C.” 41, 76 

Clark, Anthony J. 62 

Conant, Carolyn 38 

Corazza, Sabrina 61 

Diaz, Paul 50 

Dudley, Joel 52 

Dufresne, Claude 73 

Duhr, Stefan 64 

Duncan, Ken 49 

Gregory, Kellan 59 

Gross, Jeffrey 71 

Guy, R. Kip 49 

Hammonds, Tim 50 

Hertzberg, Bob 58 

Hoey, Timothy 68 

Hogenesch, John 70 

Houck, Keith 79 

Hu, Xiao 67 

Inglese, James 64 

Jacobson, Stephen C. 38 

Kammonen, Juha 47 

King, Frederick J. 70 

Langewald, Juergen 61 

Leach, Craig Allan 68 

Leveridge, Melanie 65 

Li, Min 77 

Lipinski, Christopher A. 43 

Jinfeng, Liu 53 

Loging, William 53 

Lounkine, Eugen 79 

Mayr, Lorenz M. 71 

McDonald, Patricia 65 

Mdluli, Khisimuzi 58 

Myer, Vic 55 

Nioi, Paul 80 

O'Connell, Jonathan 46 

Palmer, Michelle 77 

Perrier, Anselme 44 

Phelps, Ken 43 

Popa-Burke, Loana 74 

Price, Jeffrey 64 

Ramsey, Michael 37 

Reed, John 41 

Russell, Rachel 47 

Schopfer, Ulrich 55 

Scott, Margaret Porter 67 

Sipes, Daniel 70 

Slack, Jay 61 

Spence, Dana M. 37 

Spicer, Timothy 55 

Su, Andrew 52 

Sugiura, Shinji 38 

Tagari, Philip 67 

Thomas, Daniel 73 

Thomas, Simon 80 

Torrance, Chris 56 

Urban, Laszlo 79 

van Deutekom, Judith C.T. 59 

Vega, Virneliz Fernandez 59 

Watson, John 73 

Weston, Andrea 46 

White, E. Lucile 76 

Ziemek, Daniel 52 






Poster Program 

M = Monday T = Tuesday W = Wednesday * = Presenting Author 

Monday, March 28; 11:30 am – 1:00 pm (presenters are available) 

M100: GABAB Receptor Allosteric Ligands Exhibit 

Pathway—Selective and Context-Dependent Effects: 

Implication for Drug Screening 

*Emmanuel Sturchler, Scripps, Florida; 


M101: Instrument-Free and High-Throughput Screening 

of Mutagenic/Carcinogenic DNA Sensitizing Drugs 

Using Gold Nanoparticles and Functional DNAs 

*Joong Kim, Bong Chung, Korea Research Institute 

of Bioscience and Biotechnology 

M102: Microfluidic Platform for High-Throughput 

Drug Screening of Angiogenesis Inhibitors During 

Endothelial Vessel Formation and Anastomosis 

*Travis Moore, Ju Hun Yeon, Sudong Kim, Hyun Jae Lee, 

Noo Li Jeon, Seoul National University 

M103: In-Vitro Assessment of Mango Extracts 

and the Phytochemicals Resveratrol, Quercetin, 

Mangiferin and Epigallocatechin Gallate on Lipid 

Accumulation in a Mouse Adipocyte Cell Line 

*Meng-Wong Taing, Meng-Wong Taing, Gregory Monteith, 

Ralf Dietzgen, Mike Gidley, Sarah Roberts-Thomson, 

Nick Shaw, The University of Queensland 

M104: Discovery of Small Molecule Inhibitors 

of the Putative Oncoprotein MgcRacGAP 

*Arjan van Adrichem, Krister Wennerberg, 

Gretchen Repasky, Laura Turunen, Institute for 

Molecular Medicine Finland FIMM 

M105: Blood-Brain Barrier and Brain Vessel 

Formation Using a Microfluidic Platform 

*Ju Hun Yeon, Noo Li Jeon, Seoul National University 

M106: Essentiality of a Constitutive Pan-Hexose 

Permease for the Plasmodium Life Cycle and 

Transgenic Models for Screening of Anti-Malarial 

Sugar Analogs 

*Nishith Gupta, Humboldt University 


M107: A Constitutive Pan-Hexose Permease for 

the Plasmodium Life Cycle and Transgenic Models 

for Screening of Anti-Malarial Sugar Analogs 

*Nishith Gupta, Martin Blume, Humboldt University; Marion 

Hliscs, Max-Planck Institute for Infection Biology; Dayana 

Rodriguez, Marco Sanchez, Scott Landfear, Oregon Health 

& Sciences University; Richard Lucius, Humboldt University; 

Kai Matuschewski, Max-Planck Institute for Infection Biology 

M108: Biophysical Technologies in Early Lead 

and Drug Discovery Efficiently Advance the 

Best Hits to the Next Stage 

*Vincent Acker, Vincent Acker, Danielle Barlier, Christian 

Bergsdorf, Aline Tirat-Boeuf, Lukas Leder, Sylvia Buhr, 

Jutta Blank, Jean-Michel Rondeau, Johannes Ottl, 

Novartis Pharma AG 

M109: Development of G9a (Histone H3K9 

methyltransferase) Assay Using HTRFÂ ® Technology 

*Koji Adachi, Chikashi Tokuda, Sceti Medical Labo K.K.; 

Fabienne Chevallier, Marc Preaudat, Cisbio Bioassays 

M110: A Lead Finding Strategy for Protein-Protein 

Interaction inhibitors Coupling a 1536-Well ELISA 

Assay With Surface Plasmon Resonance Follow-up 

*Gregory Adam, Joseph Rizzo, Edward DiNunzio, Kartik 

Narayan, Jason Cassaday, Tim Hare, Edward Hudak, 

Alicja Krasowska-Zoladek, Anthony Kreamer, Robert Liehr, 

Carissa Quinn, Keith Rickert, Srivanya Tummala, Kevin Lumb, 

Jeffrey Hermes, Darrell Henze, Merck & Co., Inc. 

M111: Efficient Hit Finding Approaches 

for HMTs–Tthe Key Parameters 

*Thomas Ahrens, Kim Beyer, Andreas Bergner, 

Stephan Fasler, Doris Hafenbradl, BioFocus 

M112: Measuring Residual Volumes Remaining 

in a Microplate After Sample Aspiration 

*Keith Albert, Artel 

M113: An Automated Multi-pH and Multi-Temperature 

Platform for Accelerated Solution Stability Testing 

in Supporting Drug Discovery 

*Yun Alelyunas, AstraZeneca


M114: The Anticancer Properties of a Novel 

(2-benzyloxy-3-methoxy) Phenyl Derivative 

*Zena Al-Mudaris, Amin Abdul Majid, USM 

M115: Efficient High-Throughput Screening of 

Difficult-to-Transfect Cells in 384-Well Format 

*Ludger Altrogge, Andreas Heinze, Timo Gleibner, 

Sheila Offizier, Gina Andretta, Meike Weigel, 

Herbert Mueller-Hartmann, Lonza Cologne AG 

M116: Rapid Exploration of Chemical and 

Biological Space: New Approaches, Informatics, 

Robotics and Libraries 

*Schabdach Amanda, Schabdach Amanda, LCGC; 

Scott Donover, Melvin Reichman, Lankenau Institute 

for Medical Research Chemical Genomics Center 

M117: Use of High Content Analysis for the Prediction 

of Mechanisms of Human Toxicity 

*Robert Annand, Apredica/Cyprotex 

M118: Human Induced Pluripotent Stem Cell Derived 

Cardiomyocytes Enable Large Scale, Robust Assays 

of Cardiac Hypertrophy 

*Blake Anson, Cellular Dynamics International; Tim 

Chendrimada, Teg Pipes, GlaxoSmithKline; Chad Koonce, 

Natsuyo Aoyama, Brad Swanson, Steve Kattman, Cellular 

Dynamics International; Eugene Grygielko, GlaxoSmithKline 

M119: A Homogenous Multiplexing Assay Studying 

the Phosphorylation-Interaction Interplay Between 

MAP2Ks and MAP Kinases 

*Mathieu Arcand, Roger Bosse, Philippe Roby, Sophie Dahan, 

PerkinElmer 

M120: Development of High-Throughput Assays to 

Study Methylases, Demethylases and Deacetylases 

Targeting Histone H3K4, H3K27 and H3K36 Residues 

*Mathieu Arcand, Mireille Caron, Julie Blouin, Claire Normand, 

Anne LabontÃ©, Hendrick Plante, Lucille Beaudet, 

Jaime Padros, PerkinElmer 

M121: A Highly Efficient and Reliable QTempo ® 

by Using A Novel Electrode QT 96 plate for 

*Yasuyuki Asai, Akina Hagino, ReproCELL, Inc; 

Shinji Morimoto Morimoto, NIPRO Corporation 

M122: One Step Preparation of Neuron Derived 

From Human iPS Cells for Drug Development 

*Yasuyuki Asai, Makoto Honda, ReproCELL, Inc. 

M123: A Novel Feeder-Free Medium for Human 

iPS Cells Requires Every-2-Day Medium Change 

on Only Weekday 

*Yasuyuki Asai, Takayuki Kitogo, ReproCELL, Inc. 

M124: A Cell-Based Assay to Identify Drug 

—Target Interactions 

*Daniel Auerbach, Mandana Rezwan, Lukas Baumann, 

Nicole Spoerri, Dualsystems Biotech AG 

M125: A New Tag-lite ® Binding Assay for GLP-1 

Receptor Compounds Screening 

*Sara Bdioui, Thomas Roux, Nathalie Costy, Cisbio Bioassays 

M126: The Next Generation of Cell-Based Imaging 

Assays for Apoptosis and Oxidative Stress from 

Molecular Probes ® 

*Daniel Beacham, Michelle Yan, Scott Clarke, Bhaskar 

Mandavilli, Shih-Jung Huang, Upinder Singh, Michael Janes, 

Nicholas Dolman, Molecular Probes, Life Technologies 

M127: A FCCS Based Platform Technology 

Accelerates Drug Discovery 

Frank Becker, Intana Bioscience GmbH 

M128: Benefits and Operational Performance 

of a Flexible and Modular ‘Plug-n-Play’ uHTS 

System in an Academic Setting 

*Stefan Vasile, Thomas D.Y. Chung, Conrad Prebys 

Center for Chemical Genomics at Lake Nona 

M129: Lead Discovery Strategies for Identification 

of Inhibitors of SUMOylation Pathway 

*Ekaterina Bobkova, Daniela Divlianska, Sharon Colayco, 

Hongbin Yuan, Anton Cheltsov, Fu-Yue Zhang, Yin Su, 

Thomas D.Y. Chung, Eduard Sergienko, Sanford-Burnham 

Medical Research Institute; Larry Tong, Steven Wong, 

Weijun Huang, Yi-Jia Li, Yuan Chen, Beckman Research 

Institute of the City of Hope 

M130: Combining Large Scale Biochemical 

and Cellular Profiling Data to Better Understand 

the Mechanism of Anti-Tumor Drugs 

*Jacob Bode, Blaine Armbruster, Sharon Nauman, 

EMD Millipore; Clare Hadden, Lynn Byers, Merck Millipore; 

Jami Stumler, EMD Millipore 

M131: Monitoring Functional Selectivity of 

GPCR Signalling Using Unbiased Label-Free 

Impedance Measurements 

*Michel Bouvier, Wayne Stallaert, IRIC-Universite de Montreal 



M132: Analysis of Volume Precision and 

Accuracy of a New Device and Method for 

Nanoliter Liquid Handling in Micro Well Plates 

*Tobias Brode, Andreas Traube, Christopher Laske, 

Fraunhofer IPA 

M133: Quality Control Measures in SAR Screening 

*Murray Brown, GlaxoSmithKline 

M134: Automation of Both Sample Preparation 

and Analysis of a Cell Migration Assay 

*Sarah Burroughs, PerkinElmer; Karen Hulkower, 

Jennifer Fronczak, Platypus Technologies; Simone 

Schicktanz, Karin Boettcher, Timothy Cloutier, PerkinElmer 

M135: CMOS-Based Laser Line Confocal Technology: 

Principles and Benefits for HCA Applications 

*Mark Campion, GE Healthcare 

M136: Enabling a Compliant Workflow 

With IN Cell Compliance Manager 

*Mark Campion, GE Healthcare 

M138: HTS for REST Inhibitors in Neural Stem Cells 

Derived From Human Embryonic Stem Cells 

*Jeremie Charboard, Anselme Perrier, Pauline Poydenot, 

I-Stem; Marc Lechuga, Institut de la Vision; Maxime Feyeux, 

I-Stem; Fabrice Casagrande, DISCNGINE; Elena Cattaneo, 

Laboratory of Stem Cell Biology and Pharmacology of 

Neurodegenerative Diseases; Marc Peschanski, I-STEM 

M139: Evaluation of IDE Activators in Multiple 

Assay Platforms 

*Kui (“Kathy”) Chen, Amgen, Inc. 

M140: The Use of a Four-Color Multiplex Antibody 

-Based Assay With Laser-Scanning High Content 

Screening to Examine Kinase Inhibitor Effects on 

Cellular Signaling 

*Jessica Cherry, Cell Signaling Technology; Paul Wylie, 

TTP Labtech; Christopher Manning, Cell Signaling 

Technology; Diana Caracino, TTP Labtech; Randall 

Wetzel, Jessica Cherry, Cell Signaling Technology 

M141: NA-Fluorâ„¢ and NA-XTDâ„¢ Influenza 

Neuraminidase Assays for Neuraminidase 

Quantitation and Inhibition Assays 

*Anthony Chiulli, Corinne Miller, Albana Mihali, 

Life Technologies 


M142: 3D Patterned Blood Vessel Network 

and its Application for Drug Screening 

*Yekyung Cho, Ju Hun Yeon, Noo Li Jeon, Yekyung Cho, 

Seoul National University 

M143: Direct, Real-time Detection of Protein 

Conformation: Revealing Therapeutic Opportunities 

Using Second Harmonic Generation (SHG) Detection 

*Joshua Salafsky, Ryan P. McGuinness, Simon Pitchford, 

Christopher B. Tom, Biodesy LLC 

M144: Analyses of Gene Expression and MicroRNA 

Profiles in Ovarian Cancer Cells and Xenograph Tumors: 

Implications in Aggressive Tumor Phenotype 

*Natalie Ciomek, Florida State University College of Medicine; 

Gregory Stoltzfus, Sarfraz Ahmad, Mohammed Merchent, 

Neil Finkler, Robert Holloway, Susan Ingersoll, Florida Hospital 

Cancer Institute 

M145: Human-Based Systems for In Vitro modeling: 

The Development and Characterization of Induced 

Pluripotent Stem Cell (iPSCs)-Derived Neurons for 

Preclinical Use 

*Carter Cliff, Cellular Dynamics International 

M146: A Multi-Modal Detection Platform For GPCR- 

& RTK-Mediated Signaling Analysis Incorporating 

The Label-Free Corning Epic ® System & Comparison 

To Conventional Assay Platforms 

*Timothy Cloutier, PerkinElmer; Janet Park-Bewsher, 

PerkinElmer; Paul Butler, PerkinElmer; Doug Lohse, Corning 

Inc.; Ravi Marala, Corning Inc.; Heidi Morgan, PerkinElmer 

M147: Assessing Protein Structural Changes 

by Dual Polarization Interferometry 

*Kristin Coan, Novartis Pharma AG; Kristin Coan, Novartis 

Pharma AG; Johannes Ottl, Novartis Pharma AG; Vincent 

Acker, Novartis Pharma AG 

M148: Inhibitor Profiling and Compound Characterization 

on a Microfluidic Mobility-Shift Platform 

*Seth Cohen, Caliper Life Sciences 

M149: Targeting Novel Binding Sites on ProteinTargets 

by High Throughput Affinity Screening 

*Kenneth Comess, Abbott


M150: chAMPion Helps Screening: 

Case Study on CB2 Receptor 

*Sabrina Corazza, Chiara Liberati, Barbara Zanone Poma, 

Loredana Redaelli, Lucia Luzzolino, Andrea Rossignoli, 

Michela Stucchi, Simone Lorenzi, Andrea Beccari, Lia 

Scarabottolo, Axxam SpA 

M151: AlphaLISA is a Homogeneous Sensitive 

Immunoassay for Detection of Analytes in a 

Variety of Biological Matrices 

*Gregory Cosentino, Zaava Ravid, Jean-Francois Michaud, 

Marie-Claude Loiselle, Julie Bedard, Philippe Bourgeois, 

Alexandre Marcil, Josee Frappier, Claire Normand, 

Veronique Brechler, Francesco Lipari, PerkinElmer Inc. 

M152: Development of Strep-Tactin-Conjugated 

Alpha Donor and AlphaLISA Acceptor Beads 

as New Tools for Homogenous Custom-Based 

Protein-Protein Interaction Assays 

*Gregory Cosentino, Lenka Rihakova, Nancy MacDonald, 

Marie Boule, Marie-Helene Venne, Thomas Lassalle, 

Anja Rodenbrock, Stephane Parent, Veronique Brechler, 

Gregory Cosentino, PerkinElmer Inc. 

M153: The FLEXYTE TM Assay Platform: Exploiting 

Fluorescence Lifetime for Drug Screening Applications 

*Graham Cotton, Almac Sciences; Beatrice Maltman, 

Colin Dunsmore, David Anderson, Adina Trinaveanu, 

Almac; Dimitry Gakamsky, Richard Dennis, Edinburgh 

Instruments Ltd 

M154: Novel High Content Stem Cell-based 

Assays for Screening 

*Evan Cromwell, Oksana Sirenko, Pierre Turpin, 

Jayne Hesley, Roger Tang, Molecular Devices 

M155: Selective HDAC4 Inhibitors as Potential 

Therapeutics for Huntington’s Disease 

*David Cronk, Omar Aziz, Julie Vann, Hannah Pett, Melanie 

Wong, Ian Gowers, Richard Martin, George McAllister, 

Elizabeth Thomas, Andrew Stott Alan Haughn, Liz Stones, 

Huw Vater, Mike Wall, Danny Allen, Perla Breccia, Giles Raphy, 

Chris Richardson, Kim Matthews, Dawn Yates, BioFocus; 

Alex Kiselyov, Jonathan Bard, Maria Beconi, Vahri Beaumont, 

Celia Dominguez, Ignacio Munoz-Sanjuan, CHDI foundation; 

Roland Burli, BioFocus 

M156: Acoustic, Touchless, Transfer of Protein 

Crystallography Fluids 

*Sammy Datwani, Richard Stearns, Royal Huang, 

David Harris, Joseph Olechno, Rich Ellson, Labcyte Inc. 

M157: Glucose Detection in Drug Discovery: 

A Novel Assay 

*Chris Davis, Novartis Institutes for BioMedical Research 

M158: HTRF ® Cellular Kinases Assays: A Simple Way 

to Study Activated Erk1/2 and Akt in Whole Cells 

*Francois Degorce, Cisbio Bioassays 

M159: Cell-Based Phosphorylated Akt (Ser473) Detection 

Using HTRF ® Technology and the PHERAstar Plus 

*EJ Dell, BMG Labtech; Laurence Jacquemart, 

Cisbio Bioassays; Franka Ganske, BMG Labtech 

M160: Use of Fluorescence Lifetime Technology 

to Provide Efficient Protection From False Hits in 

Screening Applications 

*Richard Dennis, Anna Gakamsky, S Smith, Dmitry Gakamsky, 

Richard Dennis, Edinburgh Instruments Ltd 

M161: Small Molecule Inhibitors of Bloom Helicase 

Identified by a High Throughput Assay 

*Thomas Dexheimer, NIH/NCGC/NCTT; Giang Nguyen, 

Laboratory of Human Carcinogenesis, Center for Cancer 

Research, NCI, NIH; Georgina Mosedale, Wai Chu, Weatherall 

Institute of Molecular Medicine, University of Oxford, John 

Radcliffe Hospital; Lena Schultz, Masaaki Sakurai, NIH/ 

NCTT/NCGC; Nicola Burgess-Brown, Structural Genomics 

Consortium, University of Oxford; Andrew Rosenthal, David 

Maloney, Ajit Jadhav, NIH/NCTT/NCGC; Curtis Harris, 

Laboratory of Human Carcinogenesis, Center for Cancer 

Research, NCI, NIH; Opher Gileadi, Structural Genomics 

Consortium, University of Oxford; Ian Hickson, Weatherall 

Institute of Molecular Medicine, University of Oxford, John 

Radcliffe Hospital; Anton Simeonov, NIH/NCTT/NCGC 

M162: A Multiplexed Method Useful 

for Defining Cytotoxic Mechanism 

*Daniel Dilks, Andrew Niles, Promega 



M163: Tide Quencher-Based FRET Protease Substrates 

and Their Applications in Screening Protease Inhibitors 

*Jack Diwu, Chunmei Wei, Jinfang Liao, Xing Han, 

AAT Bioquest, Inc. 

M164: Miniaturized Assays to Monitor the 

Enzymatic Activity of Human Flap Endonuclease 

and Related Enzymes 

*Dorjbal Dorjsuren, David Maloney, Ajit Jadhav, NIH Chemical 

Genomics Center, National Human Genome Research Institute, 

Nationl Institutes of Health; David Wilson III, Laboratory of 

Molecular Gerontology, National Institute on Aging, NIH; Anton 

Simeonov, NIH Chemical Genomics Center, National Human 

Genome Research Institute, National Institutes of Health 

M165: Molecular Interaction Studies 

Using Microscale Thermophoresis 

*Stefan Duhr, NanoTemper Technologies 

M166: Labcyte Access Laboratory Workstation 

*Randy Dyer, Labcyte Inc. 

M167: Development of Optimized 3D Migration 

and Invasion Assays for siRNA Screening 

*Victoria Echeverria, BellBrook Labs; Esteban Carrillo, 

Patricia Keely, University of Wisconsin, Madison 

M168: Template-Directed Assembly of Signaling 

Complexes Using Cloned Fragments of Membrane- 

Associated Kinases Restores Biological Function 

*Edward Esposito, Scott Gridley, Anxhela Kole, 

Blue Sky Biotech 

M169: NMR as an Analytical Tool to Study 

Suspensions and Dispersions 

*David Fairhurst, XiGo Nanotools LLC; Terrence Cosgrove, 

Stuart Prescott, University of Bristol 

M170: High-Throughput LanthaScreen ® Cellular 

Assays for Interrogating Post-Translational Modifications 

of p53 and Histone H3 

*Mark Federici, Thomas Machleidt, Kun Bi, Life Technologies 

M171: Genetically Encoded, SH2 Domain-Based 

Fluorescent Reporters of Endogenous Receptor 

Tyrosine Kinase Activity in Living Cells 

*John Fetter, Dmitry Malkov, Nathan Zenser, Keming Song, 

Sigma-Aldrich 


M172: Tag-lite ® is a Useful Technology for the Screening 

and Characterization of Therapeutic Antibodies Targeting 

Tyrosine Kinase Receptor: An EGFR1 Case Study 

*Michel Fink, Fabienne Charrier-Savournin, Julie Vallaghe, 

Cisbio Bioassays 

M173: Validation of 57 Tag-lite ® Ligand Binding 

Assays Starter Packs. Correlation of Agonist and 

Antagonist IC50s Obtained With Tag-Lite and 

Radioactive Ligand Binding Assays 

*Michel Fink, Thomas Roux, Jean-Luc Tardieux, 

Cisbio Bioassays 

M174: A Pathway to Chemical Probes That 

Target Sfp Phosphopantetheinyl Transferase 

*Timothy Foley, Adam Yasgar, Ganesha Rai, Ajit Jadhav, 

David Maloney, James Inglese, Christopher Austin, NIH 

Chemical Genomics Center; Michael Burkart, University 

of California, San Diego; Anton Simeonov, NIH Chemical 

Genomics Center 

M175: TNF-Enhances the Migratory Response 

of Human Adipose-Derived Mesenchymal Stem 

Cells to Kidney Injury Molecule-1 

*Heung-Myong Woo, Stem Cell Institute, School of Veterinary 

Medicine, Kangwon National University, Renal Division, 

Brigham and Women’s Hospital, Harvard Medical School; 

Hyun-Suk Nam, Kyung-Mee Park, Ho-Hyun Kwak, Stem Cell 

Institute, School of Veterinary Medicine, Kangwon National 

University; JV. Bonventre, Renal Division, Brigham and 

Women’s Hospital, Harvard Medical School 

M176: Epigenetic Target Profiling—The Tailor-Made 

Solution for Cellular Epigenetic Selectivity Analysis 

*Jutta Fritz, Christian Eckert, Sebastian Wandinger, 

Klaus Godl, Stefan Mueller, Kinaxo Biotechnologies 

M177: Development and Utilization of Activated 

STAT3 Detection Assays for Screening Library of 

Secreted Proteins 

*Natalie Fursov, Irina Gates, Tadas Panavas, Jill Giles-Komar, 

Gordon Powers, Centocor Research & Development 

M178: KINOMEscan TM : A Comprehensive Biochemical 

Screening Solution that Enables New Paradigms for 

Kinase Inhibitor Drug Discovery 

*Paul Gallant, DiscoveRx Corporation


M179: The Time Has Come for 

Fluorescence Lifetime in HTS 

*Gregory Gillispie, Chad Maccammon, Kurt Peterson, 

Fluorescence Innovations, Inc. 

M180: Targeting the Malarial Protein Kinase PfCDPK1 

*Keith Ansell, Hayley Jones, David Whalley, Simon Osborne, 

Nathalie Bouloc, Tim Chapman, Jonathan Large, Claire 

Wallace, Kristian Birchall, Andy Merritt, Justin Bryans, 

Catherine Kettleborough, Debbie Taylor, MRC Technology; 

Robert Moon, Barbara Clough, Judith Green, Tony Holder, 

NIMR 

M181: Small-Volume HTS Assays With Automated 

Dispensing of Reagents 

*Jon Call, Olga Golovleva, Edgar Johnson; 

Titertek Instruments Inc. 

M182: Neutrophil Adhesion: A HCS Compatible 

Assay Using the Acumen eX3 

*Diane Caracino, Paul Wylie, Diane Caracino; TTP Labtech Inc. 

M183: Implementing Digital Video Recording to 

Increase Laboratory Efficiency 

*Larry Chin, Martin Schwalm, RTS Life Science 

M184: Development of an Improved One-Wash ELISA 

System for Analyte Detection: Fast, Sensitive, Simple 

and Automatable Detection of Phosphoproteins 

*Michael Crouch, Antony Sheehan, Ron Osmond, 

TGR BioSciences 

M185: Antimicrobial Drug Discovery: Dose Response 

High Throughput Screening of Compound Libraries 

against Acinetobacter Baumannii 

*Michael Enervold, John Anderson, Lucile White, 

Anna Manouvakhova, Sara McKellip, Mary-Beth Minyard, 

Miranda Nebane-Akah, Rasmussen Lynn, Lakshmi Reddy, 

Robert Reynolds, Melinda Sosa, Nichole Tower, 

LaKeisha Woods, Kanupriya Whig, Russell Sheppard, 

Southern Research Institute 

M186: High-Content Analysis of Signaling Networks 

Using Protein Fragment Complementation Assays (PCA) 

*Nicole Faust, Lonza Cologne GmbH 

M187: HT RNAi Screening of Anti-Cancer Targets With 

Pooled shRNA Libraries 

*Alex Chenchik, Donato Tedesco, Kyle Bonneau, Mikhail 

Makhanov, Cellecta, Inc.; Costas G. Frangou, Fred Hutchinson 

Cancer Research Center; Peiqing Sun, The Scripps Research 

Institute; Andrei Gudkov, Roswell Park Cancer Institute 

M188: Studying G Protein-Coupled Receptor 

Internalization Using Live Cell Flow Cytometry 

*Radhika Venkat, Multispan Inc. 



Tuesday, March 29; 12:00 – 1:30 pm (presenters are available) 

T300: 300 Nanoliter qPCR in a One Step Process 

From Cells to Cp Utilizing the Echo Liquid Handler 

*Celeste Glazer, Howard Lee, Maria Sonntag, Sammy Datwani, 

Labcyte Inc. 

T301: Site Specific Biotinylated Protein Kinase is 

Easy-to-Use Solution in the SPR Technology for Kinase 

Inhibitor Evaluation 

*Masaki Gouda, Carna Biosciences, Inc./Department of 

R&D; Takeshi Kumagai, Bio-Rad Laboratories K.K./Research 

Solution Center; Yasuyuki Kirii, Masanori Nakamura, Carna 

Biosciences, Inc.; Rita Lim-Wilby, CarnaBio USA, Inc. HQ; 

Mariko Hatakeyama, Koichi Yokota, Carna Biosciences, Inc. 

T302: Turbidometric Performance of Thermo 

Scientific Multiskans 

*Hanna Granö-Fabritius, Jorma Lampinen, Marika Raitio, 

Reija-Riitta Harinen, Thermo Fisher Scientific 

T303: Assay Performance With IN Cell Analyzer 6000 

*Robert Graves, GE Healthcare 

T304: High-Throughput Screening of Chemical Libraries 

With IN Cell Analyzer; Use of IN Cell Miner for Data 

Review and Integration 


T305: Oris TM Pro 384 Cell Migration Assays 

Run on IN Cell Analyzer 2000 


T306: The 3D-Screen Technology: an Innovative 

Cell-Based Assay to Identifify Small Chemical 

Molecules Able to Modulate the Tri-Dimensional 

Structure of a Biological Target 

*Philippe Guedat, Vivalis 

T307: Fluorescence Lifetime Assays— 

An Attractive Addition to the Toolbox of 

Fragment Screening Technologies 

*Doris Hafenbradl, Kim Beyer, Thomas Ahrens, Daniela 

Brodbeck, Stephan Fasler, BioFocus 


T308: Utilizing Endoplasmic Reticulum Stress 

as a Tool for Compound Safety Profiling 

*Christa Hahmann, Scripps Florida; Patricia McDonald, 

Scripps Research Institute; Thomas Schroeter, Pfizer; 

Amiee Weiser, Derek Duckett, Scripps Florida 

T309: Screening and Identification of GPCR 

Agonists Utilizing the Label-Free xCELLigence 

System Impedance-Based, RTCA-HT Instrument 

*Rachid Hamid, Theresa Truitt, David Mark, Hoffmann 

La Roche; Ning Ke, Yama Abassi, Acea Biosciences; 

Kiarat Madin, Roche Diagnostics 

T310: The PrestoBlue TM Cell Viability Reagent: 

Measure Cell Viability in a Fraction of the Time 

*Bonnie Hanson, Life Technologies 

T311: Appraisal of Polyelectrolyte Surfaces for 

Multiplexed Protein-Chip Bio-Sensors Based on 

Surface Plasmon Resonance (SPR) Microscopy 

*Michael Hart, Institute for Systems Biology; Andrew Weber, 

Plexera, Institute for Systems Biology 

T312: A Fluorescence Microplate-Based Assay 

Workflow Enabling the Functional Characterization 

of Multidrug Resistance Transporters in Living Cells 

*Paul Held, BioTek Instruments; Irina Lebedeva, 

Enzo Life Sciences; Peter Banks, BioTek Instruments; 

Dee Shen, Wayne Patton, Enzo Life Sciences 

T313: High Content Analysis of an Automatable 

3-Dimensional Cell Invasion Assay 

*Renee Herber, Jennifer Fronczak, Platypus 

Technologies LLC; Tim Baranowski, Molecular Devices; 

Keren Hulkower, Platypus Technologies LLC 

T314: Human iPS-Derived Cardiomyocytes 

for Cardiotoxicity Screening 

*Jayne Hesley, Nick Callamaras, Evan Cromwell, 

Oksana Sirenko, Molecular Devices; Blake Anson, 

Cellular Dynamics International 

T315: Viscosity Effect on Protein Self Assembly, 

Conformational Change, and Amyloid Fiber Formation 

*Kathryn Holder, Jonathan Kucharyson, Samuel Breit, 

Shaohua Xu, Tiffany Teske, Megan Cronin, Florida 

Institute of Technology


T316: Targeted Integration of Genes for 

Cell Based Assays 

*Allyson Holmes, Jean Pierre Cabaniols, Cellectis bioresearch; 

Olivier Nosjean, Institut de Recherches Servier 

T317: Targeted Transgene Integration in a 

CHO-S Hotspot for the Fast and Reproducible 

Production of High Protein Titers 

*Allyson Holmes, Jean Pierre Cabaniols, Karim Mekideche, 

Cellectis bioreasearch 

T318: Development of High Throughput Cell Based 

Assay for Aldehyde Dehydrogenase 2 

*Khai Huynh, Greta Lundgaard, Sarah Wise, Helen Yu, David 

Koditek, Latesh Lad, Nikos Pagratis, Gilead Sciences, Inc. 

T319: Assessing Function of the Calcium Release 

Activated Calcium (CRAC) Channel Using the 

xCELLigence RTCA System 

*Jeffrey Irelan, ACEA Biosciences 

T320: Multimode Screening for Modulators of 

GPCR Function Using the xCELLigence RTCA 

High Throughput System 

*Jeffrey Irelan, ACEA Biosciences 

T321: Evaluation of Orthogonal Compound Mixture Sets 

for High Throughput Screening of a Sodium Ion Channel 

*Angela Jaramillo, Laszlo Kiss, Ansu Bagchi, Bradley Fueston, 

Edward Hudak, Robert Liehr, Carissa Quinn, Angela Jaramillo, 

Merck 

T322: An Integrated Solution for Automated Nanoliter 

Hit-Picking 

*Joby Jenkins, TTP Labtech Ltd; Manuel Baader, Biofocus; 

Chloe Carter, Stephen Starkie, TTP Labtech Ltd. 

T323: Flexible Nanoliter Liquid Handling for Reliable 

Assay Miniaturisation 

*Joby Jenkins, Ben Schenker, Rob Lewis, Chloe Carter, TTP 

Labtech Ltd 

T324: A Non-Radioactive Assay for Binding 

Affinity Screening in 3456-Well Plate Format 

*Sylvie Jezequel-Sur, Eric Johnson, Merck 

T325: IonWorks Barracuda Automated Electrophysiology 

System Measures Ligand- or Voltage-gated Ion 

Channels Simultaneously in 384 Wells 

*Xin Jiang, James costantin, Molecular Devices, Inc. 

T326: A Novel Platform for Automated Production and 

Screening of Scaffold-Free, Organotypic Microtissues 

*Jens Kelm, Maren Drewitz, Daniel Caminada, Wolfgang 

Moritz, Jan Lichtenberg, Marianne Helbling, InSphero AG; 

Cornelia Kasper, Leibniz University Hanover 

T327: Novel Cell Models and Assays for Improved 

In Vitro Cardiotoxicity Testing 

*JM Kendall, Stephen Minger, Rahman Ismail, GE Healthcare 

T328: scanMODE: A Biochemical Tool that Provides 

Kinase Inhibitor Binding Mode Information in the 

Absence of Cocrystal Structures 

*Pyare Khanna, DiscoveRx Corporation 

T329: 3D Cell-Based HTS Platforms: In Search of Physiologically 

Relevant Microtissue Formation Biomarkers 

*William Kisaalita, Yinzhi Lai, Amish Asthana, University 

of Georgia 

T330: Development and Validation of a Generic 

Fluorescence Methyltransferase Activity Assay based 

on the Transcreener ® AMP/GMP Assay 

*Karen Kleman-Leyer, Tony Klink, Matt Staeben, 

Rebecca Josvai, Robert Lowery, BellBrook Labs 

T331: Do Plate Readers Agree? Understanding 

Performance Differences Between Different Plate 

Reader Makes/Models 

*Tanya Knaide, Artel 

T332: Automated Optimization of Murine Embryonic 

Stem Cell Differentiation Into Cardiomyocytes 

*Michael Kowalski, Amy Yoder, Li Liu, Laura Pajak, 

Beckman Coulter 

T333: Analysis of Libraries and Off-Target Effects 

in RNAi Screens 

*Karol Kozak, ETH Zurich University 

T335: PathHunter ® Pathway Assays: 

Cell-Based Assay Tools for Cell Signaling 

*Sailaja Kuchibhatla, DiscoveRx Corporation 

T336: Development and Validation of a Generic 

Fluorescent Activity Assay for Acetyltransferases 

Based on the Transcreener ® AMP/GMP Assay 

*Meera Kumar, Robert G. Lowery, BellBrook Labs 



T337: Primary Human Cells from Life Technologies- 

Offerings, Scale and Applications in HCS and HTS 

Formats 

*David Kuninger, Nicholas Dolman, Kevin Chambers, 

Coby Carlson, Daniel Beacham, Life Technologies 

T338: A Label-Free Screening Approach 

to the Histone Acetyltransferase Family 

*William LaMarr, Peter Rye, Biocius Life Sciences 

T339: Measurement of Narrow Stoke’s Shift Labels 

With Monochromator and Filter Based Fluorometers; 

Fluorescent Proteins as Examples 

*Jorma Lampinen, Reija-Riitta Harinen, Marika Raitio, 

Thermo Fisher Scientific 

T340: High Throughput Determination of Enzyme 

Kinetic Parameters With Microplate Photometry 

*Jorma Lampinen, Reija-Riitta Harinen, Marika Raitio, 

Thermo Fisher Scientific 

T341: A Homogeneous Assay to Quantify 

Endogenous AKT Phosphorylation in Human 

Umbilical Endothelial Cells 

*Brad Larson, Peter Banks, BioTek Instruments, Inc.; 

Stephanie Nickles, George Klarmann, Lonza Walkersville, Inc.; 

Sylvie Crawford, Cisbio US; Mark Rothenberg, 

Corning Life Sciences 

T342: Automated 384-Well Cell-Based Cytochrome 

P450 Inhibition Assays Using Cryopreserved Human 

Hepatocytes in Suspension 

*Brad Larson, Peter Banks, BioTek Instruments, Inc.; 

Timothy Moeller, Celsis IVT; Mary Sobol, Tracy Worzella, 

Dongping Ma, James Cali, Promega Corporation 

T343: Utility of a Sensitive, Fluorescence-Based Assay for 

the Detection of Histone Deacetylase 6 (HDAC6) Activity 

*Brad Larson, Peter Banks, BioTek Instruments Inc.; Diana 

Hulboy, Kara Cannon, Wayne Patton, Enzo Life Sciences 

T344: Utility of the Synergy TM H1 Multi-Mode 

Microplate Reader in Combination With Transcreener ® 

ADP2 FP, TR-FRET and FI Assays for the Measurement 

of ADP Accumulation 

*Brad Larson, Peter Banks, Xavier Amouretti, BioTek 

Instruments, Inc.; Meera Kumar, Ann Krohn, BellBrook Labs 


T345: Utility of Automated Drug Transport Assays in 

96-Well Format, using Permeable Support Systems 

*Brad Larson, BioTek Instruments, Inc.; Hilary Sherman, 

Corning Life Sciences; Mark Rothenberg, Corning Life 

Sciences; Peter Banks, BioTek Instruments, Inc. 

T346: Cell-Based Cytochrome P450 Induction, Inhibition, 

and Viability Assays Using Cryopreserved Human 

Hepatocytes in an Automated, Multiplexed Format 

*Brad Larson, Peter Banks, BioTek Instruments, Inc.; James 

Cali, Promega Corporation; Timothy Moeller, Celsis IVT 

T347: A 1536-Well Based Kinetic Assay for Thioredoxin 

Glutathione Reducase Inhibitor Discovery and 

Antischistosomal Drug Development 

*Wendy Lea, NIH/NCGC; Ganesha Rai, Ajit Jadhav, Christopher 

Austin, James Inglese, Craig Thomas, NIH Chemical 

Genomics Center; David Williams, Department of Immunology/ 

Microbiology, Rush University Medical Center; David Maloney, 

Anton Simeonov, NIH Chemical Genomics Center; Ahmed 

Sayed, Department of Biochemistry/Ain Shams University 

T348: Accurate and Precise Low Volume Transfer 

of Antibody and Enzyme Solutions Stored in Glycerol 

Using the Echo Liquid Handler 

*Howard Lee, David Harris, Richard Stearns, Celeste Glazer, 

Sammy Datwani, Labcyte Inc. 

T349: Multimode High Throughput Measurement 

of Intracellular cAMP 

*Jinfang Liao, Chunmei Wei, Xing Han, Zhenjun Diwu, 

AAT Bioquest, Inc. 

T350: A Robust and Convenient Fluorimetric Assay 

for Measuring Acetylcholinesterase Activity and 

Screening Acetylcholinesterase Inhibitors 

*Jinfang Liao, Qin Zhao, Zhenjun Diwu, AAT Bioquest, Inc. 

T351: mES Cell-Derived Cardiomyocyte 

Characterization Using Immunostaining 

*Li Liu, Michael Kowalski, Amy Yoder, Laura Pajak, 

Beckman Coulter 

T352: Integration of Compound Structure and 

Activity With Clinical Adverse Drug Reactions 

*Eugen Lounkine, NIBR 

T353: Expression, Capture and Display of Native GPCRs 

on Soluble Mammalian Membrane Particles 

*Kevin Lowitz, Sanjay Vasu, Kevin Lowitz, Life Technologies


T354: Chemical Biology Consortium Sweden 

*Thomas Lundback, Karolinska Institutet; Jonas Eriksson, 

Umeå University; Per Artursson, The Uppsala University 

Drug Optimization and Pharmaceutical Profiling Platform; 

Hanna Axelsson, Karolinska Institutet; Marcus Carlsson, Inger 

Cullman, Mikael Elofsson, Per-Anders Enquist, Jonas Eriksson, 

Anders Esberg, Umeå University; Anna-Lena Gustavsson, Lars 

Hammarström, Martin Haraldsson, Annika Jenmalm Jensen, Lars 

Johansson, Karolinska Institutet; Lucia Lazorova, The Uppsala 

University Drug Optimization and Pharmaceutical Profiling 

Platform; Thomas Lundbäck, Karolinska Institutet; Maria Mastej, 

The Uppsala University Drug Optimization and Pharmaceutical 

Profiling Platform; Weixing Qian, Umeå University; Kristmundur 

Sigmundsson, Karolinska Institutet; Richard Svensson, The 

Uppsala University Drug Optimization and Pharmaceutical 

Profiling Platform; Hanna Uvel, Öhman Anders, Umeå University 

T355: Poster Submission 

*Brian Lupotsky, GSK 

T356: High Throughput Screening for Specific 

Inhibitors of Phospholamban-AKAP18 Interaction 

Using AlphaScreen technology 

*Birgitte Lygren, Anne Jorunn Stokka, Kjetil Taskén, 

The Biotechnology Centre of Oslo 

T357: The Use of BacMam Technology 

to Produce Aequorin Cell Lines for HTS 

*Jacquelyn Lyons, Thao Ung, Murray Kristen, 

Beverly Holskin, Rita Raddatz, Sheryl Meyer, Bruce Jones, 

Cephalon; Emir Duzic, ChanTest Corp. 

T358: An In Vitro Model of Acute Epilepsy Suitable for 

MTS: Synchronized Repetitive Calcium Oscillations in 

Primary Neurons Cultured in a 384 Well-Microplate 

*Nasire Mahmudi, G. Roussignol, Y. Ju, S. Boularand, 

O. Chao, B. Biton, G. Dargazanli, P. Avenet, O. Curet, 

Sanofi-Aventis Recherche 

T359: Automated High Content Assays in Biological 

3D Extracellular Matrix 

*John Majer, Victoria Echeverria, Melissa Ritter, 

Allyson Skoien, , Steven Hayes, BellBrook Labs 

T360: Determination of Association (kon) and 

Dissociation (koff) Rate Constants of Spiperone on the 

Dopamine D2 Receptor Using the Tag-lite ® Platform 

*Gerard Mathis, Cisbio Bioassays; Nicolas Pierre, Cisbio US, 

Inc.; Jean-Luc Tardieux, Cisbio Bioassays 

T361: Improvement of MRP1 Activity for Early 

ADME Studies 

*Peter Meszaros, UMCG; Karin Klappe, Jan Willem Kok, 

University of Groningen 

T362: Image-Based Analysis of Primary Human 

Neutrophil Chemotaxis in an Automated Assay 

*Ivar Meyvantsson, Elizabeth Vu, Casey Lamers, 

Daniella Echeverria, Allyson Skoien, Victoria Echeverria, 

Steven Hayes, BellBrook Labs 

T363: Next-Generation Chemiluminescent 

Secreted Placental Alkaline Phosphatase (SEAP) 

Reporter Gene Assay 

*Corinne Miller, Laura Thibodeau, Brian D’Eon, 


T364: A High-Throughput Cell Migration Assay 

Using the GNF Plate Washer/Dispenser 

*Loren Miraglia, Buu Tu, Orzala Sharif, John Joslin, Ghislain 

Bonamy, The Genomics Institute of the Novartis Foundation 

T365: Micro-Patterned Cell Culture Substrates for 

Enhanced Transgene Activity, Primary Cell Culture 

and Stem Cell Differentiation 

*Sven Mühlfriedel, Heike Hübner, Günther Knebel, Anna-Lena 

Winkler, Greiner Bio-One GmbH 

T366: The High Throughput of ADME Screens and 

Computational Models in Drug Discovery 

*Goutam Mukhopadhyay, Jadavpur University 

T367: Reporter Displacement Assay Technologies 

Applied to Epigenetic Targets: Fragment Screening, 

residence time optimization, kinetic selectivity and 

high throughput thermodynamics 

*Lars Neumann, Dirk Ullmann, Konstanze von Konig, 

Proteros Biostructures 

T368: Endogenous GPCR Transcript Profiling of Life 

Technologies’ Primary Cell Offerings: Opening the 

Door to Physiologically Relevant Cell Systems for 

Pharmaceutical Screens 

*Rhonda Newman, Life Technologies; David Kuninger 



T369: Homogeneous High Throughput Live Cell 

GPCR Functional and Surface Binding Assays 

*Estelle N’Garwate, Cisbio US, Inc.; Oksana Sirenko, 

Molecular Devices; Marie-Laure Lebreton, Cisbio Bioassays 

T370: Quantification of Cytokines on the SpectraMax ® 

Paradigm ® Multi-Mode Microplate Detection Platform 

Using Alpha Technology 

*Cathy Olsen, Molecular Devices; Harald Hundsberger, 

University of Applied Sciences Krems, Austria 

T371: Enhancement Factors for BacMam-Mediated 

Gene Expression 

*Christina Pao, Thomas Kost, David Taylor, GlaxoSmithKline; 

Frederick Boyce, Harvard; Quinn Lu, Robert Ames, 


T372: Decellularized Bioscaffolds in Large Animal Model 

*Kyung-Mee Park, Heung-Myong Woo, Hyun-Suk Nam, 

Ho-Hyun Kwak, Jae-seok Woo, Kangwon National University 

Stem Cell Institute; Joseph V. Bonventre, Harvard Medical 

School, Brigham and Women’s Hospital 

T373: Bell Brook Labs Transcreener AMP/GMP Assay 

Technology Allows for Convenient High-Throughput 

Screening of AMP-Producing Enzymes 

*Jonathan Parsons, Kenneth Bonanno, Christian Gross, 

Michael Wynn, Vertex Pharmaceuticals 

T374: Pharmacological Profiling in Human Embryonic 

Progenitor Cells Using High Content Analysis 

*Umesh Patel, Andrew Ball, Janet Anderl, Chris Benjamin, 

Jacob Bode, Lisa Thompson, Jeff Till, Blaine Armbruster, 

EMD Millipore 

T375: Identification of Efficient Hits From a Small 

and Beautiful Set of Compounds 

*Mehul Patel, Pat Brady, Nicola Richmond, Stephen Pickett, 

Jeffrey Gross, Stan Martens, Anthony Jurewicz, James 

Chan, Julio Martin, Ricardo Macarron, Snehal Bhatt, 

GlaxoSmithKline; Andrew Pope, Platform Technology 

& Science 


T376: Ultra-High Throughput Screen for NOX-1 

Inhibitors Using the Diogenes Cellular Luminescence 

Enhancement System 

*Amita Patel, Merck and Co. Inc.; Justin Murray; Lauretta 

LeVoci, Daniel Blom, Priya Kunapuli, Oleg Kornienko, 

Eric Johnson, Merck and Co. Inc. 

T377: A Novel Cell-Based Microplate Assay for 

High-Throughput Screening of Compounds Modulating 

Protein Aggregation 

*Wayne Patton, Dee Shen, Kui Tian, Wayne Patton, 

Enzo Life Sciences 

T378: BioPharma Results of Using HP’s New Digital 

Titration Technology 

*Kevin Peters, Hewlett-Packard High-Performance Dispensing 

T379: Applications of High Throughput Electroporation 

in Genomic Screening 

*Johan Pihl, Mattias Karlsson, Sara Aspengren, Cellectrion AB 

T380: Direct, Real-time Detection of Kinase 

Type II Inhibitors Using Second Harmonic 

Generation (SHG) Detection 

*Simon Pitchford, Ryan McGuinness, Joshua Salafsky, 

Biodesy LLC 

T381: Luminescence Polymerase Activity Assay for 

Antiviral Drug Discovery 

*Val Golovlev, Kalvin Gregory, Nelson Chen, Ye Sun, 

Val Golovlev, SCI-TEC, Inc. 

T382: A Novel Method for High-Throughput Colony 

Isolation in Multi-Well Plates 

*Kristi Hohenstein-Elliott, Olivier Dery, Cory Peterson, 

Alicia Winquist, Cyntellect, Inc.; Natalia Kan, Burnham 

Institute; Fredrik Kamme, Cyntellect, Inc.; Brandon Nelson, 

Mark Mercola, Burnham Institute 

T383: Antibody Characterization Using Multiplexed SPR: 

Case Study XOMA 052 

*Hassan Issafras, XOMA LLC


T384: Bioluminescent Sensor for Monitoring Intracellular 

cGMP in Live Cells 

*Adam Keeton, Yanjie Sun, Nan Li, Heather Tinsley, Southern 

Research Institute; Brock Binkowski, Promega Corporation; 

Gary Piazza, Southern Research Institute; Braeden Butler, 

Promega Corporation 

T385: High-Throughput Method for Profiling Genetically 

Characterized Cancer Cell Lines With Small Molecules 

*Hanh Le, Joshua Bittker, Jaime Cheah, Edmund Price, 

Michelle Palmer, Alykhan Shamji, Stuart Schreiber; 

Broad Institute 

T386: The Future of Toxicity Testing Utilizing Robotics 

and Integration by Wako Automation 

*David Lorenz, Robert Bukar, Wako Automation; Menghang 

Xia, Sam Michael, NIH; Paul Queeney, Wako Automation 

T387: Screening Technology for Treatment Research 

in Parkinson’s Disease 

*Nathalie Maubon, Marie-Christine Bret, Christelle Odrobina, 

Philippe Masson, Mireille Tallandier; Laboratoires Fournier 

T388: Development of a Fully Automated Transactivation 

Assay Using the CompacT SelecT 

*Nathalie Maubon, Christelle Valaire, Saverine Michelin, 

Philippe Masson, Laboratoires Fournier 



Wednesday, March 30; 12:00 – 1:30 pm (presenters are available) 

W501: HTS for Inhibitors of Statin Mediated Toxicity 

in Human ESC-Derived Mesodermal Cells 

*Pauline Poydenot, Benjamin Brinon, Anne-Laure Jaskowiak, 

I-Stem; Fabrice Casagrande, Discngine; Marc Peschanski, 

I-Stem; Marc Lechuga, Institut de la Vision; Christian Pinset, 

I-Stem 

W502: Technology That Enables Routine 3D 

Cell Culture for Applications in Research, 

Toxicity Testing and Safety Screening 

*Stefan Przyborski, Reinnervate Limited 

W504: The Development of a Universal, HTS-Compatible 

Platform for Monitoring Receptor Internalization 

*Elizabeth Quinn, DiscoveRx Corporation 

W505: Automated Data Analysis Pipeline for High- 

Throughput Compound Screening Using Flow Cytometry 

*Bartek Rajwa, Nicole Lewis, Peter Carlsgaard, Valery 

Patsekin, Raymond Fatig, Larisa Avramova, Cheryl Holdman, 

Kathryn Ragheb, Purdue University; Paul Rigby, University 

of Western Australia; Jennifer Sturgis, Ana Juan-Garcia, 

J. Paul Robinson, V. Jo Davisson, Purdue University 

W506: The Optimization of FRET Substrates 

for Detection of Cathepsins Activity 

*Vera Rakhmanova, Deepa Mohan, Aneta Tawfik, Aimin Song, 

Jianjun He, AnaSpec 

W507: A Substrate-Independent Histone 

Deacetylase Inhibitor Assay 

*Steve Riddle, Steve Fakhoury, Bryan Marks, Jack Frazee, 

Hildegard Eliason, Life Technologies 

W508: Do You Really Know What Your Robot 

is Doing?—The Importance of Paying Attention 

to Liquid Handling Details 

*George Rodrigues, Keith Albert, George Rodrigues, Artel 

W509: High Content Screening of a Cardiotoxic 

Liability Compound Set Using GE Healthcare Human 

Cardiomyocytes in a Live Multiplexed Cytotoxicity Assay 

*Liz Roquemore, Nick Thomas, Cath Hather, GE Healthcare; 

Hirdesh Uppal, Genentech; Stephen Minger, GE Healthcare 


W510: Development of High-Throughput Assays 

to Study Histone H3K4 Methyltransferases & H3K9 

Methyl- and Acetyltransferases 

*Nathalie Rouleau, Liliana Pedro, Nancy Gauthier, Anne 

Labont, Valerie Paquet, Anja Rodenbrock, Marjolaine Roy, 

Alexandre Marcil, Hendrick Plante, Lucille Beaudet, 

Roberto Rodriguez-Suarez, PerkinElmer 

W511: Development of a Non-Radioactive, No-Wash 

Biochemical Assay for High-Throughput Screening of 

Small Molecule Modulators of DNA Methyltransferases 

*Nathalie Rouleau, Luis Rafael Silva, Ilya Ryabov, Philippe 

Roby, Alexandre Marcil, PerkinElmer 

W512: Development of a High Throughput Cytotoxicity 

Assay Using High Content Screening Technology 

*Nathalie Maubon, Bruno Loillier, Pascale Tuyaa-Boustugue, 

Annick Reboul, Philippe Masson; Laboratoires Fournier 

W513: The Importance of Drug-Target Binding Kinetics 

for Drug Efficacy 

*Eric Roush, Markku Hamalainen, GE Healthcare 

W514: Creating a Holistic Screening Strategy for Label 

Free Technology in a Plate Based Screening Group 

*Rachel Russell, Alex Alderton, Jamie Bilsland, Sarah Birch, 

Darren Cawkill, Mellissa Clark, Juha Kammonen, Linda 

Kitching, Anne Phelan, Frank Stuhmeier, Toby Winchester, 

Pfizer Global Research & Development 

W515: Fluorescent-Based Assay to Screen Drugs 

Against Alzheimer’s Disease 

*Clarisa Salado, Danel kortazar, Meritxell Roura, Rosa Maria 

Mella, Patricia Villaca, Innoprot 

W517: KINOMEscanâ In-Vitro Kinase Assays and 

PathHunter ® Cell-Based Assays: Synergistic Platforms 

to Evaluate Kinase Inhibitor Selectivity 

*Sunitha Sastry, DiscoveRx Corporation 

W518: Smarter Screening for Tricky Targets: 

NaV1.7 Sodium Channel and Thallium Dyes 

*Lia Scarabottolo, Alberto Di Silvio, Cinzia Nucci, Angela 

Molteni, Viviana Agus, Alessandro Taddei, Michela Stucchi, 

Axxam SpA


W519: Targeting Enzymatic Glycation as a 

Treatment for Diabetes Complications 

*Amanda Schabdach, LCGC; Scott Donover, Melvin Reichman, 

Lankenau Institute for Medical Research; Alice Marcy, Frank 

Kappler, Annette Tobia, Dynamis Pharmaceuticals Inc. 

W520: A Mix-and-Read Cell-Based Assay for Antibody 

Screening Against Epidermal Growth Factor Receptor 

*Ben Schenker, Wayne Bowen, David Onley, Tristan Cope, 

TTP Labtech Ltd 

W521: The Future of Compound Management 

*Ben Schenker, Richard Kim, Simon Tullett, TTP Labtech Ltd 

W522: Efficient High-Throughput Transfection 

of Neuronal Networks Using NucleofectionTM 

*Jenny Schroeder, Lonza Cologne GmbH; Dietmar Lenz, 

Lonza Cologne GmbH; Elke Lorbach, Lonza Cologne GmbH; 

Thomas Koblizek, Lonza Cologne GmbH; Andreas Heinze, 

Lonza Cologne GmbH; Andrea Toell, Lonza Cologne GmbH; 

Gina Andretta, Lonza Cologne GmbH; Stefanie Buesch, 

Lonza Cologne GmbH; Sandra Domzalski, Lonza Cologne 

GmbH; Daniela Litzenberger, Lonza Cologne GmbH; Sabine 

Schaepermeier, Lonza Cologne GmbH; Sonja Spicker, Lonza 

Cologne GmbH; Nicole Spottke, Lonza Cologne GmbH; 

Herbert Mueller-Hartmann, Lonza Cologne GmbH 

W523: Lumigen Hyperblu TM Technology: Superior 

Stability for the Detection of Hydrogen Peroxide 

*David Schumm, Beckman-Coulter; Jessica Schneck, 

GlaxoSmithKline; Robert Eickholt, Beckman-Coulter 

W524: Calcium Signaling in mESC Derived 

Cardiomyocytes: From Single Cells to HTS 

*Silke Schwengberg, Andreas Ehlich, Ben Bohlen, 

Axiogenesis AG; Bernd Kalthof, Mark Meininghaus, 

Eike Sonnenhol, Bayer Schering Pharma AG; Oliver Griesbeck, 

Max Planck Instiute of Neurobiology; Heribert Bohlen, 

Axiogenesis AG 

W525: Identification of Selective Modulators for 

Human Alkaline Phosphatases 

*Eduard Sergienko, Ying Su, Brock Brown, Russel Dahl, 

Robert Ardecky, Yalda Mostofi, Shyama Sidique, Nicholas 

Cosford, Thomas D.Y. Chung, Sonoko Narisawa, Jose Luis 

Millan, Sanford-Burnham Medical Research Institute 

W526: Monitoring Post-Translational Modifications 

and Protein-Protein Interactions Using the Proximity 

Ligation Assay 

*Tina Settineri, Kristin Huwiler, Rica Bruinsma, Bryan Marks, 

Mark Shannon, Shiaw-Min Chen, David Ruff, Barry Schweitzer, 

Life Technolgies 

W527: Assessment of the Overall Epigenetic State of 

a Cell Using Methyltransferase/Demethylase Arrays 

*Pavel Shashkin, Marianna Tcherpakov, Adam Powell, 

Yiming Chen, Junguk Park, Michelle Kimbara, Liz Lau, 

Angela Boettcher, Kristen Karnay, Robert Kennedy, 

Jean-Francois Charlot, Lindsay Yang, Suzan Oberle, 

Henry Zhu, BPS Bioscience, Inc. 

W528: Coupling Automated Electrophysiology With 

Microfluidic Perfusion to Drive Hit to Lead and Lead 

Optimisation Studies for Voltage- and Ligand-Gated 

Ion Channel Targets 

*Joanne Shearer, Gary Clark, Emma Hollands, Andrew 

Southan, BioFocus 

W529: Ultrasonic Fluid Proceesing Improves Triolein 

Measurement Accuracy in Mass Spectrometry Assays 

*Jean Shieh, Microsonic Systems; Lauren Frick, Biocius; 

Jim O’Keefe, Microsonic Systems; Jennifer Rossi, Biocius; 

Jean Shieh, Microsonic Systems 

W530: Acoustic Instruments Duet for High-Quality, 

High-Throughput Screening 

*Jean Shieh, Bruce Jamieson, Microsonic Systems; 

Dalin Nie, Astrazeneca 

W531: Speeding Up NGS Sample Preparation: 

Using Bulk Lateral Ultrasonic Technology for 

High-Throughput DNA Shearing 

*Jean Shieh, Bruce Jamieson, Kapil Dev, Smriti Sharma, 

Vibhu Vivek, Microsonic Systems 

W532: Development of and Screening in a Label-free 

Fragment Binding Assay Using BIND ® 

*Scott Perschke, CDAS 

W533: Identification and Characterization of Novel 

GPCR Heterodimer Pairs Using the PathHunter eXpress 

Assay System 

*Khandaker Siddiquee, Jessica Hampton, Sanford Burnham 

Medical Research Institute at Lake Nona; Daniel Bassoni, 

Tom Wherman, DiscoveRx Corporation; Layton Smith, 

Sanford Burnham Medical Research Institute at Lake Nona 



W534: New Label-Free Screening Assays 

to Accelerate Drug Discovery 

*Christopher Silva, Sriram Kumaraswamy, ForteBio 

W535: Automated Functional Cellular Analyses 

of Human iPS-derived Cardiomyocytes 

*Oksana Sirenko, Nick Callamaras, Jayne Hesley, Xin Jiang, 

Carole Crittenden, Roger Tang, Molecular Devices; Blake 

Anson, Cellular Dynamics International; Evan Cromwell, 

Molecular Devices 

W536: A Novel Technology for Multiplex, Label-Free, 

Real Time Monitoring of Bio-Interactions 

*Jay Smith, Plexera LLC 

W537: Development of a High-Throughput Compatible 

Cell-Based Assay to Monitor Galanin 3 Receptor Activity 

*Anthony Smith, Scripps Research Institute 

W538: A Simple Fluorescence-Based HTS Assay 

for UGT1A6 

*Anne Soikkeli, Division of Pharmaceutical Technology, 

Faculty of Pharmacy, University of Helsinki; Mika Kurkela, 

Centre for Drug Reseach, Faculty of Pharmacy, University 

of Helsinki; Jouni Hirvonen, Division of Pharmaceutical 

Technology, Faculty of Pharmacy, University of Helsinki; 

Marjo Yliperttula, Division Biopharmacy and Pharmacokinetics, 

Faculty of Pharmacy, University of Helsinki; Moshe Finel, 

Centre for Drug Reseach, Faculty of Pharmacy, University 

of Helsinki 

W539: Integration of Phenomic Screening and 

Phenomic ID in Drug Discovery at IP-Korea 

*Veronica Soloveva, Jonathan Cechetto, YongJun Kwon, 

Auguste Genovesio, Michael Hansen, Ulf Nehrbass, IP-Korea 

W540: Time Resolved Fluorescence Measurements 

Utilizing Quad Monochromator Technology on the 

PerkinElmer EnSpire ® Multimode Plate Reader 

*Barbara Sonnenberg, Norbert Garbow, Alexander Ehlers, 

PerkinEmer 

W541: Data Management Support of a High 

Throughput Assay to Determine TCID50 Values 

*Melinda Sosa, Southern Research Institute 


W542: Deconvolving the Microdilution Checkerboard: 

Towards Appropriate and Agreed Upon Results Analysis 

of Antimicrobial Synergism Testing 

*Timothy Spicer, Peter Chas, Peter Hodder, The Scripps 

Research Institute 

W543: Development and Characterization of Human 

Hepatocytes Derived From Induced Pluripotent Stem 

Cells (iPSCs): A Novel In Vitro Model System for Drug 

Discovery and Development 

*Michelle Stevens, Peter Fuhrken, Christian Kannemeier, 

Jennifer Luebke-Wheeler, Wen Bo Wang, Brad Swanson, 

Vanessa Ott, Emile Nuwaysir, Cellular Dynamics International 

W544: High-Throughput Screening of the Ezrin: EBP50 

Complex Which is Involved in T Cell Immunomudulation 

*Anne Jorunn Stokka, Birgitte Lygren, Kjetil TaskÃn, 

The Biotechnology Centre of Oslo 

W545: The Application of Mechanism of Action 

Studies for Enzymes in Early Drug Discovery 

*John Strelow, Eli Lilly and Company 

W546: Targeting the Transcription Factor UPC2 

for Antifungal Drug Discovery 

*Ilana Stroke, Melissa Manners, Robert Swanson, 

Denise Dimitrov, Christina Gallo, Joseph Nickels, 

Ilana Stroke, Venenum Biodesign 

W547: Label-Free Assay 

*Chi Sum, Sarah Malmstrom, John Lehrach, Liang Schweizer, 

Litao Zhang, BMS 

W548: Data Management for Outsourced Kinase Profiling 

*Dongyu Sun, Merck 

W549: SoPRano TM : Label-Free Detection on 

Standard Laboratory Equipment Using Protein-Gold 

Nanoparticle Conjugates 

*Sergei Svarovsky, Pharmadiagnostics NV; David Ricketts, 

Patricia De Pril, Frederik Van de Velde, Meike Roskamp, 

Anne Van Hoonacker, Patrick Englebienne, Zellik 

W550: Development of an oGPCR Activation Assay 

Using ß-galactosidase Complementation 

*Sahba Tabrizifard, Scripps Florida; Patricia McDonald, 

Scripps Research Institute


W551: A 384-Well Based High-Throughput Method 

for In Vitro Combination Study of Anti-HCV Agents 

*Yang Tian, Nikos Pagratis, Yu-Jen Lee, Gilead Sciences 

W552: Kinetic HTS for Agonists and Allosteric Modulators; 

A Cell Based Homogeneous 2 Step Addition Paradigm 

*Steve Titus, Melanie Bryant, NIH Chemical Genomics 

Center; Ke Liu, Burnham Institute; Wei Zheng, 

NIH Chemical Genomics Center 

W553: Detecting Aggregation in a High Throughput 

Label-Free System 

*Todd Upton, David Randle, Kathleen Krebs, Corning, Inc. 

W554: Utilities of In Vitro Safety Pharmacology 

in Early Drug Discovery: Mitigation of ADRs 

*Laszlo Urban, NIBR 

W555: New Tools for Drug Discovery: Monitoring 

Intracellular Ca2+ Fluxes in Primary Cell Types 

with High-Throughput Formats 

*Silke Valentin, Bodo Ortmann, Kristin Atze, 

Nadine Breuer, Mathias Kuehn, Steffi Franke, 

Nicole Faust, Lonza Cologne GmbH 

W556: Kinome Activity Profiling; Applications 

in Translational Research 

*Rinie van Beuningen, PamGene International B.V. 

W557: High Content Drug Screening with 

Engineered Musculoskeletal Tissues 

*Herman Vandenburgh, Brown University; Janet Shansky, 

Myomics, Inc.; Frank Benesch-Lee, Myomics, Inc. 

W558: Simply Sensitive; Phosphate Detection Made Easy 

*Kevin Vedvik, Kevin Kupcho, Caroline Wessely, Steve Riddle, 


W559: A Successful Example of Using Refolded 

Protein for HTS Campaign: Screen for Activators 

of Transcriptional Factor Delta FosB 

*Lili Wang, Broad Institute; Gabby Rudenko, University of 

Michigan Medical School; Eric Nestler, Mount Sinai School 

of Medicine; Shawn Clark, Xtal Biostructures, Inc; Christian 

Soule, Yan-Ling Zhang, Michelle Palmer, Stuart Schreiber, 

Broad Institute 

W560: Improved Dose-Response Analyses 

Using Direct Dilution With Picoliter Dispense 

*Ken Ward, Michael Day, Christie Dudenhoefer, Jeff Nielsen, 

Heather Paris, Hewlett-Packard Company; Kevin Peters, 

Hewlett-Packard High-Performance Dispensing; Debora 

Thomas, Joshua Yu, Hewlett-Packard Company 

W561: SPR Capable Cell Free In Situ Synthesized 

Protein Array 

*Andrew Weber, Plexera; Jinsong Zhu, National Center 

for Nanosciences and Technology 

W562: Interrogate Your Compounds for Ligand 

Bias With a Suite of PathHunter ® and HitHunter ® 

GPCR Screening Platforms 

*Tom Wehrman, Daniel Bassoni, Mong Saetern, Uyen Le, 

Qumber Jafri, Bill Raab, Phil Achacoso, Judy Leon, Mimi 

Nguyen, Chin Yee-Loh, Tom Wehrman, DiscoveRx Corporation 

W563: Evaluation of A Fluorescence Lifetime-Based 

Approach for Compound Interference 

*Yang Wen, Hoffmann-La Roche 

W564: A Flexible Kinase Inhibitor Assay Platform for 

Active, Non-Activated, and Impure Kinase Preparations 

*Caroline Wessely, Steve Riddle, Kun Bi, Jason Ellefson, 

Laurie Reichling, Connie Lebakken, Caroline Wessely, 


W565: Two Novel Approaches for Fighting TB 

*Lucile White, Robert Reynolds, Southern Research 

Organization; William Bishai, Johns Hopkins School 

of Medicine 

W566: An Image Based, High-Throughput Screening 

Assay for Molecules That Induce Excess DNA Replication 

in Human Cancer Cells 

*Jennifer Wichterman, NIH/NCTT; Wenge Zhu, George 

Washington University Medical Center; Chrissie Lee, 

National Institue of Child Health and Human Development; 

Ronald Johnson, Ruili Huang, Raj Guha, NIH Center for 

Translational Therapeutics; Melvin DePamphilis, National 

Institute of Child Health and Human Development 



W567: Using a pKB Assay Format to Improve 

Clone Selection and Pharmacological Evaluation 

of a GPCR Target With the Promega GloSensor TM 

Technology 

*David Winpenny, Graham Rickett, Pfizer Worldwide 

Research and Development; Linda Kitching, Linda Strand, 

Paul Abel, Jo Mulgrew, Frank Stuhmeier, Rachel Russell, 

Pfizer Worldwide Research and Development 

W568: A Multiplexed Assay to Monitor Cell Health 

and Reporter Gene Expression 

*Tracy Worzella, Andrew Niles, Mike Valley, Promega; 

Jerome Lasker, Puracyp; Trista Schagat, Halina Zakowicz, 

Kevin Kopish, Pam Guthmiller, Promega Corporation; 

Judy Raucy, Puracyp 

W569: Beat to Beat Contraction Based Functional 

Assay Using Human iPS Cell-Derived Cardiomyocytes 

for Identification of Pro-Arrhythmic Compounds and 

Screening of Anti-Arrhythmic Agents 

*Biao Xi, William Zhang, Wayne Ouyang, Min Zheng, 

Jenng Zhu, Nancy Li, Wallson Xu, Xiao Xu, XiaBo Wang, 

Yama Abassi, ACEA Biosciences 

W570: Analysis of Differentiation of Embryonic 

Stem Cells by Automated Flow Cytometry Sample 

Preparation on the Biomek ® NXP 

*Amy Yoder, Michael Kowalski, Li Liu, Laura Pajak, 

Beckman Coulter Inc. 

W571: Detecting ATPase Activity Modulators 

of ABC Transporters Using ADP-Glo Max 

*Hicham Zegzouti, Terry Riss, Said Goueli, Promega 

Corporation 

W572: Kinase Profiling Using a Universal Luminescent 

ADP Detection platform With Complete Kinase Enzyme 

Systems 

*Hicham Zegzouti, Tracy Worzella, Joseph Bessetti, 

Said Goueli, Gregg Cameron, Promega Corporation 

W573: Development of Novel Knock-In Cell Lines With 

Target Genes Endogenously Tagged by Fluorescent 

Reporters Utilizing Zinc Finger Nuclease Technology 

*Fan Zhang, Deborah Vassar, Hongyi Zhang, Nathan Zenser, 

Dmitry Malkov, Sigma-Aldrich Biotechnology 


W574: Development of a Multiplexed Assay in 

1536-Well Format to Measure Cell Viability and 

Identify Small Molecule Inhibitors of Nrf2 in an 

Effort to Discover Potential Therapies that Enhance 

Cancer Chemotherapy 

*Yaqin Zhang, NIH 

W575: Discovery of Small Molecule Inhibitors 

for RGS Proteins Using the RGScreen ® Platform 

*Tom Zielinski, Cori Pinchard, Robert G. Lowery, 

Bellbrook Labs 

W576: Cell-based HTS Strategy Identifies Small 

Molecule Activators of UPR Signaling and Apoptosis 

in Oral Squamous Cell Carcinoma Cells 

*Andrew Fribley, Justin Miller, Michael Callaghan, 

Wayne State University; Randal Kaufman, University 

of Michigan 

W577: Easy and Effective Automation of High-Throughput 

Immuno-Fluorescent Assays in Suspension and Loosely 

Adherent Cells Utilizing DropArray Technology 

*Mark Phong, Namyong kim, Melvin Lye, Lili Li, Kong Leong 

Cheong, WanYee Leong, Liyana Nor, Jason Tan, Curiox 

Biosystems 

W578: A High Throughput Screen to Identify 

Novel Compounds Which Inhibit the Binding 

of E3L to Z-DNA in Pox Viruses 

*Larry Ross, Southern Research Institute 

W579: Measurement of Glucagon-Like Peptide 1 

With the HTRF ® Assay 

*Chikashi Tokuda, Koji Adachi, Sceti Medical Labo K.K.; 

Marc Preaudat, Cisbio Bioassays 

W580: Rapid Development of a Cell Based Assay 

With Large Scale Transiently Transfected Cells Using 

MaxCyte STX Scalable Transfection System 

*Yoshida Tomohiro, Astellas Pharm Inc. 

W581: Developing Ortholog GPCR Cell Lines for 

Compound Screening 

*Radhika Venkat, Helena Mancebo; Multispan Inc.


W582: A Plasma-Based High Throughput Screen in 

1536-Well Format to Identify a Novel Oral Treatment 

for Haemophilia A and B 

*Fredrik Wågberg, Jane McPheat, Mattias Rohman, Sofi 

Nielsen, Jianming Liu, Ola Fjellstram, Tomas Fex, Johan 

Ulander, Emelie Jarkvist, David Gustafsson, AstraZeneca 

W583: Automating Sample Management Without 

Losing Sight of Sample Quality 

*Chris Walsh, Mike Pollard, Simon Sheard, RTS Life Science 

W584: Efficient High Throughput Transfection of 

Neuronal Networks Using Nucleofection 

*Jenny Schroeder, Dietmar Lenz, Elke Lorbach, Thomas 

Koblizek, Andreas Heinze, Andrea Toell, Gina Andretta, 

Stefanie Buesch, Sandra Domzalski, Daniela Litzenberger, 

Sabine Schaepermeier, Sonja Spicker, Nicole Spottke, 

Herbert Mueller-Hartmann; Lonza Cologne GmbH 

W585: Sumoylation of Sp3 is Required 

for Tooth Development 

*Tojan Rahhal, Jonathan Horowitz, Shannon Chiera, 

North Carolina State University 

W586: Investigation of Target Modulators 

Using Epic ® Label-Free Technology 

*Siddhartha De, Sonalee Athavanakar, Srividya Malkapuram, 

Rakesh Singha, Nicolas Andre, Advinus Therapeutics Ltd. 



Special Interest Groups 

SBS 2011 Special Interest Groups (SIGs) are where important discussions happen. There is no fee to attend 

Special Interest Groups. 

Tuesday, March 29, 2:00 – 4:00 pm 

Academic Outreach 

Location: Sanibel 

Chair: Sandra Nelson, University of Cincinnati 

The mission of the Academic Outreach Committee is to 

foster greater interaction among academia, government, 

pharmaceutical research companies and suppliers. In 

keeping with that mission, the Academic Outreach SIG 

provides a venue for academics to meet and exchange 

ideas, common problems and solutions. 

ADMET 

Location: Tampa 

Chair: Charles Crespi, BD Biosciences 

The mission of the Absorption, Distribution, Metabolism 

and Toxicology SIG is to advance drug discovery and 

development by promoting the discussion and dissemination 

of principles, topics and ideas for the integration of higher 

throughput technologies with methods for determining 

toxicity, pharma-cokinetics and metabolism. The goal is 

to accelerate the drug-discovery pipeline and shorten the 

time of the development of new drugs that cure illnesses 

and improve quality of life. This special interest group 

creates a bridge and network between scientists working 

in the fields of preclinical research, pharmacology, 

pharmacokinetics and those who are the producers 

of combinatorial libraries. 

Automation Quality Control 


Chairs: John Thomas Bradshaw, Artel; 

Jack Dawson, HighRes Biosolutions 

The Automation Quality Control SIG provides a forum 

for discussion of topics relating to optimizing performances 

of laboratory instrumentation. The objective is to encourage 

development of procedures that should be of interest to 

instrument vendors and practitioners alike. 


Data and Image Analysis 


Chair: Chip Allee, Ceutical Soft, Inc.; 

Co-Chair: Mann Shoffner, SRU Biosystem 

The Data and Image Analysis SIG is dedicated to sharing 

best practices, experiences and expertise, and to 

encouraging collaboration. The group will actively address 

issues in the area of information technology and strategies 

and foster discussions, information sharing and meetings 

among group members. 

Drug Repositioning 


Chair: Roger Bosse, PerkinElmer 

The SIG on Drug Repositioning is a broad-based BSS 

initiative allowing its members to proactively address the 

specific challenges pertaining to their respective fields of 

expertise (technical, operational, legal, etc.) in relation to 

needs and benefits of repurposing drugs. 

Microplate Standards 


Chairs: Amer El-Hage, Beeston Engineering; 

Michael Shanler, BD Biosciences 

The Microplate Standards SIG exists to recommend, 

develop and maintain standards to facilitate automated 

processing of microplates on behalf of and for acceptance 

by the American National Standards Institute (ANSI). Once 

such standards are approved by the MSWG, they are 

presented to the BSS Executive Council for approval 

and submission to ANSI. Participation in this SLAS working 

group is open to all interested parties directly and materially 

affected by its activities, including nonmembers of SLAS.


Sample Management 


Chairs: Richard Kuo, Novartis; Timothy Dawes, Genetech, Inc. 

The Sample Management SIG provides a forum for 

discussing sample library management issues in the 

modern drug-discovery high-throughput screening 

laboratory. Sample libraries include discrete compounds, 

defined compound mixtures, natural product extracts, 

and biologics (tissues, cells, DNA, RNA, and antibodies). 

Topics of critical importance include issues involved in 

Sample Collection; Materials Management; and 

Instrumentation and Laboratory Automation. 

Screen Design and Assay Technology 


Chair: Kenda Evans, Agilent Technologies 

The goals of the Screen Design and Assay SIG are to: 

share current best practices and experiences in the design 

of screens for high- and ultra high-throughput screening 

programs; provide a platform to encourage an open discussion 

among group members of any new screening technologies 

that can be beneficial to the screening community; encourage 

academic and industrial members to actively contribute to 

the SIG; identify any gaps in reagent(s) and instrumentation 

and/or in the screening environment, and seek to influence 

the appropriate supplier(s); and evaluate new technologies 

and instruments on a voluntary basis and share findings 

at technology-based user group meetings on a more 

frequent basis. 

Stem Cells 


Chairs: Marcie Glicksman, Harvard NeuroDiscovery Center; 

Sitta Sittampalam, University of Kansas Medical Center 

The mission of the Stem Cells in Drug Discovery SIG is to 

promote the discussion and dissemination of information 

on new enabling technologies related to the use of stem 

cells and primary cells in drug discovery. We will discuss 

current developments in stem cell biology, human and mouse 

pluripotent stem cells, and reprogrammed stem cells. This 

group will function to create a bridge between the network 

of scientists working in the fields of regenerative medicine, 

stem cell biology, chemical biology and drug discovery. 



Exhibitor Workshops 

Sunday, March 27, 

9:00 am – 12:00 pm 

From Well to Cell and Beyond: 

Widen the Physiological Perspective 

(Part One) 

Sponsored by: PerkinElmer, Inc. 


Emerging technologies are opening up the possibilities 

to study the cell signaling continuum in entirely new 

ways. Explore advances in label-free analysis, epigenetic 

profiling, cellular and in vivo imaging that enable phenotypical 

characterization of even the toughest targets 

from an orthogonal, systems biology perspective. 


Sunday, March 27, 

1:30 – 4:30 pm 

From Well to Cell and Beyond: 

Widen the Physiological Perspective 

(Part Two) 

Sponsored by: PerkinElmer, Inc. 


Emerging technologies are opening up the possibilities 

to study the cell signaling continuum in entirely new 

ways. Explore advances in label-free analysis, epigenetic 

profiling, cellular and in vivo imaging that enable phenotypical 

characterization of even the toughest targets 

from an orthogonal, systems biology perspective. 

Overcoming Kinase Inhibitor 

Discovery Challenges Using 

KINOMEscan, The Industry’s 

Largest Kinase Panel, and PathHunter ® 

HTS-Friendly Cell-Based Assays 

Sponsored by: DiscoveRx Corporation 


The discovery of selective, biologically relevant small 

molecule kinase modulators is hampered by off-target 

activity and few HTS-friendly cell-based assays. Here 

we present select case studies from leading experts 

leveraging the industry’s largest kinase panel and 

cell-based assays to drive the discovery of potent 

and selective kinase inhibitors.


Exhibitor Tutorials 

Tuesday, March 29, 

8:00 – 8:55 am 

Multiplexed Analysis of GPCR Signaling 

in Live Cells for Drug Discovery 

Sponsored By: Promega 


Promega has developed a live cell method for kinetic 

measurement of Ca2+ and cAMP by multiplexing Aequorin 

and GloSensor cAMP bioluminescent sensor technologies 

using the Hamamatsu FDSS/uCell in HTS formats. In addition, 

cell health/cytotoxicity assays can be readily multiplexed 

with second messenger detection platforms and provide 

a simple solution for GPCR assays. 

“Transcreening” Epigenetic Targets 

Sponsored By: BellBrook Labs 


We will describe how the Transcreener ® HTS Assay 

platform can be leveraged for universal detection of the 

enzyme families that catalyze covalent modifications to 

the genome including methylation, glycosylation, 

phosphorylation, sumoylation and acetylation. 

Drug Testing Using 3D Microtissues 

Sponsored By: Insphero AG 


More physiological in vitro cell models will foster the 

efficiency of the drug development process. InSphero 

provides an in-depth review of different 3D-cell-culture 

technologies used to create microtissue models. 

Application in oncology and toxicology as well as examples 

of the successful use of 3D models up to the regulatory 

level for skin applications are presented. 

Epigenetic Target Profiling— 

The Tailor-Made Solution for Cellular 

Epigenetic Selectivity Analysis 

Sponsored By: KINAXO Biotechnologies GmbH 


Histone deacetylase inhibitors (HDACi) are an emerging 

class of anticancer drugs, as they show tumor-specific 

antiproliferative effects while not affecting healthy tissue. 

Epigenetic Target Profiling facilitates reliable selectivity 

analysis of HDACi in cells and tissue. As prediction of 

off-target liabilities and compound toxicity in a native 

context delivers pivotal information to optimize drug 

efficacy, Epigenetic Target Profiling provides a rational 

approach to designing HDACi and allows transfer of 

superior preclinical profiles to the clinic. 

Introducing SRU Biosystems’ High 

Resolution Label-Free BIND ® Scanner 

Sponsored By: SRU Biosystems 


The SCANNER enables optical-based, label-free detection 

of individual cellular responses to perform functional cellbased 

assays. Assays can be performed at low densities 

and with mixed cell populations making it ideal for primary 

cultured cells. Specific applications will include receptor 

response assays (GPCRs, ion channels), cardio- and 

hepato-toxicity, and cellular migration. 

Enabling Drug Discovery Through the 

Use of Simple, Robust Automation 

Sponsored By: BioTek Instruments, Inc. 


We will demonstrate how BioTek’s instrumentation can 

be used to enable a variety of research applications. 

Topics to be discussed include cell-based signal transduction, 

biochemical kinase profiling and metabolic inhibition, and 

cell-based drug-drug interaction. Validation and pharmacology 

data will prove how simple, yet robust semi-automated 

solutions can ease workloads, and provide repeatable, 

accurate results. 

Optimizing 3D Cell Growth Using 

Alvetex—A Unique New Product 

for Routine 3D Cell Culture 

Sponsored By: reinnervate 


» Genuine 3d growth following easy-to-use protocols 

» Development of specialized components to optimize 

3d culture 

» Compatibility with standard molecular and cellular 

assay techniques 

» Comparing 2D and 3D cell culture growth 

and performance 

» Exemplification with common cell types and 

specialized tissues 



Introduction and Validation of the 

IonWorks Barracuda Automated 

Electrophysiology Instrument 

Sponsored By: Molecular Devices, Inc. 


An introduction to the IonWorks Barracuda instrument will be 

presented at this tutorial as well as validation data collected 

from voltage- and ligand-gated ion channels (LGICs or VGICs). 

The IonWorks Barracuda instrument measures ionic currents 

in parallel in 384-wells using individual amplifiers dedicated 

to each well. A 384-well pipettor provides the capability 

to simultaneously add ligand while measuring currents in 

all 384-wells. We present here data from LGICs including 

nicotinic acetylcholine (a1 and a7 nACh) receptors, acid 

sensing ion channels (ASIC), and GABA chloride channels, 

as well as VGICs including NaV, KV and hERG channels. 

Data will also be presented on 10 – 90% exchange rates 

for individual wells using high K+ solutions showing rapid 

exchange required for LGIG’s. Pharmacological data will 

be presented on the blockade of these channels provide 

validation that the IonWorks Barracuda is appropriate for 

screening ion channel targets in a drug discovery setting. 

Automated High Throughput and High 

Content Analysis by Flow Cytometry 

Sponsored By: Beckman Coulter 


Presentations on cell handling, screening, and automated 

analysis describe a high throughput approach using the 

Biomek ® Liquid Handling systems, HyperCyt Plate loader 

and CyAn ADP Cell Analyzer. Advanced tools for evaluation, 

statistical analysis and visualization of data are described. 

Innovative approaches for analysis of high content flow data 

are discussed. 


12:30 – 1:25 pm 

SPR in Early Phases of Low Molecular 

Weight Lead Discovery—Part One 

Sponsored By: Bio-Rad Laboratories 

Location: Naples 1-2 

Biophysics technologies are playing an increasingly important 

role in the early phases of low molecular weight lead discovery. 

We do have a quite broad biophysics technology portfolio, but 

SPR is playing a key and central role for us in hit identification 

with focused screening (e.g. fragment based screening) or 

for validating and characterizing the binding of low molecular 

weight hit compounds identified in high throughput screening 

campaigns. One of our key prerequisites for such efforts is 

good sensitivity for direct protein binding assays paired with 


robustness and high throughput. The presentation will show 

how we tackle such SPR projects from assay development 

until screening and data evaluation to identify those hits 

that have the biggest potential to serve as lead optimization 

candidates. 

SPR-Based Analysis of Membrane 

Proteins Using MemLAYER—Part Two 

Sponsored By: Bio-Rad Laboratories 

Room: Naples 1–2 

Membrane proteins constitute more than half of today’s 

drug targets and there is from a pharmaceutical stand point 

a continuous need for improved and also new methods to 

analyze these proteins. Surface Plasmon Resonance (SPR) has 

in the last decades become the most important biosensor tool 

for high-throughput analysis of biomolecular, such as protein, 

interactions but has had limited success when used for studies 

on membrane proteins. The memLAYER products facilitate 

and improves biosensor-based analysis of membrane protein 

interactions and enables SPR-based analysis of membrane 

protein mediated transport. The applicability of memLAYER 

for membrane protein analysis is demonstrated in a GPCRantibody 

interaction study performed using a SPR-instrument, 

ProteOn XPR36 system, from Bio-Rad. 

Accelerated High Content Screening 

and Homogeneous Quantification of 

Soluble IgG Levels 

Sponsored By: Genetix 


CellReport is a compact, high-resolution fluorescent 

imaging system that supports myriad cell-based high content 

applications. Moreover, the system can be used to quantify 

soluble protein concentrations using the homogenous FLISA 

approach typically read on the FMAT ® system. Here, we 

present a range of typical CellReporter applications to 

provide a general overview of the system. 

Kinetic Profiling Services for Epigenetic 

Targets: Residence Time Optimization, 

Kinetic Selectivity, Fragment Screening 

and High Throughput Thermodynamics 

Sponsored By: Proteros Biostructures GmbH 

Location: Tampa 1–3 

Proteros has expanded their kinetic profiling services 

to epigenetic targets. Showcases are presented 

demonstrating how the Proteros Reporter Displacement 

Assay can be used to develop drugs with tailor-made 

residence time, optimized kinetic selectivity, and 

balanced thermodynamic signatures.gener


IonFlux System—Automated 

Electrophysiology With Plate 

Reader Simplicity 

Sponsored By: Fluxion Biosciences, Inc. 


In this tutorial, you will learn how the IonFlux System 

can be utilized for a variety of ion channel applications. 

The basic principles of operation will be reviewed along 

with representative data and performance specifications. 

Key benefits include: highest throughput, lowest running 

cost, simple plate reader format, and suitable for both 

voltage-and ligand-gated channels. 

A Multiplexed 96-Well Format 

Apoptosis Screening Assay Using 

the HTFC Screening System 

Sponsored By: IntelliCyt 


We have developed a multiplexed, fluorescent screening 

assay that simultaneouslt interrogates critical pathways 

to assess early-stage apoptosls with our HTFC Screening 

System. We will discuss the 96-well assay validation that 

measures cell viability, caspase 3/7 activation, annexin V 

binding, mitochondrial membrane integrity, and cell size 

with individual cell resolution. 

Case Studies for the High Throughput 

Transfection of Functional Targets Using 

the MaxCyte ® STX Scalable Transfection 

System 

Sponsored By: MaxCyte, Inc. 


MaxCyte Flow Electroporation technology enables the rapid 

development and production of (co)transfected primary cells, 

stem cells and cell lines for screening ion channels, GPCRs, 

and other targets of interest. This transient transfection 

technology reproducibly transfect up to 1x1010 cells in less 

than 30 minutes and offers a cost-effective alternative to 

stable cell lines and transfection reagents. In this workshop, 

MaxCyte scientists will present data demonstrating the broad 

cell type compatibility of the MaxCyte STX including stem 

cells, primary cells and other historically difficult-to-transfect 

cell lines. Performance of transfected cells in downstream 

functional assays will be presented as well as comparisons to 

stable cell line performance. In addition, Dr. Oliver Klotzsche, 

Managing Director of CCS Cell Culture Services GmbH, will 

present case studies for preparing bulk quantities of assayready 

Frozen Instant Cells highlighting the simplicity and 

scalability of the MaxCyte STX. 

Label-free Impedance Technology in 

Cardiac Safety Pharmacology, In Vitro 

Toxicology and GPCR HTS Drug Discovery 

Sponsored By: Roche Applied Science 


Roche Applied Science provides innovative scientific 

research tools for genomic and cellular analysis. The new 

xCELLigence RTCA HT instrument provides real time label 

free cell monitoring on robotic platforms utilizing up to four 

384 well plate stations in parallel. The new xCELLigence 

RTCA Cardio instrument resolves cardiomyocyte beating 

patterns to assess the arrhymic liabilty of lead compounds 

in 96-well plates. 

Measure, Detect and Improve 

With RTS Tube Auditor 

Sponsored By: RTS Life Sciences 


Real world customer case studies discussing how high-speed 

volume measurement and precipitate detection techniques are 

currently being used to minimize sample variability, from initial 

solubilisation through to preparation of assay plates. Learn 

how the RTS Tube Auditor can reduce your screening costs 

and improve the quality of your sample collection. 

Profiling and Characterizing Kinases Using 

a Flexible Multi-Assay Screening System 

Sponsored By: BMG LABTECH, Hudson Robotics 

and Promega 


Promega’s universal ADP-GloTM Kinase assay has 

been combined with unique instrumentation and software 

from Hudson Robotics and BMG LABTECH to profile 

and characterize different panels of kinase families. This 

tutorial will detail the universal kinase screening platform 

that was created by combining the distinct technologies 

of these three companies. The relative activity of known 

inhibitors against several CMGC kinases, including ERK, 

CDK and P38 will be profiled in this tutorial. 

PathHunter ® Receptor Internalization: 

A Novel Platform for Quantifying GPCR 

Trafficking and Studying Ligand Bias 

Sponsored By: DiscoveRx Corporation 

Location: Daytona 

PathHunter ® Internalization uses a mix-and-read, 

chemiluminescent format for quantifying receptor 

endocytosis and has been successfully applied to 

>100 known GPCR targets. By measuring internalization, 

-Arrestin and G-protein activation, compound attributes 

and functional selectivity can be accurately described to 

uncover novel compound phenotypes. Applications to 

other targets will also be presented. 




4:30 – 5:25 pm 

Analysis of Post Translational Modifications 

in Cellular Signaling 

Sponsored By: Cell Signaling Technology 


Cell Signaling Technology (CST) develops the highest 

quality antibodies, kits, and related reagents for the study 

of cellular signal transductions pathways. Our XP line of 

rabbit monoclonal antibodies with exceptional performance 

across a broad range of applications is generated using 

XMT, a proprietary monoclonal technology developed 

in-house. We will discuss the newest CST multi-plex and 

multi-target antibody products/kits/arrays with specific 

emphasis on their utility in drug discovery screening 

applications including HTS, HCS and cell based assays. 

We will also discuss CST custom profiling services and 

recombinant growth factors and cytokines. 

Recent Advances in Label-Free Screening 

for Pharmaceutical and Biotherapeutic R&D 

Sponsored By: ForteBio 


Direct binding, real-time assays based on Biolayer 

Interferometry provide ease-of-use, fast assay development, 

enhanced throughput, versatility in assay design and the 

ability to rapidly screen target libraries to help accelerate 

the discovery and development processes. The rapid growth 

of biosensor tools used over the last few years in antibody 

and protein therapeutics efforts, as well as in pharmaceutical 

lead characterization efforts are aided by modern, high 

throughput assay methods such as Fortebio’s Octet platform. 

This presentation will discuss the latest advances in the 

platform for cell line development, lead characterization 

of biologics and pharmaceuticals, membrane protein 

interactions and vaccine development. 

Expanding the Boundaries of High-Content 

Analysis: Latest Tools, Software and Biology 

From GE Healthcare 

Sponsored By: GE Healthcare 

Location: Naples 1-2 

High-Content Analysis (HCA) utilizing high-throughput 

automated microscopy with multi-parameter image analysis, 

is a powerful and rapidly advancing approach to the study 

of cellular processes. The combination of multi-color fluorescent 

imaging and detailed morphological analysis provides data both 

for research and for drug discovery applications, from target 

identification and validation, high-throughput screening and 

lead optimization, to the evaluation of compound toxicology. 

This presentation will introduce the range of latest tools (IN 

Cell Analyzer) image analysis software (IN Cell Investigator) 


and biological reagents from GE Healthcare. Application topics 

discussed will include signal transduction, cell cycle analysis, 

cyotoxicity and neurite outgrowth. 

User-Upgradable High Throughput 

Screening System—SpectraMax 

Paradigm Platform 



Learn the latest assay possibilities on our newest platform. 

SpectraMax ® Paradigm ® System from Molecular Devices, Inc. 

is the only user upgradable microplate reader on the market. 

This future-ready platform can easily be adapted to meet 

constantly evolving application needs and ever advancing 

detection technologies while accommodating a range of 

budgets. 

Efficient Analysis of Label-Free Data With 

Genedata Screener Kinetics Analyzer 

Sponsored By: Genedata 


This workshop will show that analyzing label-free data with 

Genedata Screener is both efficient and flexible. In a real 

world example from a customer, we demonstrate the full data 

analysis workflow, from import to result report generation, 

highlighting the ease-of-use of Screener Kinetics Analyzer. 

Customization and Modular Assembly 

of Key Cell Biology Capabilities to Address 

Changing Needs in the Drug Discovery 

Workflow 

Sponsored By: Life Technologies 


Life Technologies has assembled a diverse toolbox for 

assay development and pathway analysis. As the discovery 

marketplace changed, our approach evolved to a modular 

solution to today’s challenges. Our workshop highlights 

integration of our capabilities in cell-line development, detection 

and primary cell systems into relevant HTS solutions. 

Introducing the Access Laboratory 

Workstation to Easily Add Automation 

to Any Echo ® Liquid Handler 

Sponsored By: Labcyte Inc. 

Location: Sanibel 1–3 

The Access workstation is the quickest way to add benchtop 

automation to the Echo liquid handler. In minutes, researchers 

can convert Echo ® software application protocols into fully 

optimized automation routines. With the Access workstation 

researchers can easily miniaturize and automate life science 

applications.


Wednesday, March 30, 

8:00 – 8:55 am 

ADP-Glo Bioluminescent ADP Detection 

Platform: Sensitive Screening and Profiling 

of Kinases and ATPases 

Sponsored By: Promega 


The ADP-Glo Kinase Assay is optimized for use with a 

large panel of complete Kinase Enzyme Systems. The new 

ADP-Glo Max is universal and sensitive, allows for high 

signal strength at low ATP conversion, and detects the activity 

of ATPases at high ATP concentrations, such as required 

for ABC drug transporters. The assay is ideal for screening 

and profiling of lead compounds in drug discovery. 

Approaches to Automatable High Content 

Assays in 3D Extracellular Matrices 

Sponsored By: BellBrook Labs 


The importance of 3-dimensional extracellular matrix on cellular 

function and behavior is clear from studies in differentiation, 

migration, tissue engineering and even molecular 

pharmacology. We present here a highly miniaturized and 

automated approach for high content immunocytochemistry 

in 3D matrices. Applications including tumor cell invasion and 

paracrine signaling using primary cells will be discussed. 

Scaling up Your HCS Operations With 

Genedata Screener High Content Analyzer 

Sponsored By: Genedata 


Scaling up the HCS infrastructure with additional 

instruments is a major challenge. In this workshop we 

will show how Screener can connect to data and images 

from any instrument, and provide a common platform for 

data analysis. A live demo will feature Screener High 

Content Analyzer, showing performance and usability. 

Stem Cell Toxicology and Drug Discovery 

Applications: iCell Cardiomyocytes Plus 

Molecular Devices Screening Platforms 



Induced pluripotent stem (iPS) cells are an ideal source of 

functional human cells that can be manufactured in large 

quantities to perform drug screening or test for toxic effects on 

specific target cell types. In this presentation we demonstrate 

the utility of using iCell Cardiomyocytes in conjunction with 

ImageXpress ® High Content Screening Systems and IonWorks 

BarracudaTM Automated Patch-Clamp System. 

Epigenetics Drug Discovery: Success 

Delivered by BioFocus 

Sponsored By: BioFocus 


BioFocus has identified novel chemotypes that have 

progressed into further optimization using intelligent high 

throughput screening. The epigenetics drug discovery toolbox 

has been significantly expanded by design of efficient and 

selective inhibitors of HMTs using proprietary chemogenomics 

tools and hit characterization and selectivity profiling by 

orthogonal assay technologies. 

An In Vitro Model of Acute Epilepsy Suitable 

for MTS: Synchronized Repetitive Calcium 

Oscillations in Primary Neurons Cultured in 

a 384-Well Microplate 

Sponsored By: Hamamatsu 


A cell-based assay measuring Ca2+ oscillations has been 

set up to identify new antiepileptic drugs. The reduction of 

Mg2+ to 0.1mM in cultured rat hippocampal neurons induced 

repetitive Ca2+ oscillations quantified using a Hamamatsu 

imaging based kinetic reader, FDSS. 

Wednesday, March 30, 

12:30 – 1:25 pm 

Shifting Ligand Binding Assay 

Paradigm With Tag-Lite 

Sponsored By: CisBio Bioassays 


Ligand binding assays provide a paramount investigation 

mean for membrane receptor compound pharmacology. 

Tag-lite now offers the capability to run an expanding number 

of receptor target binding and functional assays under a 

homogeneous non-radioactive format. This tutorial will review 

the latest users’ findings using Tag-lite technological platform. 

Understanding The Dynamics Of 

Cell-Based Assays—From Designing The 

Assay To Finding Out What Went Wrong 

Sponsored By: Corning Inc. 


This tutorial, featuring Mark E. Rothenberg, Corning 

Incorporated-Life Sciences, investigates the different steps 

involved in designing and troubleshooting cell-based assays. 

We start with understanding the importance of cell-based 

assay dynamics as well as discuss the various components 

of the cellular microenvironment. A discussion about design 

errors and various issues which could arise will also be 

included. 



Best Practices: Microplate Washing 

Methodologies and Optimizing Liquid 

Handler Performance 

Sponsored By: BioTek Instruments, Inc. 


BioTek will present proven wash setting recommendations 

for applications including ELISA, bead technologies and 

cell-based assays and discuss the importance of proper 

instrument maintenance. Artel will discuss best practices 

in understanding and optimizing liquid handler performance. 

Are your liquid handlers and pipettes working for your assays? 

Use of Disposable Label-Free Real-Time 

Biosensors in the Drug Discovery of 

Monoclonal Antibodies 

Sponsored By: ForteBio 


This talk introduces a novel 384-well platform based on 

bio-layer interferometry (BLI) detection equipped with 

disposable fiber-optic tips that can be used for characterizing 

antibody interactions. Re-rackable banks of 16 biosensors 

move to samples without any microfluidics, which opens up 

the possibility of immobilizing and regenerating batches of 

ligands on- or off-line to expedite screening. We compare 

data generated using BLI with those obtained by SPR to 

highlight the advantages of using this label-free real-time 

biosensor platform in identifying lead monoclonal antibodies 

with the desired epitopes for drug discovery. The ability of 

the Octet to characterize kinetics is also addressed. 

RNAi Genetic Screening 

for Drug Target Discovery 

Sponsored By: Cellecta 


Lentiviral-based pooled shRNA libraries enable rapid 

and reliable identification of genes regulating most cell 

responses and potential drug targets. The silencing effects 

of shRNAs targeting thousands of genes can be assayed 

in a single screen using representative shRNA libraries and 

HT sequencing. We will describe applications of Cellecta’s 

RNAi screening platform with data from several cancer cell 

viability screens. 

Screening of Enzymes and Ion Channels 

Through a Combination of Unique 

Instrumentation, Reagents, and Software 

Sponsored By: BMG LABTECH, Hudson Robotics 

and Life Technologies 


Invitrogen Life Technologies, Hudson Robotics and BMG 

LABTECH have combined their distinctive products to create 


an intelligent profiling platform for a wide range of applications. 

This tutorial will show solutions for cost effective, single-assay 

platforms such as ELISA screens, as well as DNA and protein 

preparation/purification protocols. It will also detail how to 

design more advanced, multi-assay screens and ADME-Tox 

profiling using multiple detection methods, such as UV-Vis, 

Luminescence, FP and TR-FRET. 

Label-Free Compound Screening and 

Characterization of Interactions With 

Novel Membrane Receptor Targets 

Using Biacore SPR and MicroCal 

ITC Instruments From GE Healthcare 

Sponsored By: GE Healthcare 


Advances in sensitivity have made Biacore SPR and 

MicroCal ITC instruments important research tools in 

drug discovery. However, transmembrane receptors such 

as GPCRs have been difficult to study by these techniques. 

Recent advances in the study of GPCRs by SPR and ITC 

will be the focus of this tutorial. 

Explore the Versatility of the Echo ® 

Liquid Handler to Optimize Your Assay 

Sponsored By: Labcyte Inc. 

Location: Sanibel 1–2 

Assay miniaturization can be hindered by precise and accurate 

transfers with tip-based pipettors. Acoustic liquid transfer and 

software flexibility of the Echo liquid handler allow for any-well 

to any-well transfer and enables efficient and cost-effective 

assay development. Workflow optimization examples for RNAi, 

cell-based assays, qPCR, and others will be presented. 

Meganucleases and TAL Nucleases: 

Efficient Tools to Engineer Isogenic 

Cell Lines for Drug Discovery 

Sponsored By: Cellectis Bioresearch 


Meganuclease-driven cGPS ® targeted integration kits 

provide easy and ready-to-use tools to quickly generate 

isogenic clones stably overexpressing the drug target of 

interest without any selection agent. High clone genotype 

homogeneity also significantly reduces clone screening while 

guaranteeing gene expression. Isogenic cGPS cell lines ready 

for ADMETox studies will be presented. The newly launched 

custom TAL nuclease service will be presented as an efficient 

and cost-effective way to generate gene knock-outs.


SBS 2011 Exhibition 

Location: Exhibit Hall, Lower Level, 


New Exhibition Hours: 




Children under the age of 18 years are not allowed 

in the Exhibit Hall. 

At SBS 2011 you not only gain valuable continuing 

education through our technical sessions, but also through 

your experiences walking the exhibit floor. Get up close 

and personal with more than 150 exhibitors with new 

technologies and techniques that are shaping innovation 

and achievement in laboratories around the world. 

New exhibit hours ensure more than enough time for 

convenient, hands-on exploration. 

Network and Nosh at 

Exhibit Hall Receptions 

New this year! A successful conference is all about 

connecting, collaborating and conversing. That’s why 

SBS 2011 plays host to a multitude of networking 

opportunities, including Exhibit Hall receptions on 

both Monday and Wednesday evening during the last 

hour of open exhibits. Feel the energy, build relationships, 

connect with exhibitors you haven’t yet met, and enjoy the 

company of friends and colleagues while exploring the 

exhibit floor and delighting in complimentary beverages 

and hors d’oeuvres. 

SBS 2011 Welcome/Networking Reception 

Monday, March 28 5:00 – 6:30 pm 

Reception in the Exhibit Hall 

Celebrating JBS 2010 Authors 


Exhibitors: Secure Your Premium 

SLAS2012 Booth Space at SBS 2011! 

Location: SLAS Show Office, Exhibit Hall, Lower Level, 





Take an Integrated Approach 

to Marketing 

The Society for Laboratory Automation and Screening 

(SLAS) proudly introduces SLAS2012, the First Annual SLAS 

Conference and Exhibition. SLAS2012 unites the best of the 

former LabAutomation and SBS conferences to increase 

collaboration and prominence for the laboratory science and 

technology community. When you partner with SLAS2012, 

you’ll discover a comprehensive marketing platform to 

advance your company. 

Short Courses: February 4–5, 2012 

Conference: February 6–8, 2012 

Exhibition: February 6–7, 2012 

Contact: Barry Sacks, SLAS Exhibit Manager at: 

bsacks@slas.org 



New Product Launches to Debut at SBS 2011 

The SBS 2011 Exhibition showcases the latest trends and advances in drug discovery. With dozens of new 

products launched at last year’s event, SBS 2011 is the premier venue to showcase cutting-edge new 

products ready to hit the market. 

BioMedTech Laboratories—Booth 1019 

Surface Coatings For High Content Screening (HCS) 

Low-base and imager compatible microplate formats for 

High-Content cell-based screening methods are now available 

coated with fibronectin, PDL, laminin, collagens, gelatin, PEI and 

more. Coated glass-bottom and clear film-bottom plates, COC/COP 

or polystyrene, are offered. Cell-specific coatings including those 

optimized for HEK and Neuronal-cells are also available. 

Neuronal-Cell Optimized Surface Coatings 

Surface coatings optimized for Neuronal-cell culture are offered 

expertly applied to all styles of microplates, flasks, dishes, rollerbottles 

and bio-production vessels Coated microplates include 

1536-well to 6-well, glass-bottom, COC/COP, lo-base, lo-volume, 

half-area, and custom. Coating of layered and multi-tier flasks, 

stacks & factories for large-scale cell production is also available. 

Stem Cell Optimized Surface Coatings 

Surface coatings optimized for Stem-cells are offered expertly 

applied to all styles of microplates, flasks, dishes, roller-bottles 

and bio-production vessels Coated microplates include 1536-well 

to 6-well, glass-bottom, COC/COP, lo-base, lo-volume, half-area, 

and custom. Coating of layered and multi-tier flasks, stacks & 

factories for large-scale cell production is also available. 

Molecular Devices, Inc.—Booth 901 

SpectraMax ® Paradigm ® Platform 

The patent-pending SpectraMax ® Paradigm ® Platform from 

Molecular Devices, Inc. is the only multi-mode user upgradable 

microplate reader on the market. This unmatched flexibility 

provides a future-ready platform that can easily be adapted to 

meet constantly evolving application needs and ever advancing 

detection technologies while accommodating a range of budgets. 

Plexera LLC—Booth 437 

PlexArray HT System 

Plexera ® makes advanced label free SPR- proteomic systems. 

The PlexArray TM HT, Launching at SBS, comprises novel hardware, 

patented biosensor chips, and data analysis software for measuring 

the highest density and throughput affinity, kinetics, and 

concentration of any current system. 


SLAS New Product 

Award (NPA) 

Designation 

Promoting the spirit 

of innovative excellence, 

each new product 

launched on the exhibit 

floor at SBS 2011 has 

the opportunity to be 

recognized for the official 

SLAS New Product Award 

(NPA) Designation. Up to three of the most 

promising new products are selected by a 

team of experts for this award. 

The winners are announced in the Exhibit 

Hall, Wednesday, March 30 at 11:30 am.

THE CASE FOR INTEGRATED MARKETING 

In 2008, K.C. Associates completed the Publications for 

Pharmaceutical Industry Study. The purpose of this study 

was to indentify the sources of news within the Pharmaceutical 

and Life Science Industry and the preference of 

individuals to receive that information. 

This independent study clearly con� rms the results of 

previously released Google and Forrester Consulting 

studies on the subject. 

* e-Conferences 

* Webinars 

* Focus Groups 

e�Conference 

ddn 

GLOBAL 

INTEGRATED 

MARKETING 

Monthly North America 

Print Edition 

Bi-weekly 

newsletter 

SPEcIal REPoRT 

TRENDS IN 

CANCER RESEARCH 

Second installment of a multi-issue series 

SEPTEMBER 2010 Volume 6, Number 9 

www.drugdiscoverynews.com 

GloBal nEwS 6 

InSTRuMEnTS & InfoRMaTIcS 14 

DIaGnoSTIcS 20 

oMIcS & SySTEMS BIoloGy 24 

RESEaRch & DEvEloPMEnT 28 

GovERnMEnT waTch 34 

fiNaNce.........................................................3 

markets.......................................................4 

editorial/commeNtary.............................12 

New products...........................................43 

facts & figures.........................................46 

The French connection 

seeking to acquire 

genzyme, sanofi-aventis 

goes public with a nearly 

$20 billion cash offer 

By JEffREy BoulEy 

PARIS—Aug. 30 finally saw the end of widespread 

speculation that French pharmaceutical 

giant sanofi-aventis was in the 

early stages of a large U.S. acquisition for 

somewhere in the neighborhood of $20 

billion when it made a non-binding offer 

to buy Genzyme Corp. for about $18.5 

billion in cash. 

Apparently, the rumors were true, as 

Pharmacogenomics harnesses power 

sanofi finally offered $69 a share in a letter 

of prediction, personalization 

to Genzyme CEO Henri A. Termeer and For much of the summer season, speculation swirled around whether sanofi-aventis would make an offer 

Branch of pharmacology stands at the precipice 

decided to go public with its bid after “sev- in the neighborhood of $20 billion for Genzyme. The French pharma finally made a formal, non-binding 

of the era of personalized medicine in 

eral unsuccessful attempts to engage offer of $18.5 billion on Aug. 30, but as Genzyme promptly rejected it, the final word on this large-figure 

cancer treatment SEE PaGE 40 

Genzyme’s management in discussions.” 

transaction—or whether sanofi-aventis will pursue a different acquisition—is yet to be written. 

Getting down to basics 

The French pharma added that it is imously rejected the offer, stating that the cally undervalues our company.” 

Researchers dig deep into the genome, not just to prepared to “consider all alternatives” to biotech is “not prepared to engage in merg- In early July, unnamed sources close to 

establish the causes of cancer, but also the best complete an acquisition. 

er negotiations with [sanofi-aventis] based the matter said sanofi had offered a price 

approaches to treatment SEE PaGE 41 

However, hardly a day passed before upon an opportunistic proposal with an just under $20 billion for Genzyme. 

Genzyme announced that its board unan- unrealistic starting price that dramati- 

SanofI coNtiNued oN page 30 

Shire hungry for share Illumina shines light 

of gastro market on Helixis acquisition 

British drugmaker announces 

company announces 

months earlier, but wasn’t made public 

until the company announced its Q2 

plans to buy Movetis NV 

purchase, launch of new pcr 

results. Still, industry observers were not 

By DavID huTTon 

product in Q2 financial report taken completely by surprise, given that 

TURNHOUT, Belgium—In an effort to boost its 

By lloyD DunlaP 

Illumina CEO Jay Flatley joined Helixis’ 

portfolio of gastrointestinal products and to 

SAN DIEGO—During its second-quarter finan- board last year as it finalized plans to 

drive its international growth, British drugcial 

report and conference call in late July, launch its new PCR product. 

maker Shire PLC has announced plans to 

Illumina Inc., a leading competitor in the Helixis CEO Alex Dickinson has agreed 

buy Belgium’s Movetis NV for $559 million. 

next-generation sequencing (NGS) space, to join Illumina as a senior vice president, 

The public tender offer is expected to 

told analysts that it has acquired Helixis of and in the coming weeks will assist in 

Shire was attracted to Turnhout, Belgium-based Movetis’ 

start upon approval by the Belgian pipeline of gastrointestinal drugs, including two drugs in Carlsbad, Calif., for $70 million in cash, plus the introduction of the new Eco Real-Time 

supervisory authority of the bid prospectus. early clinical development and several drugs that have $35 million in contingent considerations. PCR system. 

GaSTRo coNtiNued oN page 11 not yet entered clinical trials. 

The acquisition was apparently made 

hElIxIS coNtiNued oN page 18 

A VisEn-ary acquisition 2010 U.S. 

PerkinElmer’s 

acquisition of VisEn healthcare bill: 

Medical will add in Good, bad or 

vivo molecular 

imaging capabilities double-edged sword? 

to enhance Report examines reform’s 

preclinical research impact on pharma 

SEE PaGE 14 SEE PaGE 35 

Larry Doyle 

Subscriber 

Drug Discovery eNews 

Where will innovation come from? 

By Peter T. Kissinger 

Innovation is critical, and we must be on 

guard both not to let it be snuffed out or 

crippled either by corporate cutbacks or 

too many onerous rules and unnecessary 

oversight. Peter Kissinger runs us through 

the complex landscape of innovation, and 

shows us the scenic views and the 

potential potholes that can be found on 

the roads running through that landscape. 

more> 

InSIDE ThIS ISSuE 

what’s iNside 

WEDNESDAY | AUGUST 25, 2010 

Jump to: 

NEWS BRIEFS 

BENCH PRESS 

INDUSTRY CALENDAR 

CURRENT ISSUE 

Life Technologies to acquire Ion Torrent for $375 million 

And that $375 million is just for starters, as the total value of the 

deal could rise by another $350 million if certain technical and timebased 

milestones are met through 2012. Of primary interest to Life 

Technologies seems to be Ion Torrent's Personal Genome 

Machine, a benchtop instrument that will be launched commercially 

later this year and will reportedly be optimal for mid-scale 

sequencing projects, such as targeted and microbial 

sequencing... 

South Africa's Aspen to buy drug business of Australia's Sigma 

for $804 million 

Aspen Pharmacare recrafts the proposed acquisition deal that 

initially started getting press in late May, and settles on a price that 

is well over $100 million more than what it had planned to pay, yet it 

will be purchasing a portion of Sigma Pharmaceuticals instead of 

doing a full takeover... 

NEWS BRIEFS was sponsored by 

Mount Sinai researchers discover drug target for autoimmune 

diseases 

New discoveries not only help enhance understanding of 

autoimmune diseases, but may soon allow pharmas to create 

therapies that will prevent autoimmune diseases from progressing, 

while causing fewer side effects than are seen with current 

treatments... 

Seek and destroy: Wake Forest researchers' "designer protein" 

finds and kills brain tumors 

The past several decades have not witnessed much progress in 

improving treatment and extending survival for patients with 

glioblastoma multiforme, but that may be about to change with new 

discoveries by a Wake Forest team, and the potential to finally 

strike some serious blows against this aggressive and particularly 

malignant brain cancer... 

Boosting R&D with a little M&A 

September 1-2, 2010, 

Ricoh Arena, Coventry, 

UK - ELRIG's Drug 

Discovery '10 meeting 

September 12-15, 

2010, 

Boston, MA - ICAAC -- 

Interscience 

Conference on 

Antimicrobial Agents 

and Chemotherapy 

September 13-15, 

2010, 

The Rancho Bernardo 

Inn, San Diego, CA - 

Charles River’s Annual 

Biotech Symposium 

Waters Corporation 

Exiqon 

Shimadzu Scientific 

All three studies con� rm that the combination of these 

different news vehicles, not one source alone, is used by the 

market to gather and process the news of the industry. 

Integrated marketing the ddn way: 

We’ve got your integrated marketing needs covered under 

the ddn multi-product umbrella. It is the most ef� cient and 

effective way to build brand awareness within the pharma 

and life sciences industries. 

august 2010 Volume 6, Number 8 


gloBal news 6 

instruments & informatics 12 

Diagnostics 16 

omics & systems Biology 20 

researcH & Development 26 

contract researcH services 30 

fiNaNce.........................................................3 

markets.......................................................4 

editorial/commeNtary.............................10 

New products...........................................36 

facts & figures.........................................38 

Back to the future with Celgene reaches into 

Parkinson’s research deep pockets again 

Michael J. Fox Foundation partners with leading CROs 

enticed by tumor drug, company announced in January its acquisition 

to develop biomarker candidates for Parkinson’s disease 

of Gloucester Pharmaceuticals, a privately 

celgene acquires abraxis 

By DaviD Hutton 

held biotechnology firm based in Cambridge, 

NEW YORK—The Michael J. Fox Foundation 

bioscience for nearly 

Mass., for $340 million in cash plus $300 mil- 

for Parkinson’s Research (MJFF) is worklion 

in future U.S. and international regula- 

$3 billion upfront and 

ing with contract research organizations 

tory milestone payments. 

(CROs) Covance Inc., Parexel Interna- 

up to $650 million if 

Intended to accelerate Celgene’s strategy to 

tional and Epitomics Inc. to develop bio- 

become a global leader in oncology, this latest 

certain goals are met 

marker candidates, with the foundation 

transaction adds ABRAXANE, Abraxis’ met- 

earmarking nearly $1.1 million for projects 

By amy swinDerman 

astatic breast cancer treatment drug, as well as 

aimed at advancing the development of 

SUMMIT, N.J.—Since announcing their $3 billion- a nanoparticle albumin bound (nab) technol- 

leading biomarker candidates for 

plus acquisition deal on June 30, biopharmaogy that leverages albumin nanoparticles for 

Parkinson’s disease (PD). 

ceutical company Celgene Corp. and Los delivery of chemotherapeutics to tumors, to 

According to Mark Frasier, associate 

Angeles-based biotechnology firm Abraxis Celgene’s portfolio of cancer products. 

director and team leader of research The Michael J. Fox Foundation has partnered BioScience Inc. have gone dark on the details ABRAXANE was approved in January 

with CROs since 2007 because their specialized 

programs at MJFF, the foundation is 

of the deal pending its finalization, but that 2005 by the U.S. Food and Drug Administration 

expertise allows for efficient and cost-effective 

“committed to developing research tools execution of specific research goals, says Mark hasn’t stopped newswires from lighting up or (FDA) for the treatment of breast cancer after 

that are critical for advancing thera- Frasier, associate director and team leader of shareholders and analysts from dissecting the failure of combination chemotherapy 

peutic targets toward the clinic, but research programs at MJFF. This made Covance, financial terms of the blockbuster agreement. for metastatic disease or relapse within 

which no single drug discovery/devel- Epitomics and Parexel attractive partners for 

Notably, this acquisition offer is Celgene’s six months of adjuvant chemotherapy. 

mJff coNtiNued oN page 33 this research effort, he says. 

second high-figure deal of the year, as the 

celgene coNtiNued oN page 27 

Human genomics Multimillion miRNA deal 

for the masses 

sanofi-aventis, Regulus 

roche and ibm collaborate on nanopore-based form strategic alliance in 

dNa sequencing technology with eyes toward microRNA therapeutics 

By lori lesko 

advancing personalized healthcare 

CARLSBAD, Calif.—Biotechnology firm 

By Jeffrey Bouley 

Regulus Therapeutics has scored a 

BRANFORD, Conn.—IBM 

coup by landing an investment of at 

launched itself into the 

least $35 million for early-stage drug 

sequencing market in life 

discovery and development from microRNAs are recently discovered small regulatory RNAs that have a major role in 

sciences in a big way in late 

French pharmaceutical giant sano- development and disease, and as such, represent a brand new class of targets for 

2009 with the announcefi-aventis. 

The potential value of this therapeutic intervention. 

ment of its DNA Transistor 

landmark deal—if certain milestones microRNA, and is also the largest on company valuation and a three- 

technology and the predic- 

are met—is $750 million. 

miRNA therapeutics alliance to date, year option worth $50 million for a 

IBM is making numerous waves in life sciences, but 

tion that it might not one big announcement is its DNA Transistor concept, The global deal, penned June 22, consisting of a $25 million upfront broader technology alliance. 

just usher in the age of announced in late 2009, which it thinks might be the marks the largest partnership in fee, a $10 million future equity invest- “The company could receive 

iBm coNtiNued oN page 14 winner in the race for the “$1,000 genome.” 

Regulus’ biotechnology specialty, ment subject to mutual agreement 

regulus coNtiNued oN page 25 

SPECIAL REPORT: TRENDS IN CANCER RESEARCH 

The first installment in a multi-part series 

LET’s wORk TOgEThER ThE BIg PICTuRE 

Peeling back the layers of integrated approaches Multiple approaches—and ultimately 

to oncology research 

more comprehensive ones—are critical to 

see page 34 

understanding and treating cancer 

see page 35 

February 2010 e-New Product Showcase FEBRUARY 2010 

14,880 ways to achieve reliable results. 1 great new 

catalog. 1 way to win. 

Varian, Inc. 

5,950 HPLC, GC and GPC columns, 1,500 sample prep 

products, 7,150 chromatography, spectroscopy, and 

dissolution supplies…over 14,000 ways to achieve reliable 

and optimal results. Each item in our broad portfolio of 

consumables is designed to offer the precision and 

reliability for which Varian is known. Sign up for the catalog 

for a chance to win: $3,000 Travel Grant; $750 Shopping 

Sprees; Digital Whiteboard. 

MORE INFORMATION: 

Varian 

Copy Number and Expression Correlation Analysis 

JMP® Genomics 

JMP Genomics is a statistical discovery software tool from 

the two most trusted names in analytic software: SAS and 

JMP. Research organizations use JMP Genomics to 

uncover meaningful patterns in high-throughput genetics, 

expression, copy number and proteomics data. Dynamically 

interactive graphics make it easy to explore data 

relationships using a comprehensive set of traditional and 

advanced statistical algorithms. 


JMP 

Accuri® C6 Flow Cytometer® System 

Accuri Cytometers 

A high-performance flow cytometer simplified, the Accuri C6 

Flow Cytometer System features two lasers, two light 

scatter and four fluorescence channels. Priced comparable 

to a fluorescent plate reader, the compact C6 has no 

special set-up requirements. With built-in capabilities to 

measure cell concentration, the C6 is a perfect tool for cell 

counts and can accommodate large assay runs with the 

optional, automated CSampler®. 


Accuri | (734) 994-8000 

CustomerService@AccuriCytometers.com 

Drug Discovery News 

Published by Old River Publications LLC 

19035 Old Detroit Road 

Rocky River, OH USA 44116 

Ph: 440-331-6600 | Fax: 440-331-7563 

FORWARD TO A COLLEAGUE | DDN PRINT SUBSCRIPTION 

insiDe tHis issue 

©2009 Ohio River Publications LLC. All Rights Reserved. 

Web site designed and managed by Offenberger & White, Inc.. 

what’s iNside 

International Digital 

Edition 

Back To: Home 

Quarterly 

E-new product 

showcase 

SEPTEMBER 2010 | VOL. 6 | NO. 9 

EVENTS | VIEW CALENDAR 

PRINT SUBSCRIPTION 

VIEW LATEST ISSUE 

DOWNLOAD PDF 

HOME ABOUT US ADVERTISING RESOURCES CONTACT US 

Facebook Twitter 

EDIT CONNECT 

Genzyme sells business unit to 

Bowel-ing them over 

LabCorp and announces 

THIS ISSUE: 

upcoming cuts 

It looks like the 

inflammatory 

DAILY NEWS: 

bowel disease 

One less potential rival for 

treatment 

CONFERENCES AND 

Genzyme’s affections? 

market is going 

EXHIBITIONS: 

to be good to a 

lot of 

SPECIAL REPORTS: 

Roche goes route of reduction 

companies in 

the coming nine 

INDUSTRY CALENDAR: 

years (including 

Shining a light on painkilling 

Abbott and Centocor Ortho Biotech) 

E-NEWSLETTER SUBSCRIPTION: 

systems in the brain 

if predictions by Datamonitor and 

EvaluatePharma hold true. (Click 

MIT researchers declare war on 

Here to read more.) 

tumors with drug ‘smuggling’ 

delivery method 

SERIES: TRENDS IN CANCER 

RESEARCH 

Don't miss our ongoing special report 

Abbott receives FDA Approval for on trends in cancer research, which 

hepatitis B assay 

continues through December. We are 

still interested in hearing from more 

companies and institutions that are 

actively engaged in oncology 

research. To lend your voice to the 

The big decision on Bilski 

series, contact Senior Editor David 

September 2010 

Hutton at 

hutton@drugdiscoverynews.com. 

Supreme Court patent ruling on 

Bilski means much for diagnostics, 

less for pharma... 

by Jeffrey Bouley 

Lilly loses method patent after use 

was disclosed in earlier patent 

Getting down to basics 



Eli Lilly & Co. recently lost an appeal 

Researchers dig deep into the 

from a final judgment of the U.S. 

genome, not just to establish the 

District Court for the Eastern District 

causes of cancer, but also the best 

of Michigan, finding claims 2, 6, and 

approaches to treatment... 

7 of U.S. Patent No. 5,464,826 

invalid for obviousness-type double 

by Jeffrey Bouley 

patenting over its earlier U.S. Patent 

No. 4,808,614. (See, Sun 

Tour of Italy 

Pharmaceutical Industries v. Lilly, 


U.S. Court of Appeals for the Federal 

Aptuit, Siena Biotech forge strategic Circuit, 2010-1105)... [ more ] 

partnership for former GSK facility in 

by Stephen Albainy-Jenei 

Verona... 

by David Hutton 

Guest Commentary: Prioritizing 

hits based on drug-target 

residence time 

Korea collaboration is key for 

cancer research 



Amid the complexity and expense of 

Pfizer forms research partnership 

the small-molecule drug discovery 

with South Korea’s Samsung to 

process, from identification and 

analyze, treat liver cancer tumors... 

validation of a “drugable” target to the 

by Lori Lesko 

development of an understanding of 

the impact of pharmacogenomic 

differences in patient populations on 

drug action, lies the “hit-to-lead” 

process in which compounds that 

show activity in an assay system are 

iteratively improved upon through 

medicinal chemistry that is guided by 

more detailed assays and filtering 

criteria. .. [ more ] 

by Dr. Kurt Vogel 

When shareholders attack, it’s not 

just the news that suffers 


It’s the phone call or e-mail that every 

publication editor dreads. It comes 

seconds before deadline time, as the 

content your editorial team has 

worked for the last month to produce 

is committed to print. It comes from a 

writer whose story has morphed so 

materially from its original state that it 

can’t run as planned—usually leaving 

PAGE UTILITIES 

a black hole in your layout to be filled 

at the eleventh hour. .. [ more ] 

PRINT CURRENT PAGE 

by Amy Swinderman 

SEND THIS PAGE TO A COLLEAGUE 

CONTACT US 

Drug Discovery News 

Published by Old River Publications LLC 

19035 Old Detroit Road 

Rocky River, OH USA 44116 

Ph: 440-331-6600 | Fax: 440-331-7563 

Home | FAQs | Search | Submit News Release | Site Map | About Us | Advertising | Resources | Contact Us | Terms & Conditions | Privacy Policy 

© Copyright 2009 Old River Publications LLC. All righs reserved. | Web site managed and designed by OffWhite. 

htt ://www.dru discover news.com/index. h ? =1 

9/14/2010 

Fully integrated 

web site 

* Whitepapers/ 

Application Notes 

* Editors’ Blog


Exhibitor Listing (as of February 25, 2011) 

Exhibitor Booth Exhibitor Booth 

AAT Bioquest, Inc. 1024 

ABS Inc. 700 

Agilent Technologies Inc. 611 

Albany Molecular Research, Inc. 1133 

Almac Sciences Ltd. 512 

Amnis Corporation 1108 

AnaSpec, Eurogentec Group 1202 

Apricot Designs 1121 

Art Robbins Instruments 518 

ARTEL, Inc. 1130 

Assaymetrics Limited 915 

Axxam SpA 900 

Beckman Coulter, Inc. 310 

BellBrook Labs 706 

Berthold Technologies 1031 

BIOCIUS Life Sciences 601 

Biodesy LLC 430 

BioFocus 1225 

Biohit, Inc. 1230 

BioInvenu 433 

BioMedTech Laboratories 1019 

BiOptix Inc. 830 

Bio-Rad Laboratories 1127 

BioSero 1123 

Biotec Co, Ltd 531 

BioTechniques 420 

BioTek Instruments, Inc. 618 

Blue Sky Biotech, Inc. 1211 

BMG Labtech, Inc. 807 

BPS Bioscience Inc. 825 

BrandTech Scientific, Inc. 619 

Bruker Daltonics 523 

Cayman Chemical Company 1219 

CCS Cell Culture Service, Inc. 1001 

Cell Signaling Technology 801 

Cellecta, Inc. 522 

Cellectis bioresearch 930 

Cellular Dynamics International 1100 

ChanTest Corp. 831 


ChemBridge Corporation 908 

Cisbio Bioassays 513 

Codex BioSolutions 434 

Computype, Inc. 623 

Corning Life Sciences 507 

Cosmo Biosciences Inc. 527 

CPC Scientific 1021 

Curiox Biosystems Pte Ltd 431 

CYTOO Cell Architects 820 

DiscoveRx Corporation 707 

Dotmatics 436 

Douglas Scientific, LLC 731 

Drug Discovery News 1122 

Drug Discovery World 423 

Dualsystems Biotech 934 

EDC Biosystems, Inc. 1125 

EMD Millipore 630 

Enamine 818 

Essen BioScience, Inc. 319 

Fluorescence Innovations 432 

Fluxion Biosciences 1104 

Formulatrix, Inc. 530 

ForteBio, Inc. 500 

GE Healthcare 813 

Genedata 1218 

Genetic Engineering & Biotechnology News 732 

Genetix 621 

GenScript 724 

Greiner Bio-One 624 

Hamamatsu Corporation 919 

Hamilton Company 607 

HighRes Biosolutions 307 

Horizon Discovery Ltd 723 

Hudson Robotics, Inc. 425 

ICx Nomadics 519 

IDBS 1124 

IDEX Health & Science 1101 

Innoprot 1022 

InSphero AG 727


Exhibitor Booth Exhibitor Booth 

IntelliCyt Corporation 1010 

InterMed Discovery GmbH 922 

International Drug Discovery 521 

Kinaxo Biotechnologies 1033 

KINOMEScan 1103 

KURARAY, Co. Ltd 823 

Labcyte, Inc 718 

LabX/Lab Manager Magazine 532 

Lathrop Engineering Inc. 1118 

LiCONiC US, Inc. 721 

Life Chemicals, Inc. 924 

Life Technologies 1231 

Lonza 906 

Lumigen 826 

Luminex Corporation 631 

Market Research Station 835 

matrical bioscience 918 

MaxCyte, Inc. 812 

MeCour Temperature Control 418 

Micronic North America, LLC 1205 

Microsonic Systems 925 

MipTec 2011 836 

Moffitt Cancer Center 323 

Molecular Devices 901 

MRC Technology 327 

Multispan, Inc. 1220 

NAEJA Pharmaceutical Inc. 1120 

Nanion Technologies Inc. 419 

Nature Publishing Group 1200 

Nexus Biosystems 1018 

Omni International, Inc. 622 

Pall Life Sciences 424 

PerkinElmer 701 

PharmaDiagnostics NV 932 

Pittcon 2012 1032 

Platypus Technologies LLC 821 

Plexera LLC 437 

Promega Corporation 501 

Proteros Biostructures GmbH 1132 

reinnervate Ltd 1131 

ReTiSoft Inc. 413 

Roche 1222 

RTS Life Science 1119 

Sanford-Burnham Medical Research Institute 520 

Scripps Florida 300 

SelectScience 933 

Sierra Sensors GmbH 1208 

Sigma Life Science 819 

Silicon Kinetics 525 

Sophion Bioscience 1005 

Specs 719 

SRU Biosystems, Inc. 713 

Tecan 710 

Technology Networks Ltd 832 

Teflabs Inc. 1025 

The Automation Partnership 1107 

Thermo Scientific 911 

Titertek Instruments Inc. 1209 

Titian Software Ltd 401 

TTP LabTech 301 

Vectalys 923 

Venenum BioDesign 524 

Viaflo 822 

Wiley 1201 

Wyatt Technology Corporation 625 


The world’s leading business review of drug discovery and development 

invites you to complete the bound-in subscription form or register 

online to guarantee your regular and personal copy of DDW. 

turning science into business 

drug discovery world 

DDW 

the quarterly business review of drug discovery & development 

www.ddw-online.com


Exhibit Hall Floor Plan 

Food Station 

Beverage 

Station 

Innovation Plaza 

SLAS 

Sales 

Cyber 

Café 

Exhibitor 

Lounge 

SLAS Member 

Center 

Food 

Food 

Men Women Women 

Men 

Entrance 

Women 

Women Men 

Up to 

Meetings 

Down from 

Meetings 

Exhibitor 

Registration 

On-Site 

Registration 

Advance 

Registration 



Exhibitor Descriptions 

AAT Bioquest, Inc.—Booth 1024 

923 Thompson Place 

Sunnyvale, California 94085 

+1.408.733.1055; +1.408.733.1304 fax 

+1.800.990.8053 toll free 

jack@aatbio.com; www.aatbio.com 

AAT Bioquest offers bioanalytical research reagents and 

assay kits. We specialize in absorption, fluorescence and 

luminescence-based technologies. Our Screen Quest 

calcium assay kits use the outstanding Quest Fluo-8 

calcium indicator that outperforms Fluo-4. We develop 

and market research reagents and assay kits for signal 

transduction research and enzyme activity analysis. 

ABS Inc.—Booth 700 

701 Cornell Drive - Suite 4 

Wilmington, Delaware 19801 

+1.302.654.4492; +1.302.654.8046 fax 

services@absbio.com; www.absbio.com 

Analytical Biological Services Inc. (ABS) has 20 years 

of experience providing human tissues and blood along 

with human RNA, proteins, cellular fractions, and primary 

cell cultures for biomedical research. Human biospecimens 

are all collected with appropriate informed consent and 

extensive clinical data. ABS also offers large scale cell 

culture services. 

Agilent Technologies Inc.—Booth 611 

5301 Stevens Creek Boulevard 

Santa Clara, California 95051 

+1.408.345.8886; +1.800.227.9770 toll free 

contact_us@agilent.com; www.agilent.com 

Agilent Technologies is a leading supplier of life science 

instrumentation ranging from liquid chromatography 

systems and mass spectrometers, to DNA microarrays 

and automation solutions. Agilent has developed products 

and services utilized along the entire discovery value 

chain, from basic biological research through drug 

discovery and manufacturing. 


Albany Molecular Research, Inc.—Booth 1133 

26 Corporate Circle 

Albany, New York 12203 

+1.518.512.2000; +1.518.512.2020 fax 

Angela.Urdanoff@amriglobal.com; www.amriglobal.com 

AMRI is a global contract research and manufacturing 

organization with 20 years of experience providing 

customers fully integrated lead discovery, development 

and manufacturing services. The company has steadily 

expanded, with more than 1400 employees located in 

facilities throughout the U.S., Europe and Asia. 

Almac Sciences Ltd.—Booth 512 

20 Seagoe Industrial Estate 

Craigvon BT63 5QD United Kingdom 

+44.0283.833.2200 

robert.grundy@almacgroup.com; www.flexyte-assays.com 

Almac presents the FLEXYTE assay platform, which 

brings all the advantages of fluorescent lifetime technology 

to bear on the process of screening and profiling. The 

FLEXYTE platform caters for a growing number of drug 

target classes including protein kinases, proteases and 

phosphatases. Fast, efficient, accurate and economic, 

the FLEXYTE assay platform will illuminate the path for 

drug discovery. 

Amnis Corporation—Booth 1108 

2505 3rd Avenue - Suite 210 

Seattle, Washington 98121 

+1.206.374.7400; +1.206.576.6895 fax 

sales@amnis.com; www.amnis.com 

Amnis Corporation develops, manufactures and markets 

instrumentation for high speed cell imaging for the life 

science research, biopharmaceutical and diagnostic 

markets. Amnis’ ImageStreamX imaging flow cytometer 

combines the speed, sensitivity, and phenotyping 

abilities of flow cytometry with the detailed imagery 

and functional insights of microscopy.


AnaSpec, Eurogentec Group—Booth 1202 

34801 Campus Drive 

Fremont, California 94555 

+1.510.791.9560; +1.510.791.9573 fax 


admin@anaspec.com; www.anaspec.com 

As a subsidiary of Eurogentec, AnaSpec offers expertise 

in peptides, detection reagents, antibodies, assay kits, 

oligonucleotides, and qPCRs. AnaSpec carries a broad 

product line of biochemicals and reagents for basic 

research, high-throughput screening and drug discovery. 

Apricot Designs—Booth 1121 

681 Arrow Grand Circle 

Covina, California 91722 

+1.626.966.3299; +1.626.966.3200 fax 

info@apricotdesigns.com; www.apricotdesigns.com 

Apricot Designs, Inc. provides accurate and affordable 

liquid handling technologies. We manufacture compact 

& robust multi-channel liquid handling systems with easy 

to use operator interfaces. Liquid handling products from 

Apricot are flexible, affordable, compact, versatile easy 

to use, reliable, and have small footprints that maximize 

your valuable laboratory space. 

Art Robbins Instruments—Booth 518 

1293 Mountain View Alviso Road - Suite D 


+1.408.734.8400; +1.408.734.8420 fax 


info@artrobbins.com; www.artrobbins.com 

ARI will be presenting the Cobra 148 series of non-contact 

nanoliter capable reagent dispensers. Choice of 1,4 and 

8 channel in bulk reagent and aspirate/dispense versions. 

Other products include the Gryphon liquid handling system 

and Cryscam imaging system. 

ARTEL, Inc.—Booth 1130 

25 Bradley Drive 

Westbrook, Maine 04092 

+1.207.854.0860; +1.207.854.0867 fax 


info@artel-usa.com; www.artel-usa.com 

ARTEL is the worldwide leader in liquid handling quality 

assurance. The MVS allows you to verify accuracy and 

precision, troubleshoot, and optimize the performance 

of your automated liquid handlers and multichannel 

pipettes. The PCS enables fast and easy frequent 

interim verifications for all of your handheld pipettes. 

Assaymetrics Limited—Booth 915 

Cardiff Medicentre 

Heath Park 

Cardiff, CF14 4UJ 

United Kingdom 

+44.29.2002.6269; +44.29.2075.0239 fax 

sales@assaymetrics.com; www.assaymetrics.com 

Axxam SpA—Booth 900 

Biomedical Science Park 

Via Olgettina 58 20132 

Milan 20132 Italy 

+39.02.210.561; +39.02.210.5602 fax 

sabrina.corazza.sc@axxam.com; www.axxam.com 

Axxam is a discovery company focused on research 

programs for the identification of new active substances 

with potential applications in the life science industry. 

Axxam provides a complete range of discovery programs, 

services and technologies related to screening assays, 

HTS, compound profiling and hit-to-lead activities on a 

fee-for-service basis or through sponsored agreements. 


Epigenetic Assays 

Check Out Our New Products 

Transcreener 

Methyltransferase Assay 

Acetyltransferase Assay 

Improved AMP 2 

/GMP 2 R 

Assay 

iuvo TM 

3D Cellular Assay Service 

Slide Devices for 3D, High Content 

Assays in Matrigel 

www.bellbrooklabs.com 

R 

3D Cell Based Assays 

Join Us at SBS Booth 706 

Attend One of Our Tutorials 

R 

Transcreener Tutorial: 

“Transcreening” Epigenetic Targets 

Tue, March 29, 8 am 

iuvo TM Tutorial: 

High Content Assays in 3D ECM 

Wed, March 30, 8 am


Beckman Coulter, Inc.—Booth 310 

250 S Kraemer Boulevard 

Brea, California 92821 

+1.714.993.5321 

srwinters@beckman.com; www.beckmancoulter.com 

Laboratories around the world rely on Beckman Coulter’s 

promise of quality, integrity and innovation. Our integrated 

solutions deliver accurate information, from life science 

research breakthroughs, to clinical trials, to laboratory 

diagnostics and point-of-care testing. 

BellBrook Labs—Booth 706 

5500 Nobel Drive - Suite 250 

Madison, Wisconsin 53711 

+1.608.443.2400; +1.608.441.2967 fax 


info@bellbrooklabs.com; www.bellbrooklabs.com 

BellBrook Labs develops tools to accelerate drug discovery 

through the use of better biology. iuvo Microconduit 

Array Plates are moving cellular assays into a new realm 

of advanced 3D cell models and high content readouts 

that more accurately reflect in vivo biology. Transcreener ® 

HTS Assays enable you to screen more targets, both well 

characterized and emerging, faster and more efficiently. 

Berthold Technologies—Booth 1031 

Calmbacher Str 22 

Bad Wildbad 75323 

Germany 

+49.7081.177.200 

andrea.langner@berthold.com; www.berthold.com/bio 

Berthold Technologies is specialized in detection 

solutions for assay development and screening: 

multimode microplate readers, microplate luminometers, 

microplate fluorometers, microplate photometers, 

microplate stackers, radio detectors for HPLC, in 

vivo imaging systems. ISO 9001 certified development 

and manufacturing practice ensure the high quality 

of all instruments. 

] Conference Sponsor 

BIOCIUS Life Sciences—Booth 601 

11 Audubon Road 

Wakefield, Massachusetts 01880 

+1.781.928.2700; +1.781.998.0054 fax 

mmullane@biocius.com; www.biocius.com 

BIOCIUS Life Sciences provides researchers with faster 

answers: Products and services committed to speed and 

accuracy to help exceed business goals. The label-free 

RapidFire® platform feeds samples directly to the mass 

spec, helping to eliminate the bottleneck of samples that 

require screening across a range of applications—drug 

discovery, ADME-tox, clinical research and applied 

markets. 

Biodesy LLC—Booth 430 

863 Mitten Road - Suite 101 

Burlingame, California 94010 

+1.650.777.5271 

simonp@biodesy.com; www.biodesy.com 

Biodesy LLC is developing the use of Second Harmonic 

Generation (SHG) detection as a direct functional measure 

of real-time protein conformation change. We are applying 

this technique across a broad spectrum of proteins 

including key therapeutic targets, protein kinases and 

integrins. Instruments and consumables are part of 

our platform. 

BioFocus—Booth 1225 

Chesterford Park - Saffron Walden 

Essex CB10 1XL United Kingdom 

+44.1799.533.500; +44.1799.531.495 fax 

info@glpg.com; www.biofocus.com 

BioFocus expands its partners’ drug pipelines by 

accelerating the gene-to-clinical candidate discovery 

process. This is achieved through an integrated discovery 

platform, which includes target discovery in human 

primary cells, in vitro and cell-based screening, 

structural biology, medicinal chemistry, ADME/PK 

services and compound library acquisition, storage 

and distribution services. 




Biohit, Inc.—Booth 1230 

3535 Rte 66 -Building 4 

Neptune, New Jersey 07753 

+1.732.922.4900; +1.732.922.0557 fax 


robert.gearty@biohit.com; www.us.biohit.com 

Electronic and mechanical pipettes, single and 

multichannel formats; all featuring state of the art 

ergonomic design and patented technology providing 

superb accuracy and precision: rLINE pipetting modules 

for OEM system integration; roboLINE pipetting 

workstation and disposable pipette tips for hand-held 

and robotic systems. MicroPlate readers and washers 

will also be displayed. 

BioInvenu—Booth 433 

50 Williams Parkway A-2 East 

Hanover, New Jersey 07936 

+1.973.585.6777; +1.973.585.6776 fax 

info@bioinvenu.com; www.bioinvenu.com 

BioInvenu develops novel cell-based LinkLight assay 

products by utilizing protein-protein interactions as 

functional signal readouts. BioInvenu offers sensitive, 

robust, selective & cost-effective GPCR ß-arrestin 

signaling, receptor tyrosine kinase and nuclear hormone 

receptor LinkLight assay-ready cells. BioInvenu also 

provides customer services to support your drug discovery 

programs. 

BioMedTech Laboratories—Booth 1019 

3802 Spectrum Boulevard - Suite 154 

Tampa Florida 33612 

+1.813.985.7180; +1.813.558.2000 fax 

biomedtech@verizon.net; www.biomedtech.com 

BioMedTech expertly coats all styles of microplates, 

flasks, roller-bottles and bio-production vessels with 

fibronectin, PDL, laminin, collagens, gelatin, PEI and 

more. Coated plates include 1536-well to 6-well, glassbottom, 

COC/COP, lo-base, lo-volume, half-area, strip, 

and custom. Coating of layered and multi-tier flasks, 

stacks & factories for large-scale cell production is 

also available. 


BiOptix Inc.—Booth 830 

1775 38th St. 

Boulder, Colorado 80301 

+1.303.545.5550; +1.303.545.5551 fax 

erik@bioptix.com; www.bioptix.com 

BiOptix is pleased to introduce the ACCOLADE, a fourfeature 

label-free system designed for biomolecular kinetic 

analysis. Built on BiOptix’ patented Surface Plasmon- 

Enhanced Interferometry technology, the ACCOLADE 

provides scientists an accurate and sensitive label-free 

system that is also easier to use, economical to operate, 

and accessible to laboratories with constrained budgets. 

Bio-Rad Laboratories—Booth 1127 

2000 Alfred Nobel Drive 

Hercules, California 94547 

+1.510.741.1000; +1.510.741.5800 fax 


laura_moriarty@bio-rad.com; discover.bio-rad.com 

Bio-Rad Laboratories has played a leading role in the 

advancement of scientific discovery for over 50 years 

by providing a broad range of innovative products and 

services to the life science research and clinical diagnostic 

markets. Founded in 1952, Bio-Rad serves research and 

industry customers around the world through its global 

network of operations. 

BioSero—Booth 1123 

4186 Sorrento Valley Boulevard - Suite H 

San Diego, California 92121 

+1.661.284.6650; +1.661.284.7583 fax 

info@bioseroinc.com; www.bioseroinc.com 

BioSero is a consortium of companies that provide 

scientists with products and services for complete 

laboratory automation solutions. The products include 

liquid handling, microplate sealing, robotic automation, 

integration & scheduling software, hoods/ enclosures 

& data analysis tools all uniquely designed with the 

highest level of engineering and performance in mind.


Biotec Co., Ltd.—Booth 531 

Furusawa Building 2-29-4 Yushima 

Bunkyo-ku Tokyo 113-0034 Japan 

+81.3.3816.6931; +81.3.3818.4554 fax 

suzuki@biotec.co.jp; www.biotec.co.jp 

Established in 1978, Biotec has been the leading 

company of the life science equipment in Japan. 

We will be exhibiting our new laboratory automation 

equipment, the multi-channel pipettor, that can handle 

1,536 channels simultaneously. We are now looking 

for distributors as well as the companies that are 

interested in the OEM business in the US. 

BioTechniques—Booth 420 

52 Vanderbilt Avenue - 7th Floor 

New York, New York 10017 

+1.212-520-2714; +1.646.666.9858 fax 

www.biotechniques.com 

BioTechniques, the international journal of life science 

methods, provides open access to first-quality, peerreviewed 

papers on laboratory techniques and protocols. 

Now in its 50th volume, BioTechniques has over 80,000 

print subscribers worldwide. The journal augments its 

peer-reviewed content with feature articles and topicspecific 

supplements. 

] Media Partner 

BioTek Instruments, Inc.—Booth 618 

Highland Park 

P.O. Box 998 

Winooski, Vermont 05404 

+1.802.655.4040; +1.802.655.7941 fax 


vanderploegt@biotek.com; www.biotek.com 

BioTek® Instruments, Inc. is a worldwide leader in 

the design, manufacture, and sale of microplate 

instrumentation and software. BioTek instrumentation 

is used to aid in the advancement of life science research, 

facilitate the drug discovery process and to enable costeffective 

quantification of disease relevant molecules in 

the clinic. 


Blue Sky Biotech, Inc.—Booth 1211 

60 Prescott St 

Worcester, Massachusetts 01605-2661 

+1.508.798.2930; +1.508.798.2649 fax 


bcain@blueskybiotech.com; www.blueskybiotech.com 

Blue Sky Biotech, Inc. is a Contract Research Organization 

(CRO) serving the life science industries. As a trusted 

One-Stop Gene to Screen service provider to 9 of 

Fortune’s Top 10 Pharmaceutical Companies, we provide 

premium quality molecular biology, protein expression, 

scale-up bioprocess & assay services and have a proven 

track record with industry leaders. 

BMG Labtech, Inc.—Booth 807 

13000 Weston Parkway - Suite 109 

Cary, North Carolina 27513 

+1.919.678.1633; +1.919.678.1640 fax 


usa@bmglabtech.com; www.bmglabtech.com 

BMG LABTECH is a leading developer and global 

manufacturer of microplate reader instrumentation with 

a wide range of measurement methods. Microplate readers 

are used in the pharmaceutical and biotech industries, 

as well as in academic research establishments, for both 

basic research analysis and high throughput screening. 

] Bronze Sponsor 

BPS Bioscience Inc.—Booth 825 

6044 Cornerstone Court W - Suite E 


+1.858.829.3082; +1.858.481.8694 fax 

info@bpsbioscience.com; www.bpsbioscience.com 

BPS Bioscience manufactures unique, high quality 

enzymes and assay kits, including epigenetic enzymes 

(HDACs, DNA and histone methyltransferases, histone 

demethylases), PARPs, PDEs, kinases and phosphatases, 

DUBs/ubiquitination proteins, and more. BPS also provides 

custom protein expression, biochemical and cell-based 

assays, and compound screening services to accelerate 

global drug discovery. 



BrandTech Scientific, Inc.—Booth 619 

11 Bokum Road 

Essex, Connecticut 06426-1506 

+1.860.767.2562; +1.860.767.2563 fax 


cpetrilli@brandtech.com; www.brandtech.com 

BrandTech will be exhibiting BRANDplates ® — 

a comprehensive line of 96-, 384- and 1536-well 

plates with surface treatments for immunoassay, 

cell culture. Also on display: a complete line of PCR 

plastics, including new white PCR plates; Transferpette 

S single and multichannel handheld pipettes; and the 

NEW HandyStep S repeating pipette. 

Bruker Daltonics—Booth 523 

40 Manning Road 

Billerica, Massachusetts 01821 

+1.978.663.3660 

ms-sales@bdal.com; www.bdal.com 

Bruker Daltonics is a leading provider of analytical 

systems for key emerging molecular diagnostic 

applications. Driven by our innovative, easy-to-use 

and cost-effective systems for microbial identification, 

molecular histology and toxicity assessment, we provide 

the latest in high performance and high value systems 

for the clinical research laboratory. 

Get a Career Plan 

that Works. 

An exceptional career requires insightful planning 

and management. That’s where Science Careers 

comes in. From job search to career enhancement, 

Science Careers has the tools and resources to 

help you achieve your goals. Get yourself on the 

right track today and get a career plan that works. 

Visit ScienceCareers.org. 

ScienceCareers.org 


Develop My Career 

Research 

Navigate 

Network 

Cayman Chemical Company—Booth 1219 

1180 E Ellsworth Road 

Ann Arbor, Michigan 48108-2419 

+1.734.971.3335; +1.734.975.3640 fax 


sales@caymanchem.com; www.caymanchem.com 

Cayman Chemical has new assays ready for screening 

histone methyltransferases and demethylases, HDACs 

and SIRTs. New biochemical screening libraries for F, 

D&E, A&J series Prostaglandins as well as Fatty Acids 

and Kinases in 96 well formats are now ready to ship. 

Custom built libraries and contract biochemical 

synthesis are also available. 

CCS Cell Culture Service, Inc.—Booth 1001 

Princeton Corporate Plaza 7 Deer Park Drive - Suite L 

Monmouth Junction, New Jersey 08852 

+1.732.329.2355; +1.732.329.0739 fax 

kark@cellcultureservice.com; www.cellcultureservice.com 

We make the Cells! We are generating tailor-made 

recombinant cell lines expressing a target of interest 

and developing cell based assays for your individual 

needs. To directly support screening campaigns we 

are providing ready to use Frozen Instant Cells in vials 

or plates as well as membranes or active proteins. 

Track 

Find My Job 

Search

September 26–27, 2011 | Sheraton Boston Hotel, Boston, MA 

Keynote Speaker | Rudolf Jaenisch, M.D. 

Founding Member, Whitehead Institute for 

Biomedical Research; Professor of Biology, MIT 

Stay updated at SLAS.org 

Symposium Sponsor:


Cell Signaling Technology—Booth 801 

3 Trask Lane 

Danvers, Massachusetts 01923 

+1.978.867.2300; +1.978.867.2400 fax 


info@cellsignal.com; www.cellsignal.com 

Cell Signaling Technology offers high quality antibodies, 

reagents, and kits for in vitro and cell-based assays, 

including our exclusive line of XP monoclonal antibodies 

– all validated on several assay platforms. PathScan ® 

Multiplex kits allow simultaneous detection of key signaling 

pathway nodes using manual immunofluorescence 

microscopy, or automated imaging and laser scanning 

HCS platforms. 

Cellecta, Inc.—Booth 522 

320 Logue Avenue 

Mountain View, California 94043 

+1.650.938.4050; +1.650.938.3911 fax 


pauld@cellecta.com; www.cellecta.com 

Cellecta provides HT RNAi-based genetic screening 

services for the discovery and functional characterization 

of novel therapeutic targets. We offer pooled lentiviral 

shRNA libraries, shRNA library screening and analysis 

by HT sequencing, and stable reporter, overexpression, 

or knockdown cell lines. 

Cellectis Bioresearch—Booth 930 

One Broadway 

Cambridge, Massachusetts 02142 

+1.617.682.3625, +1.617.401.3684 fax 

event@cellectis-bioresearch.com; www.cellectisbioresearch.com 

Cellectis bioresearch develop targeted integration kits 

for the fast and effortless generation of isogenic cell lines. 

cGPS (cellular Genome Postionning System) kits provide 

easy and ready-to-use tools to quickly generate stable 

clones. Ideal for cell-based assays for drug screening 

and drug profiling and generation of cell lines in ADMET 

studies. ADMET cell lines released during 2011. 


Cellular Dynamics International—Booth 1100 

525 Science Drive 


+1.608.310.5100; +1.608.310.5101 fax 

mstafford@cellulardynamics.com; 

www.cellulardynamics.com 

Cellular Dynamics International is the world’s largest 

producer of fully functional human cells derived from 

induced pluripotent stem (iPS) cells. Our iCell product 

lines provide industrialized quantities of pure, homogenous, 

terminally differentiated human cells enabling basic 

research, drug discovery programs, and predictive toxicity 

and efficacy screening through in vitro clinical trials. 

ChanTest Corp.—Booth 831 

14656 Neo Parkway 

Cleveland, Ohio 44128 

+1.216.584.0551 

ksiver@chantest.com; www.chantest.com 

ChanTest offers the largest collection of Ion Channel 

services and products and an extensive offering of 

GPCR assays for screening and profiling. The company 

is also leading provider of pre-clinical safety testing 

and consultation services, and has been recognized as 

“the most trusted and most used ion channel services 

company” in independent surveys. 

ChemBridge Corporation—Booth 908 

11199 Sorrento Valley Road - Suite 206 


+1.858.451.7400; +1.858.451.7401 fax 


sales@chembridge.com; www.chembridge.com 

ChemBridge Corporation is a discovery chemistry CRO 

offering an extensive portfolio of chemistry, including 

800,000 in-stock screening compounds with leadlike 

properties that are diverse or target focused and 

customized library production and research services. 

For 17 years, ChemBridge has provided cost-effective 

enabling chemistry solutions for all stages of drug 

discovery.


Cisbio Bioassays—Booth 513 

Parc Marcel Boiteux BP84175 

Codolet 30200 France 

+33.466.796.705; +33.466.791.920 fax 

dlodola@cisbio.com; www.cisbio.com 

Cisbio Bioassays is a global developer of technologies 

that are used in assay development and drug screening. 

Cisbio pioneered the field of homogenous fluorescence 

methodologies via its proprietary technology, HTRF ® , 

a highly sensitive, robust technology for the detection 

of molecular interactions and widely used by the 

pharmaceutical industry in HTS. 


Codex BioSolutions—Booth 434 

19632 Club House Road 

Montgomery Village, Maryland 20886 

+1.301.538.5852, +1.240.683.5852 fax 

jimmy_lu@codexbio.com; www.codexbio.com 

Computype, Inc.—Booth 623 

2285 West County Road C 

St. Paul, Minnesota 55113 

+1.651.633.0633 

lab@computype.com; www.computype.com/laboratory 

Computype offers Barcode and Data Matrix identification 

products for your laboratory samples that allow you to 

focus on the task at hand. We’ll work with you to build 

solutions tailored to fit your needs using pre-printed and 

blank labels, label printers, automatic label applicators, 

software, and Label Ease pre-labeled labware. 

Corning Life Sciences—Booth 507 

900 Chelmsford St - Tower 2, 4th Floor 

Lowell, Massachusetts 01851 

+1.978.442.2200; +1.978.442.2476 fax 

clswebmail@corning.com; www.corning.com/lifesciences 

Corning Life Sciences, together with its subsidiary 

Axygen BioScience, is a global manufacturer of tools for 

molecular biology, cell culture, storage and drug screening. 

Products include automation-friendly robotic tips, filter 

plates, storage and assay plates, PCR tubes, bar coded 

storage tubes, sealing mats/tapes, cell culture flasks and 

DNA/RNA isolation kits. 

Cosmo Biosciences Inc.—Booth 527 

8, Nanyun 4thRd, Sciences City 

Guangzhou Guangzhou 510663 China 

+86.20.3229.0823; +86.20.321.8258 fax 

info@cosmobrand.com; www.cosmobrand.com 

Cosmobrand focus on lifescience plastic ware and 

precision mold manufacturing, we not only provide the 

microplates for high throughput screening applied to cell 

culture, immunoassay, sample analysis, and through our 

professional experience to provide Customized services. 

CPC Scientific—Booth 1021 

1245 Reamwood Avenue 


+1.408.734.3800; +1.408.734.3810 fax 


irvs@cpcscientific.com; www.cpcscientific.com 

CPC is an ISO certified and GMP licensed peptide 

producer with 250 employees making over 1,000 peptides 

per month from 1 mg to multiple KG. We make all 

commercially available modifications and every peptide 

comes with HPLC, MS, solubility and a 100 percent 

satisfaction guarantee. 


PORTFOLIO: 

• 700,000 screening 

compounds: 

targeted & diverse 

• Discovery Chemistry 

Services 

• Novel Building Blocks 

• Hit2Lead.com 

chemical store 

Please visit us at Booth # 908 

CHEMBRIDGE CORPORATION 

Setting the Gold Standard in 

Discovery Chemistry 

SUCCESS 

PORTFOLIO 

EXPERIENCE: 

• More than 17 years of chemistry 

excellence 

• Client exclusive libraries 

• Highly skilled chemists 

EXPERIENCE 

SUCCESS: 

• Over 500 international clients: pharma, 

biotech, & academic 

• Dependability in quality & delivery 

• Proven results in literature citations 

San Diego, California | 1-800-964-6143 | sales@chembridge.com 

WWW.CHEMBRIDGE.COM


Curiox Biosystems—Booth 431 

Pte Ltd 180 Ang Mo Kio Avenue 8 

Block Q Unit 501, Singapore 

569830 Singapore 

+65.6459.2312 

namyong@curiox.com; www.curiox.com 

Curiox Biosystems is a bioinstrumentation company 

enabling the miniaturization and automation of 

immunostaining assays such as ELISA and cell 

immunostaining assays including non-adherent cells. 

Curiox’s patent-pending SBS-compatible “wall-less” 

DropArray plates and washer provides up to 12 – 50 

times savings in sample and reagent consumption by 

running assays at 2 µl per “well” or data point. 

CYTOO Cell Architects—Booth 820 

161 Worcester Road- Suite 303 

Farmingham, Massachusetts 01701 

+1.508.270.8870; +1.508.270.8872 fax 

bcarmichael@cytoo.com; www.cytoo.com 

CYTOO Cell Architects develops, manufactures and 

markets innovative enabling technologies and products 

destined for high-content cell analysis. CYTOO’s 

technology is available in chip and well plate formats, 

and allows researchers to work with arrays of cells 

adopting the same internal organization, shape and 

morphology. 

DiscoveRx Corporation—Booth 707 

42501 Albrae St 


+1.510.979.1415; +1.510.979.1650 fax 

info@discoverx.com; www.discoverx.com 

DiscoveRx ® is a fast growing innovative company, 

dedicated to the development and commercialization 

of proprietary assays and services to study GPCR, 

Kinases, NHR and Proteases. Our cutting-edge 

biochemical and cell-based assays and profiling 

services are widely used in primary, secondary 

screening as well as SAR and lead optimization groups 

in pharmaceutical and biotech laboratories worldwide. 

Dotmatics—Booth 436 

665 Beacon Street, Suite 203 

Boston, Massachusetts 02215 

+1.617.266.9408 

info@dotmatics.com; www.dotmatics.com/index.jsp 

Douglas Scientific, LLC—Booth 731 

3600 Minnesota St 

Alexandria, Minnesota 56308 

+1.320.762.6888; +1.320.762.6259 fax 

jill.walerius@douglasscientific.com; 

www.douglasscientific.com 

Douglas Scientifics’ patented continuous Array Tape 

and proprietary inline liquid handling and scanning 

platforms – Nexar and Araya – provide a miniaturized, 

highly automated, and flexible microplate replacement; 

meeting laboratory demand for the highest quality data 

with exceptional ultra-high throughput gains and cost 

reductions. 

Drug Discovery News—Booth 1122 

19035 Old Detroit Road - Suite 203 

Rocky River, Ohio 44116 

+1.440.331.6600; +1.440.331.7563 fax 

poorman@drugdiscoverynews.com; 


Drug Discovery News is an innovative business news 

tabloid focusing on serving the information needs of 

managers and scientists involved in drug discovery, 

research and development. It provides a balance of 

articles that broadly address current issues, industry 

trends and product news that impact decision-makers 

from the bench to the board room. 




Drug Discovery World—Booth 423 

39 Vineyard Path 

London, SW14 8ET 


+44.208.487.5656 

robert@rjcoms.com; www.ddw-online.com 

Drug Discovery World, a decade on, continues to challenge 

the Industry with thought provoking articles relating to 

the Drug Discovery and Development process. Articles 

are written by Industry experts aiming to discuss the 

commercial implications of implemnenting new and next 

generation technologies. 


Dualsystems Biotech—Booth 934 

PO Box 6698 

San Pedro, California 90734 

+1.650.678.5324; +1.866.434.9933 fax 

malvika.bhatt@dualsystems.com; dualsystems.com/ 

Dualsystems Biotech is a provider of custom screening 

services for industry and academia, specializing in drug 

and target profiling, protein interaction discovery and in 

situ protein complex analysis. We help our clients speed 

up their drug development by providing real-time 

information about drugs: their targets, mechanism 

of action and downstream cellular effects. 

EDC Biosystems, Inc.—Booth 1125 

49090 Milmont Drive 


+1.510.257.1500; +1.510.257.1186 fax 


hchow@edcbiosystems.com; www.edcbiosystems.com/bio 

Providers of nanoliter acoustic liquid dispensing used 

in a number of drug discovery applications including 

screening, cell-based assays, protein crystallography, 

dose responses, and arrays. Now with TubeDowser 

technology you can also measure the concentration of 

DMSO stored in vials or tubes accurate to within 2% 

(by vol) without decapping. 


EMD Millipore—Booth 630 

290 Concord Road 

Billerica, Massachusetts 01821 

+1.800.225.3384 toll free; +1.978.715.1393 fax 

orders@millipore.com; www.millipore.com 

EMD Millipore is the Life Science division of Merck 

KGaA of Germany, supporting customers in 

research, development and production of biotech 

and pharmaceutical therapies. Our expert scientists 

support customers in cell analysis, stem cell culture, 

immunodetection, sample preparation, selectivity/ 

toxicity profiling, and bioanalytical service support 

for research and clinical studies. 

Enamine—Booth 818 

7 Deer Park Drive - Suite M3 

Monmouth Junction, New Jersey 08852 

+1.732.274.9150; +1.732.274.9151 fax 

ed.holland@enamine.net; www.enamine.net 

Essen BioScience, Inc.—Booth 319 

300 W Morgan Road 

Ann Arbor, Michigan 48108 

+1.734.769.1600; +1.734.769.7295 fax 

sales@essenbio.com; www.essenbioscience.com 

Essen BioScience IncuCyte provides time-lapse, 

microscopic imaging of cells inside your cell culture 

incubator. CellPlayer kinetic assays including apoptosis, 

angiogenesis, gene reporter, cell migration and cell 

proliferation are available for the IncuCyte and as 

services. Essen BioScience also provides Ion Channel 

Drug Discovery and Cardiac Safety studies as services.

Keep informed. Stay connected. 

Gain a competitive edge. 

Scientists around the globe rely on 

Genetic Engineering & Biotechnology News 

(GEN) to stay current in the areas of genomics, 

proteomics, drug and biomarker discovery, 

bioproduction, clinical research and diagnostics, 

collaborations, business trends and more. 

GEN, biotech’s leading news and technology 

magazine, is an indispensable resource for 

anyone involved in the business of translating 

discoveries at the bench into solutions that 

fi ght disease and improve health, agriculture, 

and the environment. 

Get your complimentary subscription today 

and join over 60,000 biotech professionals who 

read it to keep informed, stay connected and 

gain a competitive edge. 

ishing, Inc. 

Subscribe Today at 

www.genengnews.com/subscriptions.aspx 

“GEN is one of the most important media for keeping abreast of the cutting-edge developments in 

the fi eld of biotechnology. If you are in biotechnology you need to read GEN.” 

— David B. Weiner, PhD, University of Pennsylvania 

“GEN’s comprehensive overviews of hot areas in biotech make it a ‘must read’ for me and my colleagues.” 

— Arthur M. Krieg, MD, Pfi zer 

“GEN is an essential source of up-to-date information. There is nothing else like it! It keeps us 

in touch with new opportunities and is invaluable.” 

— Professor Sir Ian Wilmut, OBE, FRS, FRSE, University of Edinburgh 

To receive a complimentary subscription to GEN go to 

www.genengnews.com/susbcriptions.aspx 

140 Huguenot Street, 3rd Floor Tel: 914-740-2100 140 Huguenot Street, www.genengnews.com 

3rd Floor Tel: 914.740.2100 www.genengnews.com 

New Rochelle, NY 10801-5215 Fax: 914-740-2112 

New Rochelle, NY 10801-5215 Fax: 914.740.2110


Fluorescence Innovations—Booth 432 

2155 Analysis Drive - Suite C 

Bozeman, Montana 59718 

+1.530.613.2767 

info@fluorescenceinnovations.com; www. 

fluorescenceinnovations.com 

Fluorescence Innovations markets instrumentation 

that measures the fluorescence lifetime properties of 

biological systems. Our proprietary Direct Waveform 

Recording technology provides a revolutionary 

combination of speed, precision, and data quality that 

can be used to solve a wide range of analytical problems. 

Our NovaFlour PR Plate Reader is the first instrument 

to utilize this technology. 

Fluxion Biosciences—Booth 1104 

Oyster Point Blvd - Suite 6 

South San Francisco, California 94080 

+1.650.241.4740; +1.650.873.3665 fax 

info@fluxionbio.com; www.fluxionbio.com 

Fluxion provides integrated workstations for running 

functional cell-based assays in research and drug 

discovery. Key applications include high throughput ion 

channel screening and physiologically-relevant shear 

flow assays. Our technologies bridge the gap between 

biochemical screening assays and in vivo studies to 

provide more powerful, predictive assays and higher 

quality lead compounds. 

Formulatrix, Inc.—Booth 530 

1254 Main Street 

Waltham, Massachusetts 02451 

+1.781.788.0228-129; +1.781.207.5522 fax 

washer@formulatrix.com; www.formulatrix.com 

Formulatrix was established in 2002 to provide 

protein crystallization automation solutions. Since then, 

we’ve started developing the next generation of liquid 

handlers using microfluidic technology. Headquartered in 

Waltham, Massachusetts, we supply software and robotic 

automation solutions to leading pharmaceutical companies 

and academic research institutions around the world. 

ForteBio, Inc.—Booth 500 

1360 Willow Road - Suite 201 

Menlo Park, California 94025 

+1.650.322.1360; +1.650.322.1370 fax 


gmilan@fortebio.com; www.fortebio.com 

ForteBio markets a novel, label-free, 96 or 384-well 

format detection platform that includes instrument 

hardware, biosensors and data analysis software to 

measure affinity, kinetics, and concentration in crude 

or purified samples. This real-time dip and read method 

allows greater throughput and cost-effectiveness in 

many applications compared to existing methods such 

as SPR, ELISA and HPLC. 

GE Healthcare—Booth 813 

800 Centennial Avenue 

P.O. Box 1327 

Piscataway, New Jersey 08855-1327 

+1.732.457.8000: +1.877.295.8102 fax 

+.1.800.526.3593 toll free 

cs-us@ge.com; www.gelifesciences.com 

GE Healthcare Life Sciences provides tools for drug 

discovery, biopharmaceutical manufacturing and cellular 

technologies, so research scientists and specialists around 

the world can be more productive, effective and creative. 

Our vision is to be the start-to-finish bioprocessing solution 

provider, the partner of choice in cell and protein research, 

and the leader in life sciences services. 

Genedata—Booth 1218 

38 Margarethenstrasse Basel CH-4053 

Switzerland 

+41.61.5118400; +41.61.5118484 fax 

screener@genedata.com; www.genedata.com 

Fastest to Hit and Lead - Genedata Screener ® captures, 

visualizes, and manages HTS, HCS and time-series data 

in an integrated platform. Its screening-oriented business 

logic enables rapid processing and comprehensive 

analysis of complete campaigns, regardless of the number 

of plates or read-outs. Genedata Screener comes ready 

to use and easily integrates with any IT infrastructure. 



Genetic Engineering & Biotechnology News 

—Booth 732 

140 Huguenot Street - 2nd Floor 

New Rochelle, New York 10801 

+1.914.740.2100; +1.914.740.2105 fax 

smccarthy@liebertpub.com; www.genengnews.com 

Genetic Engineering and Biotechnology News (GEN) is the 

longest-running, most widely read, and largest circulated 

global biotechnology news publication. Published 21 times 

a year and recently redesigned to focus on Biobusiness, 

OMICS, Drug Discovery, Bioprocessing, and Translational 

Medicine, GEN reports on key news developments and 

technology trends in the bioindustry. 


Genetix—Booth 621 

120 Baytech Drive 

San Jose, California 95134 

+1.408.719.6407; +1.408.719.6401 fax 

bernette.jones@genetix.com; www.genetix.com 

Genetix provides scientists and clinicians with unrivalled 

solutions for imaging and intelligent image analysis 

to facilitate development of pharmaceuticals and 

biotherapeutics, mainstream research, and clinical 

diagnostics. For more information, visit www.genetix.com 

GenScript—Booth 724 

120 Centennial Avenue 

Piscataway, New Jersey 08854 

+1.732.885.9188; +1.732.210.0262 fax 


nicky@gnescript.com; www.genscript.com 

GenScript is a leading biology CRO focusing exclusively 

on early drug discovery and development services. 

Built on our assembly-line mode, one-stop solution, 

continuous improvement, and stringent IP protection, 

GenScript provides a comprehensive portfolio of services 

which can be effectively integrated into your value chain 

and your operations. 


Greiner Bio-One—Booth 624 

4238 Capital Drive 

Monroe, North Carolina 28110 

+1.704.261.7874; +1.704.261.7899 fax 

brad.helton@gbo.com; www.us.gbo.com 

Greiner Bio-One manufactures platforms for varied 

disciplines including Cell-Culture, ELISA Diagnostic, 

Protein Crystallization, Biochips, HTS. Precision 

engineering, premium materials & diverse surface 

technologies empower paramount efficiency for industry 

automation/ detection. Current focus on state-of-the-art 

developments in the microstructures field. Adept design; 

world-renowned OEM expertise. 

Hamamatsu Corporation—Booth 919 

360 Foothill Rd 

Bridgewater NJ 08807 

+1.908.231.0960; +1.908.231.0852 fax 

sdu@hamamatsu.com; http://www.systems.hamamatsu. 

com 

Hamamatsu Corporation is the North American 

subsidiary of Hamamatsu Photonics K.K. (Japan), 

a leading manufacturer of optoelectronic components 

and detector systems for scientific, industrial, and 

commercial applications. Our FDSS7000 and 

FDSS/µCELL are reliable “add & read” plate readers 

for GPCR and ion channel research. 


Hamilton Company—Booth 607 

4970 Energy Way 

Reno, Nevada 89502 

+1.775.858.3000; +1.775.858.3024 fax 

kelli.cavallaro@hamiltoncompany.com; www. 

hamiltoncompany.com 

Hamilton Robotics is dedicated to the design and 

manufacture of automated liquid handling workstations. 

Key to our products is our air displacement pipetting 

and monitoring technology and software controlling 

our systems. Our workstations and software serve as 

a common high precision and flexible base upon which 

to provide automated solutions.

The Label-Free 384-Well 

Revolution 

Octet 384 instrument series: 

label-free quantitation and 

kinetics for the masses 

label-free HigH tHrougHput 

Octet RED384 and Octet QK384 support 

two 384- or 96-well plates, and provide 16well 

simultaneous read-out for k a , k d , K D 

characterization and screening 

DireCt QuaNtitatioN 

Sub-ng/mL protein quantitation, IgG titer, HIS-tagged 

proteins, residual Protein A and low-affinity anti-drug 

antibody detection assays 

Dip aND reaD simpliCity 

As always, our forte: real-time analysis of protein, 

small molecules and fragments in crude mixtures 

and in the presence of DMSO 

afforDability 

SPR-quality data at a fraction of the cost, disposable 

biosensors with optional biosensor regeneration 

and re-racking deliver lowest cost per data point 

Octet RED384 Octet QK384 

Make your lab more productive by visiting 

www.fortebio.com, or call 800-oCtet-QK to 

request a demonstration in your lab 

Begins 

Now 

atteND our tutorial 

preseNtatioNs 

recent advances in label-free 

screening for pharmaceutical and 

biotherapeutic r&D 

Sriram Kumaraswamy, Ph. D., 

ForteBio, Inc. 

Tuesday, March 29, 2010, 4:30 –5:30 pm 

Room Osceola 3/4 

use of Disposable label-free 

real-time biosensors in the Drug 

Discovery of monoclonal antibodies 

Yasmina Abdiche, Ph. D., 

Associate Research Fellow, Rinat-Pfizer 

Wednesday, March 30, 12:30 –1:30 pm 

Room Osceola 3/4 

Visit us at bootH 500 

Fast. Fast. Accurate. EASY.


HighRes Biosolutions—Booth 307 

299 Washington Street 

Woburn, Massachusetts 01801 

+1.781.932.1912; +1.781.938.0813 fax 

mnichols@highresbio.com; www.highresbio.com 

HighRes designs and builds innovative robotic systems 

and laboratory devices used by pharmaceutical and 

biotech companies and academic research laboratories. 

HighRes helps scientists accelerate drug discovery, highthroughput 

genotyping, siRNA screening, next-generation 

sequencing sample prep, biorepository science and 

molecular diagnostics with highly flexible, expandable and 

modular automation. 


Horizon Discovery Ltd—Booth 723 

IQ Cambridge, Waterbeach 

Cambridge CB25 9TL United Kingdom 

+44.1223.655.580; +44.1223.862.240 fax 

j.kapp@horizondiscovery.com; www.horizondiscovery.com 

Hudson Robotics, Inc.—Booth 425 

10 Stern Avenue 

Springfield, New Jersey 07081 

+1.973.376.7400; +1.973.376.8265 fax 

dpeterson@hudsonrobotics.com; 

www.hudsonrobotics.com 

Hudson Robotics, Inc. is a leader in providing automation 

solutions to accelerate life sciences research. We offer 

a unique mix of instrumentation, customized software 

and scientific knowledge. We are dedicated to finding 

flexible strategies and economic solutions. All of Hudson’s 

equipment is tied together by our powerful, but easy-to-use 

SoftLinx TM scheduler and control software. 


ICx Nomadics—Booth 519 

800 Research Parkway - Suite 100 

Oklahoma City, Oklahoma 73104 

+1.405.236.8600; +1.405.235.8608 fax 

tom.jobe@icxt.com; www.discoversensiq.com 

ICX Nomadics supplies Surface Plasmon Resonance 

systems to researchers performing biomolecular 

interaction Analysis. SensiQ instruments range from a 

simple manual instrument to a fully automated system. 

IDBS—Booth 1124 

2 Occam Court Surrey Research Park 

Guildford Surrey GU2 7QB United Kingdom 

+44.1483.595.000; +44.1483.595.001 fax 

info@idbs.com; www.idbs.com 

IDBS is proven to increase efficiency, reduce cost and 

improve operational efficiency of our global customers 

by providing unique, innovative and leading data 

management and analytics solutions. Customers enjoy 

protection of their IP, security, flexibility across their 

organization which in turn supports both Good 

Laboratory and Manufacturing Practice. 

IDEX Health & Science—Booth 1101 

619 Oak Street 

Oak Harbor, Washington 98277 

+1.360.682.4248; +1.360.682.4151 fax 

bbradley@idexcorp.com; www.idex-hs.corp 

IDEX Health & Science’s Innovadyne liquid handling 

solutions are ideal for Genomics PCR, HTS, Sequencing, 

Bead and Cell Dispensing, Protein Crystallography, 

Diagnostics, and Custom Manufacturing applications. 

This robust, non-contact, nanoliter dispense technology 

offers tools that increase throughput, provide state-of- 

the-art accuracy and precision while significantly 

lowering reagent costs.

Unlimited speed? 

The Autobahn – made in Germany. 

The SyncroPatch 96 – made by Nanion (booth 419). 

Automated Patch Clamp – The Next Generation 

Speed up your ion channel screening! The SyncroPatch ® 96 

provides the highest throughput on the market for giga-seal 

recordings, cost efficient con sumables and high data quality. 

Schedule your demo – see for yourself! 

Nanion Technologies • www.nanion.de

Using inflUence and PersUasion 

to get What YoU Want 

Do your proposals fall on “deaf ears?” Lose 

momentum? Are your best ideas still a secret? 

Learn how to apply four influence skills that 

eliminate interpersonal roadblocks so that you 

can achieve your goals faster and with less 

stress. You’ll walk away with communication 

skills essential to gaining acceptance of your 

ideas, sustain motivation during projects when 

the road gets rough, get more done in less time, 

increase your personal clout, run more efficient 

meetings, and facilitate smarter decisions. 

BUilding ProdUctive Work 

relationshiPs throUgh conflict 

ManageMent 

Whenever two or more people work together, 

expect interpersonal conflict. Ironically, conflict 

can be one of a lab manager’s best ways of 

discovering staff disconnects in values, goals, 

roles, statuses, and perceptions that contribute 

to project delays, costly mistakes, and missed 

opportunities. You will learn five conflict 

management strategies, when to apply each, 

steps for resolving conflict, and how to create 

an organizational culture in which conflict is a 

healthy catalyst for positive change. 

As an attendee, you will learn to lead with vision, motivate and 

empower with passion, facilitate effective communication and 

delegate with clarity to get the best from individuals and teams. 

effective coMMUnication skills; 

selling YoUr ideas to others 

If communication can be defined as the transmission 

of information, thought or feeling so 

that it is satisfactorily understood, then dealing 

with difficult people is essentially a communication 

skill. Communication with another person 

with RESPECT is not a science; it doesn’t have 

a precise set of procedures. Yes, there are 

sound principles and themes but there are also 

hundreds of variations of those themes. Thus, 

communication is a SKILL. In this session, you’ll 

get the TOOLS to ease the challenges of difficult 

conversations as well as insights into how to 

improve your everyday interactions.

Use All That SLAS Offers You to Transform Your Future 

As the reagent that combined the Society for Biomolecular Sciences and the Association for Laboratory Automation, 

SLAS has fostered a reaction that impacts the entire scientific research and discovery community. As a member of 

this innovative community, make sure that you experience all that SLAS has to offer. The scientific education, practical 

information, professional career-building, and valuable networking opportunities to which you have access can open 

many doors to personal and professional success. 

SLAS Community Highlights: 

• SLAS.org: a centralized hub for all things SLAS, 

industry news, industry knowledge and education, 

and networking opportunities 

• The Journal of Biomolecular Screening (JBS)*: 


discovery sciences. Available in print and online 

• The Journal of Laboratory Automation (JALA)*: 


forum devoted exclusively to the advancement of 

technology in the laboratory. Available in print and online 

• Deep member discounts on registration for leading 

conferences, symposia and virtual courses 

• Access to professional career-building services 

via SLAS Career Connections 

An International Community Advancing Scientific 

Research and Discovery Through Laboratory Technology 

Explore all that SLAS has to offer at SLAS.org 

• LabAutopedia: the world’s leading online 

repository of laboratory automation knowledge 

• The Market Place: the ultimate online product and 

service directory for laboratory automation and screening 

• Society and Section committees and work groups 

offering rich volunteer and leadership opportunities 

• Networking and collaboration with like-minded 

peers in drug discovery, agrochemical, biotechnology, 

chemical, clinical diagnostic, consumer product, 

energy, food, forensic, pharmaceutical, security 

and other industries 

*Biomolecular Sciences Section membership includes a subscription 

to JBS, Laboratory Automation Section membership includes a 

subscription to JALA, and combined Section members receive both. 

Watch for further information about the of�cial launch of 

SLAS and our new, comprehensive website later this year.


Innoprot—Booth 1022 

Parque Tecnologico Bizkaia 

Edf. 502, 1 Planta 

Derio 48160 Spain 

+34.94.4005355 

innoprot@innoprot.com; www.innoprot.com 

Innoprot is a global provider of human/animal primary 

cells and stable cell lines intended to be used in High 

Content Screening (HCS) and High Throughput Screening 

(HTS). Innoprot also offer screening services (HCS, HTS) 

their property cell lines. Stable cell lines developed by 

Innoprot are target-oriented, focused mainly in GPCRs, 

NHRs, neurodegenerative diseases and oncology. 

InSphero AG—Booth 727 

Technoparkstrasse 1 

Zurich 8005 Switzerland 

+41.44.515.049-0; +41.44.515.0491 fax 

manuela.vujevic@insphero.com; http://www.insphero.com 

InSphero develops and manufactures ready-to-use 

3D microtissues for improved drug testing. The scaffoldfree 

microtissues from liver and a variety of tumors have 

an excellent size and density variability. The microtissues 

are delivered in standard 96-well plates and allow for 

a straightforward upgrade of cell-based assays from 

monolayers to 3D microtissues. 

IntelliCyt Corporation—Booth 1010 

317 Commercial Street NE 

Albuquerque, New Mexico 87102 

+1.505.345.9075 

ltrinkle@intellicyt.com; www.intellicyt.com 

IntelliCyt Corporation develops and markets products 

and services to accelerate discovery utilizing novel cell 

and bead-based screening tools. Their HTFC Screening 

System and validated MultiMetric Screening Assays 

combined with powerful informatics tools provide the 

sensitivity and speed required to screen compound or 

biologic libraries with suspension cells in a 96 or 384 

well format. 


InterMed Discovery GmbH—Booth 922 

Otto-Hahn-Str15 

Dortmund 44227 Germany 

+49.231.9742.6060; +49.231.9742.6061 fax 

erik.metz@intermed-discovery.com; www.intermeddiscovery.com 

InterMed Discovery is a world class Natural Product 

lead-discovery company, driving innovation through 

the generation of novel product candidates for the life 

science industries. Using one of the most powerful 

validated Natural Product discovery engines, InterMed 

Discovery generates proprietary product pipelines of 

early stage pharmaceuticals and supports partners in 

research and lead generation. 

International Drug Discovery—Booth 521 

9225 Priority Way W Drive - Suite 120 

Indianapolis, Indiana 46240 

+1.317.816.8787; +1.317.816.8788 fax 

svetlana.varkonyi@russpub.com; www. 

internationaldrugdiscovery.com 

IDD is a leading publication of business and technology 

in the drug discovery arena across the globe. Each 

issue offers our 20,000 readers unbiased editorial on 

the following topics: gene expression, laboratory 

automation, stem cells, HTS, HCS, HCA, translational 

medicine, biomarkers, flow cytometry, next generation 

sequencing, imaging, neuroscience, RNA based 

technologies, qPCR, epigenetics! 


Kinaxo Biotechnologies—Booth 1033 

Am Klopferspitz 19a Martinsried 

82152 Germany 

+49.89.461.3363; +22.49.89.4613363.20 fax 

j.fritz@kinaxo.de; www.kinaxo.com 

KINAXO combines chemical proteomics and quantitative 

mass spectrometry to allow comprehensive analysis 

of a compound’s mode of action and its influence on 

signal transduction processes. KINAXO thus enables 

prediction of a drug’s therapeutic outcome, backing 

tailor-made therapy to increase the individual’s therapeutic 

benefit and reduce the risk of unwanted side effects. 

] Bronze Sponsor


KINOMEScan—Booth 1103 

4215 Sorrento Valley Boulevard 


+1.858.334.2181; +1.858.630.4600 fax 

djones@ambitbio.com; www.kinomescan.com 

KURARAY, Co. Ltd.—Booth 823 

41 Miyukigaoka Tsukaba 

305-0841 Japan 

+81.29.853.1569 

masaya_hosoda@kuraray.co.jp; www.kuraray.co.jp/en 

Kuraray is a Japanese chemical manufacturer having 

a strong base in polymer production, processing and 

fabrication. Using our micro fabrication technology, 

a unique “Micro-Space Cell Culture Plate” is being 

developed. In micro-space, certain types of cells 

spontaneously aggregate to better mimic in vivo 

morphology and maintain their inherent functions. 

Labcyte, Inc.—Booth 718 

1190 Borregas Avenue 


+1.408.747.2000; +1.408.747.2010 fax 

info@labcyte.com; www.labcyte.com 

Labcyte is revolutionizing life science with the Echo ® 

liquid handler which uses acoustic energy to transfer 

liquids. This touchless technology provides dramatically 

better results by eliminating pipette tips and their 

associated problems, while saving hundreds of thousands 

of dollars annually in decreased consumables. Labcyte 

technologies have broad application in many fields. 

LabX/Lab Manager Magazine—Booth 532 

478 Bay St, P.O. Box 216, 

Midland, Ontario L4R 5G2, Canada 

+1.705.528.6888; 888.781.0328 toll free 

+1.705.528.0270 fax 

angelab@labx.com; www.labx.com 

LabX has evolved as a highly specialized business-tobusiness 

marketplace where scientific equipment & supplies 

can be bought & sold. Professionals from all industries visit 

LabX. Lab Manager Magazine is written with managers 

in mind & provides practical information on business, 

leadership & staffing as well as the industry & technology 

news needed to effectively manage today’s lab. 


Lathrop Engineering Inc.—Booth 1118 

1101 S. Winchester Boulevard - Building B110 


+1.408.260.2111; +1.408.260.2242 fax 

cherylenes@lathropengineering.com; 

www.lathropengineering.com 

Lathrop is a fast track, full service product development 

organization. We specialize in developing commercial 

level instrumentation and medical diagnostic devices. 

From concept through to production, we have expertise 

in microfluidics, optical detection systems, robotics, 

thermal, electronics, industrial design, software, firmware, 

plastics, FEA, system integrations and manufacturability 

ISO9001. 

LiCONiC US, Inc.—Booth 721 

21F Olympia Avenue 


+1.781.933.2050; +1.781.933.2260 fax 

pmu@liconic.com; www.liconic.com 

LiCONiC is the leading manufacturer of automated 

solutions for storage needs ranging from -80...200c. 

We pride ourselves on handling custom solutions for 

our clients. 


Application Notes 

eMarketing 

Forums 

Industry News 

Technology 

Networks.com 

Scientifi c Communities 

Job Listings 

Latest Publications 

Poster Presentations 

Product Directory 

Resources 

Upcoming Events 

Videos 

Webcasts 

Scientifi c Communities

Advance Science Achieve Great Things Be United 

Introducing SLAS2012. The Society for Laboratory Automation and Screening (SLAS) proudly introduces 

SLAS2012, the First Annual SLAS Conference and Exhibition. SLAS2012 unites the best of the former 

LabAutomation and SBS conferences to increase collaboration and prominence for the laboratory science 

and technology community. 

The powerful SLAS2012 scientific program will target science, 

technology and drug discovery in a unique format to advance: 

º 

º 

Drug Target Biology 

Assay Development 

and Screening 

As a participant, you will be among those working 

in drug discovery and development efforts, as well 

as clinical diagnostics, food and agricultural sciences, 

forensics and security sciences, petrochemicals 

and energy, and consumer products. 

Be part of the scientific savvy, technical 

innovation and energy that will be SLAS2012. 

Look for the Call for Abstracts 

submission details mid-April. 

Stay updated at—SLAS2012.org 

º 

º 

High-Throughput 

Technologies 

Micro/Nano Technology 

Short Courses: February 4–5 

Conference: February 6–8 

Exhibition: February 6–7 

º 

º 

º 

Scan the code with your smart phone 

to go directly to SLAS2012.org. 

Bioanalytical Techniques 

Diagnostics 

Informatics 

Keynote Speaker 

Peter G. Schultz, Ph.D. 

Scripps Family Chair 

Professor; Department 

of Chemistry; The Scripps 

Research Institute


Life Chemicals, Inc.—Booth 924 

2477 Glenwood School Drive - Suite 203 

Burlington, Ontario L7R 3R9 Canada 

+1.905.634.5212; +1.905.634.4719 fax 


lifechemicals@lifechemicals.com; www.lifechemicals.com 

Life Chemicals Inc. Burlington, Canada, specializes in 

state-of-the-art organic synthesis for drug discovery and 

agrochemical R&D. Our products include: Over 750,0000 

drug-like and lead-like compounds for HTS; carefully 

designed targeted libraries (Kinase, NHR, Protease, Ion 

Channel, GPCR and other); custom libraries and custom 

synthesis projects; proprietary building blocks. 


Life Technologies—Booth 1231 

5791 Van Allen Way 

Carlsbad, California 92008 

+1.760.603.7200 

www.lifetechnologies.com 

Life Technologies is a global biotechnology tools 

company dedicated to improving the human condition. 

Our customers do their work across the biological 

spectrum, working to advance personalized medicine, 

regenerative science, molecular diagnostics, agricultural 

and environmental research, and 21st century forensics. 

Lonza—Booth 906 

8830 Biggs Ford Road 

Walkersville, Maryland 21793 

+1.301.898.7025; +1.301.845.7900 fax 


donpaul.kovarcik@lonza.com; www.lonza.com 

Lonza provides innovative product and service solutions 

designed to support all phases of drug discovery and 

development. Our offering includes Odyssey Thera 

Compound Profiling Service, Cardiac Liability Screening 

Services, Clonetics ® & Poietics ® Primary Cells and Media, 

Amaxa ® Nucleofector ® Technology; BioAssay Products, 

Conditionally Immortalized Human Cells, and Cells On 

Demand Services. 


Lumigen—Booth 826 

22900 W 8 Mile Road 

Southfield, Michigan 48033 

+1.248.351.5600 

afgaglio@beckman.com; www.lumigen.com 

Lumigen, Inc., (a Beckman Coulter Company) is an ISO 

9001:2008 Registered Corporation, and is one of the 

world’s largest suppliers of chemiluminescent reagents to 

the clinical immunodiagnostics market and the life science 

research market. 835 Market Research Station Share 

your views and get free stuff! Visit the Market Research 

Station to participate in a data collection exercise that 

examines the thoughts, views and motivations of scientists. 

Information collected is kept completely anonymous, 

and you will receive a free gift for participating. The 

research is not endorsed or affiliated with SLAS. 

Luminex Corporation—Booth 631 

12212 Technology Boulevard 

Austin, Texas 78727 

+1.512.219.8020; +1.512.219.5195 fax 

info@luminexcorp.com; www.luminexcorp.com 

Luminex Corporation develops proprietary biological 

testing technologies with applications throughout the 

life sciences and diagnostic industries. The company’s 

xMAP ® Technology is an open-architecture, multi-analyte 

technology platform that delivers fast, accurate and 

cost-effective bioassay results. 

matrical bioscience—Booth 918 

1003 E. Trent Avenue - Suite 110 

Spokane, Washington 99202 

+1.509.343.6225; +1.509.343.6220 fax 

bob.alexander@matrical.com; http://www.matrical.com 

Matrical bioscience is a worldwide supplier of automated 

cell culture systems (MACCS), automated storage 

platforms (MiniStore), a high throughput sonication 

device (SonicMan), and a universal microplate washer 

(SQUIRT). Matrical bioscience also offers consumable 

microwell plates in 96, 384, and 1536 formats and 

proprietary MatriTube technology for chemical and 

biological sample storage.


MaxCyte, Inc.—Booth 812 

22 Firstfield Road - Suite 110 

Gaithersburg, Maryland 20878 

+1.301.944.1700; +1.301.944.1703 fax 

kdonato@maxcyte.com; http://www.maxcyte.com 

MaxCyte is a leader in cell transfection and modification, 

bringing to market its patented flow electroporation 

technology for use in the discovery and development 

of small molecule drugs, biotherapeutics, protein 

production and innovative cellular therapeutics. 

MaxCyte flow electroporation technology uniquely 

fulfills the needs for high quality, fully scalable cell 

modification. 

MeCour Temperature Control—Booth 418 

10 Merrimack River Road 

Groveland, Massachusetts 01834 

+1.978.372.6085; +1.978.372.8462 fax 

+1.877.398.6085 

mail@mecour.com; www.mecour.com 

MeCour’s heating/cooling thermal systems provide 

+/-0.1C uniform temperature management across the 

entire Thermal Block that accommodates all consumables 

for integration with benchtop and automated applications. 

Operate between -100C to +250C with complete 

programmable control. Thermal Blocks easily connect 

to the circulator. Contact us at +1.978.372.6085, 

mail@mecour.com or visit www.mecour.com. 

Micronic North America, LLC—Booth 1205 

901 Washington Road - Suite 302 

McMurray, Pennsylvania 15317 

+1.724.941.6411; +1.724.941.8662 fax 

micronicna@cs.com; www.micronicna.com 

Micronic offers a comprehensive line of plastic and glass 

non-coded, Alphanumeric, and 2D barcoded sample 

storage tubes (including Screw Cap tubes), caps and racks; 

a full line of barcode readers, automated tube sorters, 

and (de)capping equipment; sample labeling solutions; 

a stability reagent line; a high-throughput multichannel 

spectrophotometer; and sample data management 

software solutions. 

Microsonic Systems—Booth 925 

76 Bonaventura Drive 


+1.408.844.4980; +1.866.404.4898 fax 

bruce.jamieson@microsonics.com; www.microsonics.com 

Microsonic Systems Inc. utilizes the Microprocessor 

for Life Sciences to process fluids in microplates and 

micro-fluidics using a powerful, patented new form of 

ultrasonic energy. Our first product, the HENDRIX SM100 

Ultrasonic Fluid Processor solubilizes, thaws, mixes and 

suspends samples. Learn more at www.microsonics.com. 

MipTec 2011—Booth 836 

Peter Merian-Strasse 80 Basel 4002 Switzerland 

+41.61.686.7777; +41.61.686.7788 fax 

walter.gammeter@congrex.com; www.miptec.com 

MipTec is the premier European conference and 

exhibition encompassing innovative approaches to 

high quality science and technology for drug discovery. 

MipTec brings together scientists from all disciplines 

of drug discovery within pharmaceutical and biotech 

companies, academic labs and technology providers. 

The scientific program covers the latest breakthroughs 

in the fields of drug discovery. 

Moffitt Cancer Center—Booth 323 

12902 Magnolia Drive 

Tampa, Florida 33635 

+1.813.745.7890; +1.813.745.7827 fax 

www.moffitt.org 

* Conference Sponsor 


© 2010-2011 PerkinElmer, Inc. 400211_02. PerkinElmer and EnSpire are trademarks of PerkinElmer, Inc. and/or its subsidiaries. Corning and Epic are trademarks of Corning Incorporated. 

LabeL-free technoLogy 

expLore 

every corner of 

your research 

Introducing EnSpire® with label-free, a multimode plate reader like no 

other. It’s the first and only platform to combine exclusive Corning® Epic® 

label-free technology and labeled detection in a benchtop plate reader. With 

this innovative platform, you can acquire richer information about cellular 

and biochemical systems, study difficult targets or weak interactions and gather more 

physiologically relevant data. Now, you can better understand every twist and turn of your 

biology, and make better decisions faster. Learn more at www.perkinelmer.com/labelfree 

Please see our new EnSpire label-free platform at SBS Booth #701


Molecular Devices—Booth 901 

1311 Orleans Drive 


+1.408.747.1700; +1.408.747.3601 fax 


candace.anderson@moldev.com; 

www.moleculardevices.com 

At Molecular Devices, we have one focus—our customers. 

Understanding your screening needs is our top priority, 

and we direct product development toward solving your 

unique issues. Our analytical products offer a full spectrum 

of detection technologies and throughput capabilities to 

detect biology, decode data, and drive discovery. Stop 

by booth #901 to learn more, or visit our website. 


MRC Technology—Booth 327 

Lynton House, 7-12 Tavistock Square 

London WC1H 9LT 


+44.207.391.2700; +44.207.391.2800 fax 

info@tech.mrc.ac.uk; www.mrctechnology.org 

MRC Technology develops and licenses cutting edge 

scientific technologies in order to create commercial 

products that benefit healthcare. We are the exclusive 

agent for the UK’s Medical Research Council, and have 

generated over $800m to fund further research. 

Multispan, Inc.—Booth 1220 

26219 Eden Landing Road 

Hayward, California 94545 

+1.510.887.0817 

admin@multispaninc.com; www.multispaninc.com 

Multispan Inc. is a California-based company focusing 

exclusively on GPCR drug discovery research. It has 

created 320 GPCR cDNA clones in its proprietary vector 

and over 300 GPCR cellular functional assays. Multispan 

provides customers worldwide with fast-turnaround 

GPCR screening and compound profiling services, 

and high quality GPCR cell lines and membranes. 

NAEJA Pharmaceutical Inc.—Booth 1120 

4290-91 A St Edmonton AB T6E 5V2 Canada 

+1.780.989.9826; +1.780.461.0196 fax 

ssalama@naeja.com; www.naeja.com 

NAEJA is a privately owned Canadian pharmaceutical 

drug discovery and development services company 

with an extensive track record of drug discovery and 

development achievements. The company was 

established in 1987 and employs over 70 scientific 

staff, over 90 percent of whom hold Ph.D. degrees. 

Nanion Technologies Inc.—Booth 419 

675 US Hwy 1 

North Brunswick, New Jersey 08902 

+1.862.221.2790; +1.732.745.7270 fax 


info@naniontech.com; www.naniontech.com 

Nanion’s automated patch clamp system, the Port-a-Patch, 

is recognized as the world’s smallest patch clamp device. 

Following the successful market introduction of the Porta-Patch 

and the Patchliner, Nanion now introduces the 

SyncroPatch 96, which vastly increases throughput while 

reducing the cost per data point to a level compatible with 

industrial ion channel screening requirements. 

Nature Publishing Group—Booth 1200 

75 Varick Street - 9th Floor 

New York, New York 10013 

+1.212.726.9200; +1.212.696.9591 fax 

institutions@nature.com; www.nature.com 

Nature Publishing Group brings leading scientific and 

medical research to your desk top. The NPG portfolio 

combines the continued excellence of Nature, its 

associated research and review journals, and 50 

leading academic and society journals in the life, 

physical and clinical sciences. Visit Booth 1200 for 

free sample copies 



Nexus Biosystems—Booth 1018 

14100 Danielson - Building 100 

Poway, California 92064 

+1.858.527.7000; +1.858.679.1255 fax 

cpowell@nexusbio.com; www.nexusbio.com 

Nexus Biosystems is the World’s leading full-service 

Autometed Sample Storage Provider. Nexus and its’ 

REMP Division provide fully automated storage systems 

for Chemical and Biological Sample Management, 

Sample Storage Systems and Solutions, and Sample 

Analysis Microplate products. 

Omni International, Inc.—Booth 622 

935-C Cobb Place Boulevard 

Kennesaw, Georgia 30144 

+1.770.421.0058; +1.800.776.4431 toll free 

omni@omni-inc.com; www.omni-inc.com 

World leaders in HOMOGENIZER technology, our superior 

benchtop homogenizers allow researchers to process 

virtually any sample, quickly and efficiently. Omni Tip 

probes eliminate cross-contamination, sample loss and 

carryover associated with other methods. Multi-sample 

solutions save time and money by eliminating bottlenecks 

caused by standard homogenizers. Visit Omni at 

www.omni-inc.com. 

Pall Life Sciences—Booth 424 

600 S Wagner Road 

Ann Arbor, Michigan 48103 7 

+1.734.665.0651; +1.734.913.6114 fax 


LabSupport@pall.com; www.pall.com/lab 

Visit Pall Life Sciences at SBS Booth #424 to learn 

about products for sample prep and chromatography 

applications. Pall continues to provide solutions that 

improve your processes and results. Stop by our booth 

to see a variety of products designed specifically for 

purification, detection, sample prep, and quality control. 


PerkinElmer—Booth 701 

940 Winter Street 


+1.781.663.6243; +1.781.663.5984 fax 

nancy.hertig@perkinelmer.com; www.perkinelmer.com 

PerkinElmer, a global leader in health sciences, provides 

instruments, reagents, software, and services for drug 

discovery/development, genetic screening, environmental 

testing, quality assurance, and health sciences end 

markets. 

] Premier Sponsor 

PharmaDiagnostics—Booth 932 

NV Z1 Research Park 310 Zellik 

B-1731 Belgium 

+32.248.160.35; +32.246.317.06 fax 

enquiries@pharmadiagnostics.com; www. 

pharmadiagnostics.com 

SoPRano is unique in enabling label-free SPR 

screening in solution using a standard absorbance 

plate-reader. Due to the phenomenon of Localized 

SPR, specifically functionalized gold nanoparticles 

(e.g. coated with a protein) show a reproducible and 

quantifiable absorbance change upon ligand interaction. 

Applications include small molecule/fragment and 

antibody screening, and ADME. 

Pittcon 2012—Booth 1032 

300 Penn Center Boulevard - Suite 332 

Pittsburgh, Pennsylvania 15235 

+1.412.825.3220 

info@pittcon.org; www.pittcon.org 

Pittcon 2012, the world’s largest annual conference and 

exposition for laboratory science, March 11-16, 2012, 

Orlando, Florida. Pittcon offers the latest innovations from 

nearly 1,000 exhibitors, unique networking opportunities 

with world renowned scientists, and exceptional 

educational opportunities. See all that Pittcon 2012 

has to offer at www.pittcon.org


Platypus Technologies LLC—Booth 821 

5520 Nobel Drive- #100 


+1.608.237.1270; +1.608.237.1271 fax 

info@platypustech.com; http://www.platypustech.com 

We develop, manufacture and sell easy to use and costeffective 

cell-based assays for investigating cell motility 

modulators of wound healing and cancer metastasis. 

Our Oris and Oris Pro products offer fully automatable 

96 and 384-well formats for high content analysis in high 

throughput settings. The assays permit visualization of 

cell motility in 2D and 3D on a variety of extracellular 

matrices. 

Plexera LLC—Booth 437 

13110 NE 177th Place #100 

Woodinville, Washington 98072 

+1.425.368.7410 

jsmith@plexera.com; www.plexera.com 

Plexera ® makes advanced SPR- Surface Plasmon 

Resonance-based solutions for functional proteomics. 

The new PlexArray HT system comprises state of 

the art hardware, patented biosensor chips, and data 

analysis software for measuring affinity, kinetics, and 

concentration. PlexArray offers unparalleled advantages 

in array density and throughput for biophysical/label-free 

analysis. 

Promega Corporation—Booth 501 

2800 Woods Hollow Road 


+1.608.274.4330; +1.608.277.2601 fax 

neal.cosby@promega.com; http://www.promega.com 

Promega is a world leader in developing bioluminescent 

technologies that deliver more biologically relevant 

data in drug screening and basic research applications. 

We offer customizable solutions for key target classes 

as well as developing custom cell-based assays and 

bioassays. Speak with a Promega representative to 

learn more about new assays or how we can develop 

a custom assay for you. 


Proteros Biostructures GmbH—Booth 1132 

Am Klopferspitz 19 Planegg/Martinsried 

82152 Germany 

+49.89.7007.61.0; +49.89.7007.6115 fax 

business@proteros.de; www.proteros.de 

Knowledge-driven engineering of lead compounds for 

integrated drug discovery. Proteros accelerates and 

improves protein structure and compound binding 

analysis. Expertise in managing complex projects and 

unique technologies for crystallography, kinetic and 

thermodynamic screening, compound and fragment 

libraries. Currently providing services to >70 clients in 

North America, Europe and Japan. 

reinnervate Ltd—Booth 1131 

NETPark Incubator Thomas Wright Way 

Sedgefield County Durham TS21 3FD United Kingdom 

+44.1740,625.266 

info@reinnervate.com; www.reinnervate.com 

Reinnervate’s core technology is alvetex ® , a unique and 

proprietary scaffold that enables routine 3D cell culture in 

the laboratory. Alvetex ® provides a nanoscale environment 

that supports genuine homogeneous 3D cell growth. Cells 

grown using alvetex ® form complex 3D tissue cultures, 

which more closely mimic normal in-vivo cell growth and 

the formation of tissues in the body. 


ReTiSoft Inc.—Booth 413 

366 Revus Av - Unit #21 

Mississauga, Ontario L5G 4S5 Canada 

+1.647.724.2398; +1.905.290.0181 

elizabethr@retisoft.ca; www.retisoft.ca 

Established in 1998, ReTiSoft is a system integrator 

company based in Mississauga, Canada. We provide 

pharmaceutical, biotechnology and research industries 

with turn-key and custom-built automated systems. 

Our products include a flexible automated workcell, 

dynamic scheduling software and a web-enabled LIMS 

for the laboratory automation market. 



Roche—Booth 1222 

9115 Hague Road 

Indianapolis, Indiana 46250 

+1.317.521.2000; +1.317.521.7900 fax 

www.roche-applied-science.com 

Roche Applied Science provides scientific research tools 

for genomic and cellular analysis. The new xCELLigence 

RTCA HT system provides real time label free cell 

monotoring on robotic platforms utilizing up to four 384 

well plate stations. The new xCELLigence RTCA Cardio 

system resolves cardiomyocyte beating to assess the 

arrhythmic liability of compounds in 96-well plates. 

RTS Life Science—Booth 1119 

Northbank, Irlam 

Manchester M44 5AY United Kingdom 

+44.161.777.2000; +44.161.777.2002 fax 

sue.jones@rts-group.com; www.rts-group.com 

RTS provides laboratory automation solutions for drug 

discovery and drug delivery applications. One of the 

pioneers in automated sample management and with 

almost 30 years experience, systems include: automated 

storage and retrieval, high throughput screening, blood 

fractionation, sample processing, automated inhaler 

and tablet testing for pharma, biotech, biobanking and 

academic institutions. 

Sanford-Burnham Medical Research Institute 

—Booth 520 

6400 Sanger Road 

Orlando, Florida 32827 

+1.407.745.2095 

svasile@sanfordburnham.org; www.sanfordburnham.org 

Sanford-Burnham Medical Research Institute combines 

the creativity of academia with the discipline of industry 

in an independent research environment. The Institute 

is recognized for its world-class capabilities in drug 

discovery and operates a NIH MLPCN Comprehensive 

Screening Center. Staffed by scientists with pharma and 

biotech expertise, Sanford-Burnham is a sought-after 

partner for industry. 


Scripps Florida—Booth 300 

130 Scripps Way #1A1 

Jupiter, Florida 33458 

+1.561.228.2100 

kemery@scripps.edu; www.hts.florida.scripps.edu 

Scripps Florida engages in all aspects of drug-discovery 

research. At SBS, we are introducing the HIAPI-CM 

instrument which combines novel technologies to perform 

rapid assessment of HTS compound library quality. 

HIAPI-CM detects & classifies typical artifacts found 

in HTS compound library microtiter plates including 

insufficient volume, compound precipitation, and 

samples containing color. 

SelectScience—Booth 933 

Church Farm Business Park - Unit 12A/B 

Corston, Bath, BA2 9AP 


+44.1225.874666 

office@selectscience.net: www.selectscience.net 

SelectScience.net is the leading online product and 

application publication for laboratory scientists featuring 

the latest news, application articles, videos, product 

directory and product reviews. Membership is fast, free 

and provides access to all of the SelectScience services. 

SelectScience.tv is a unique video news channel for 

laboratory application and product information. 


Sierra SensorsGmbH—Booth 1208 

7 Austin Avenue - Suite 1A 

Greenville, Rhode Island 02828 

+1.401.404.5549 +1.262.922.4101 fax 

info@sierrasensors.com; www.sierrasensors.com 

Sierra Sensors GmbH is a global supplier of label-free 

molecular interaction analysis systems. By combining 

proprietary microfluidics with high-sensitivity biosensor 

detection and flexible surface chemistry, we provide 

high-performance analytical instruments for all research 

levels. Our systems are ideal for the analysis of proteins, 

antibodies, DNA/RNA, cells, membranes, and small 

molecules.


Sigma Life Science—Booth 819 

3050 Spruce Street 

St. Louis, Missouri 63103 

+1.800.325.5052; +1.800.325.3010 

mike.earley@sial.com; www.sigma-aldrich.com 

Silicon Kinetics—Booth 525 

10455 Pacific Center Court 


+1.858.437.2305; +1.858.646.5401 fax 

sbibikov@siliconkinetics.com; www.siliconkinetics.com 

Silicon Kinetics provides 3D biosensors on silicon and 

SKi Pro instruments for sensitive label-free analysis 

of biomolecular interactions in multiple applications. 

3D biosensors also allow SKi Pro to be used as a 

mass-spec front-end instrument, for capturing small 

molecules by affinity, then direct elution for identification 

by MS. 

Sophion Bioscience—Booth 1005 

Baltorpuej 154 Ballerup 

DK 2750 Denmark 

+45.446.088.00 

jlu@sophion.com; www.sophion.com 

Sophion Bioscience, a leader in the automated patch 

clamp field, helps drug discovery companies make more 

and better drugs, faster. Sophion’s focus is to provide 

advanced products and integrated solutions for automated 

patch clamping. The QPatch family of products provides 

high-quality patch clamp data on a truly industrial basis 

on all types of ion channels. 

Specs—Booth 719 

11201 Superfos Drive 

Cumberland, Maryland 21502 

+1.401.782.2994 

david.hayes@specs.net; www.specs.net 

Compound Management Services and Compound 

Screening Libraries: Specs has 20+ years of experience 

in handling research compounds: reformatting, plating, 

dry weighing, plate replication, compound procurement, 

quality control, etc. Additionally, Specs continues our 

traditional business of supplying high quality research 

compounds and building blocks to the life science 

community. 

SRU Biosystems, Inc—Booth 713 

14-A Gill Street 


+1.781.933.7255; +1.781.933.5960 fax 

info@srubiosystems.com; www.srubiosystems.com 

SRU Biosystems is a global provider of novel, labelfree, 

detection tools. Our BIND ® technology analyzes 

biomolecular interactions of cells, proteins, genomic 

materials, peptides, antibodies and small molecule 

compound libraries. BIND technology represents a 

fundamental advance in the ability to monitor label-free 

biological interactions with high sensitivity and high 

throughput. 

Tecan—Booth 710 

4022 Stirrup Creek Drive - Suite 310 

Durham, North Carolina 27703 

+1.919.361.5200; +1.919.361.5201 fax 

claire.rhodes@tecan.com; www.tecan.com 

Tecan is a leading global provider of laboratory 

instruments and solutions. The company specializes 

in the development, production and distribution of 

instruments and automated workflow solutions for 

laboratories in the life sciences sector. Its clients 

include pharmaceutical and biotechnology companies, 

university research departments, forensic and 

diagnostic laboratories. 



Technology Networks Ltd—Booth 832 

Unit 6, Woodview, Bull Lane 

Sudbury, Suffolk, CO10 0FD 


+44.1787.314234 

a.board@technologynetworks.com; 

www.technologynetworks.com 

From our UK headquarters just outside of London, we run, 

update and provide outstanding web-based information 

solutions for those working within the Life Science and 

Drug Discovery community. Over the past 12 years 

Technology Networks has expanded its portfolio to 

include over 30 communities. All of which are available 

through our homepage TechnologyNetworks.com 


Teflabs Inc.—Booth 1025 

9415 Captiol View Drive 

Austin, Texas 78747 

+1.512.280.5223; +1.512.280.4997 fax 

probes@teflabs.com; www.TEFLabs.com 

Since 1993, TEFLabs has developed innovative 

fluorescent ion indicators for cell research and high 

throughput screening. With the launch of the Asante 

line of next generation indicators, TEFLabs is proud 

to introduce to the high throughput screening community 

the availability of novel indicators for Calcium, Sodium, 

and Potassium. 

The Automation Partnership—Booth 1107 

20 Montchanin Road 

Greenville, Delaware 19807 

+1.302.478.9060; +1.302.478.9575 fax 

matthew.walker@automationpartnership.com; 

www.automationpartnership.com 

TAP Biosystems (formerly The Automation Partnership) 

provides advanced automation systems and services 

for life science research, development and production. 

TAP Biosystems focuses primarily on bioprocessing, 

cell therapies, cell-based testing/screening, discovery 

research, tissue engineering and sample management 

applications. At SBS2011, the new RAFT 3D tissue 

modeling system will be launched. 



Thermo Scientific—Booth 911 

81 Wyman Street 


+1.905.332.2000; +1.905.332.1114 fax 

info.labautomation@thermofisher.com; 

www.thermoscientific.com/automate 

Visit Thermo Scientific booth and see our impressive 

portfolio of robotics, automation workflow software, and 

automated incubation. The following Thermo Scientific 

products will be featured: RapidStak microplate stacker, 

Orbitor microplate mover, Momentum automation software, 

and Cytomat automated incubators. Ask how our solutions 

can help accelerate your research. 

Titertek Instruments Inc.—Booth 1209 

330 Wynn Drive – Suite 100 

Huntsville, Alabama 35805 

+1.256.859.8600; +1.256.859.8671 fax 

inquiry@titertek.com; www.titertek.com 

Titertek Instruments is a manufacturer of liquid 

handling and lab automation equipment. Our compact, 

yet versatile washers and dispensers fill the gap between 

single-function equipment and multipurpose workstations. 

Our high-throughput liquid handling workstations and 

customized, application-tailored lab automation systems 

process the most challenging applications with no 

compromises. 

Titian Software Ltd—Booth 401 

2 Newhams Row 

London SE1 3UZ 


+44.20.7367.6869; +44.20.7367.6868 fax 

michael.girardi@titian.co.uk; www.titian.co.uk 

Titian Software leads the industry in the supply 

of software and consultancy services that empower 

customers in their management of scientific samples. 

Founded in 1999, 11 of the Top 20 biopharma companies 

utilize Titian’s Mosaic sample management software 

to provide increased quality, service levels, and sample 

conservation while reducing errors and costs.


TTP LabTech—Booth 301 

Melbourn Science Park Melbourn 

Royston HERTS SG8 6EE United Kingdom 

+44.1763.262626; +44.1763.261.964 fax 

sales@ttplabtech.com; www.ttplabtech.com 

TTP LabTech supplies innovative and robust laboratory 

instrumentation for life sciences. Its products include: 

mosquito ® nanolitre liquid handler; Acumen eX3 ® versatile 

high content screening platform; Mirrorball ® for screening 

mix-and-read assays for antibody discovery; comPOUND ® 

modular sample storage and management and Lab2Lab 

for optimising the use of analytical equipment. 

Vectalys—Booth 923 

Rue Pierre et Marie Curie Prologue Biotech 

Labege 31682 France 

+33.561.287.075; +33.562.261.244 fax 

isabel.cassa@vectalys.com; www.vectalys.com 

Vectalys is an R&D company, with state-of-the-art 

technology platform for customized viral vector production. 

The company has developed a unique process to reach 

high titer high purity lentiviral vector for optimal knockdown 

or over expression in relevant models such as 

primary and stem cells for in-vitro and in-vivo gene 

target validation. 

Venenum BioDesign—Booth 524 

8 Black Forest Road 

Hamilton, New Jersey 08691 

+1.609.249.9550 

mwebb@venenumbiodesign.com; 

www.venenumbiodesign.com 

Venenum BioDesign’s mission is to improve patients’ 

lives through discovery of novel therapeutics. We offer 

state-of-the-art assay development, ultra-high throughput 

screening against our propriet ary 5.5 million compounds, 

structural biology, medicinal chemistry, and other core 

capabilities. We have collaborations with several groups 

and are seeking further relationships. 

Viaflo—Booth 822 

2 Wentworth Drive 

Hudson, New Hampshire 03051 

+1.603.578.5800; +1.603.577.5529 fax 


loneil@viaflo.com; www.viaflo.com 

NTEGRA will be displaying NEW liquid handling platforms 

SBS 2011 in Orlando, FL! One new product is the 96 

channel handheld electronic pipettor. The 96 channel 

pipettor features interchangeable pipetting heads, 

pipetting capabilities from .5uL to 1250uL and the same 

user interface featured on the award winning VIAFLO 

electronic pipettes. 

Wiley—Booth 1201 

111 River Street 

Hoboken, New Jersey 07030 

+1.877.762.2974; +1.800-597-3299 fax 

wileycustomer@wiley.com; www.wiley.com 

Wiley publishes an enormous range of top quality 

consumer, professional, educational and research 

material. Wiley-Blackwell, the scientific, technical, 

medical and scholarly publishing business of John 

Wiley & Sons, is the leading society publisher and 

offers libraries peer-reviewed primary research 

and evidence based medicine across 1250 online 

journals, books, reference works and databases. 

Wyatt Technology Corporation—Booth 625 

6300 Hollister Avenue 

Santa Barbara, California 93117 

+1.805.681.9009; +1.805.681.0123 fax 

swilson@wyatt.com; www.wyatt.com 

DynaPro dynamic light scattering instruments for 

determining size, oligomerization (assembly states), 

protein-protein interactions, and protein stability 

across an array of solution conditions. The DynaPro 

Plate Reader automates DLS analysis by measuring 

samples directly from industry-standard microplates 

(96, 384, or 1536 well plates) and using as little as 

5 microliters of sample per well. 



Advertiser Index 

Bell Brook Labs page 118 

Cell Signaling Technology Inside back cover 

ChemBridge Corporation page 126 

Cisbio Bioassays page 2 

Drug Discovery News page 111 

Drug Discovery World page 114 

Enamine page 129 

Forte Bio page 133 

Genetic Engineering and Biotechnology News page 130 

Lab Manager page 136 

Molecular Devices Inside Front Cover, Back Cover 

Nanion Technologies page 135 

PerkinElmer page 144 

Science Magazine page 122 

SLAS2012 page 141 

Stem Cell 2011 Symposium page 123 

Technology Networks page 140 



Notes 


Notes 




Notes 


Notes 




Notes 


Notes 




Notes 


Notes

Welcome to SBS 2011 - SLAS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?